2015 Cancer Drug List PDF

2015 Medicines in Development for Cancer
Bladder Cancer
Product Name
Sponsor
Indication
Development Phase
ABI-009
(nanoparticle albumin-bound
mTOR inhibitor)
AADi
Pacific Palisades, CA
non-muscle invasive bladder cancer
Phase I/II
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
platinum-refractory bladder cancer

(combination therapy)
(see also head/neck, hematological, leukemia,
lung, lymphoma, myeloma, pancreatic)
Phase II
www.acerta-pharma.com
ALT-801
(immunotherapy fusion protein)
Altor BioScience
Miramar, FL
advanced bladder cancer,

Phase II
www.altorbioscience.com
ALT-803
(IL-15 superagonist complex)
Altor BioScience
Miramar, FL

(see also hematological, myeloma, skin)
Phase I/II
apatorsen
(Hsp27 inhibitor)
OncoGenex Pharmaceuticals
Bothell, WA
metastatic bladder cancer

(see also lung, pancreatic, prostate)
Phase II
www.oncogenex.com
apaziquone
(DNA synthesis inhibitor)
Spectrum Pharmaceuticals
Henderson, NV

(Fast Track)
Phase III
www.sppirx.com
ASG-15ME
(antibody drug conjugate)
Agensys
Santa Monica, CA
Seattle Genetics
Bothell, WA
relapsed bladder cancer
Phase I
www.agensys.com
www.seattlegenetics.com
B-701
(anti-FGFR3 mAb)
BioClin Therapeutics
San Ramon, CA
metastatic bladder cancer (2nd-line)
Phase II
www.bioclintherapeutics.com
BC-819
(gene therapy)
BioCancell Therapeutics
Jerusalem, Israel
bladder cancer (2nd-line)

(see also pancreatic)
Phase II
www.biocancell.com
Bladder Cancer
Product Name
Sponsor
Indication
Development Phase
CG0070
(oncolytic virus therapy)
Cold Genesys
Newport Beach, CA
Phase II/III
www.coldgenesys.com
CV-301
(CEA/MUC-1 targeted active
immunotherapy)
Bavarian Nordic
Mountain View, CA
bladder cancer
Phase II
www.bavarian-nordic.com
Cyramza
ramucirumab
Eli Lilly
Indianapolis, IN
urothelial cancer
(see also liver, lung, stomach)
Phase III
www.lilly.com
Phase II
www.lilly.com
DN24-02
(active cellular immunotherapy)
Dendreon
Seattle, WA
HER2-positive urothelial cancer
Phase II
www.dendreon.com
Halaven
eribulin
Orphan Drug
Eisai
Woodcliff Lake, NJ
bladder cancer
(see also lung, sarcoma)
Phase I/II
www.eisai.com
instiladrin
(gene therapy)
FKD Therapies
Kuopia, Finland
superficial bladder cancer
Phase II
JNJ-42756493
(FGFR inhibitor)
Janssen Research & Development

Raritan, NJ
urothelial cancer
(see also lymphoma)
Phase II
www.janssenrnd.com
MCNA
(mycobacterium phlei cell
wall-nucleic acid complex)
Telesta Therapeutics
Point Claire, Canada
refractory non-muscle invasive

bladder cancer (Fast Track)
application submitted
www.telestatherapeutics.com
Keytruda
pembrolizumab
Merck
Kenilworth, NJ
bladder cancer
(see also breast, head/neck, lung, lymphoma,
stomach)
Phase III
www.merck.com
Bladder Cancer
Product Name
Sponsor
Indication
Development Phase
mocetinostat
(HDAC inhibitor)
Mirati Therapeutics
San Diego, CA
bladder cancer
(see also hematological, lymphoma)
Phase II
www.mirati.com
Opdivo
nivolumab
Bristol-Myers Squibb
Princeton, NJ

(see also brain, colorectal, head/neck, hematological,
kidney, liver, lung, lymphoma, skin, solid tumors,
stomach, other)
Phase II
www.bms.com
RG7446
(anti-PD-L1 mAb)
Genentech/Roche
South San Francisco, CA
bladder cancer (2nd-line) (Breakthrough Therapy)

muscle invasive bladder cancer (adjuvant)
(see also breast, kidney, lung, lymphoma, skin)
Phase III
www.roche.com
bladder cancer (1st-line)
Phase II
www.roche.com
TMX-101
(TLR7 agonist)
Orphan Drug
Telormedix
Bioggio, Switzerland
bladder cancer
Phase II
www.telormedix.com
vesigenurtucel-L
(cancer immunotherapy)
Heat Biologics
Durham, NC
bladder cancer
Phase II
www.heatbio.com
2B3-101
(doxorubicin liposomal)
BBB Therapeutics
Leiden, Netherlands
brain metastases in advanced solid tumors,

brain metastases in breast cancer (combination therapy)
Phase II
www.bbbtherapeutics.com
ABT-414
Orphan Drug
AbbVie
North Chicago, IL
glioblastoma
(see also solid tumors)
Phase I/II
www.abbvie.com
ADU-623
(therapeutic bivalent vaccine)
Aduro Biotech
Berkeley, CA
glioblastoma
Phase I
www.adurobiotech.com
Brain Cancer
Product Name
Sponsor
Indication
Development Phase
AG-120
(IDH1 inhibitor)
Agios Pharmaceuticals
Cambridge, MA
Celgene
Summit, NJ
glioma
(see also leukemia, solid tumors)
Phase I
www.agios.com
www.celgene.com
aglatimagene besadenovec
(gene therapy)
Orphan Drug
Advantagene
Auburndale, MA
glioma
(see also pancreatic, prostate)
Phase II
www.advantagene.com
glioma (pediatric)
Phase I/II
www.advantagene.com
aldoxorubicin
(delivery-enhanced doxorubicin)
Orphan Drug
CytRx
Los Angeles, CA
glioblastoma
(see also lung, sarcoma)
Phase II
www.cytrx.com
AMG 595
(anti-EGFRvIII antibody drug
conjugate)
Amgen
Thousand Oaks, CA
anaplastic astrocytoma, recurrent glioblastoma
Phase I
www.amgen.com
ANG 1005
(peptide-paclitaxel conjugate)
Orphan Drug
Angiochem
Montreal, Canada
brain metastases from breast cancer and

NSCLC, recurrent glioblastoma (Fast Track)
Phase II
www.angiochem.com
antineoplaston A10/AS2-1
Orphan Drug
Burzynski Research Institute

Houston, TX
diffuse intrinsic brainstem glioma
Phase II
www.burzynskiresearch.com
Avastin
bevacizumab
Genentech/Roche
glioblastoma (1st-line)
(see also breast, lung, ovarian, other)
Phase III
www.roche.com
BGJ398
(FGF-R kinase inhibitor)
Novartis Pharmaceuticals
East Hanover, NJ
recurrent glioblastoma
Phase II
www.novartis.com
Brain Cancer
Product Name
Sponsor
Indication
Development Phase
buparlisib (BKM120)
(PI3K inhibitor)
East Hanover, NJ
glioblastoma
(see also breast, solid tumors)
Phase I/II
www.novartis.com
CC-122
(pleiotropic pathway modifier)
Celgene
Summit, NJ
glioblastoma
(see also leukemia, liver, lymphoma)
Phase I
www.celgene.com
Cometriq
cabozantinib
Exelixis
astrocytoma, glioblastoma
(see also kidney, liver)
Phase II completed
www.exelixis.com
Cotara
iodine I 131 derlotuximab biotin
Orphan Drug
Peregrine Pharmaceuticals
Tustin, CA
recurrent glioblastoma (Fast Track)
Phase II completed
www.peregrine.com
crenolanib
(PDGFR inhibitor)
Orphan Drug
AROG Pharmaceuticals
Dallas, TX
glioma (pediatric)
(see also leukemia, lung, stomach)
Phase II
www.arogpharma.com
CTO
(carboxyamidotriazole orotate)
Tactical Therapeutics
New York, NY
glioma (combination therapy)

(Fast Track)
Phase I/II
www.tacticaltherapeutics.com
DCVax-L
dendritic cell-based vaccine
Orphan Drug
Northwest Biotherapeutics
Bethesda, MD
glioblastoma
Phase III
www.nwbio.com
DM-CHOC-PEN
(non-neurotoxic derivative of
penclomidine)
Dekk-Tec
New Orleans, LA
brain tumors
Phase II
www.dekk-tec.com
DNX-2401
(oncolytic virus)
Orphan Drug
DNAtrix
Houston, TX
glioblastoma (Fast Track)
Phase I
www.dnatrix.com
Brain Cancer
Product Name
Sponsor
Indication
Development Phase
ERC1671
(therapeutic vaccine)
Epitopoietic Research
Pasadena, CA
University of California
Irvine, CA
grade IV glioblastoma
Phase II
www.ercbelgium.com
ETS2101
(dexanabinol)
e-Therapeutics
Oxfordshire, England
Moores UCSD Cancer Center
La Jolla, CA
glioma
Phase I
www.etherapeutics.co.uk
evofosfamide (TH-302)
(hypoxia-activated prodrug)
Threshold Pharmaceuticals
University of Texas
San Antonio, TX
high grade glioma

(see also hematological, lung, pancreatic, sarcoma,
skin)
Phase I/II
www.thresholdpharm.com
galunisertib
(TGF-beta 1 kinase inhibitor)
Eli Lilly
Indianapolis, IN
glioblastoma
(see also liver, pancreatic)
Phase II
www.lilly.com
glioma
Phase I/II
www.lilly.com
Gilotrif
afatinib
Boehringer Ingelheim Pharmaceuticals

Ridgefield, CT
recurrent glioma
(see also head/neck, lung)
Phase II
www.boehringer-ingelheim.com
heat shock protein vaccine

(Prophage Series)
Orphan Drug
Agenus
Lexington, MA
recurrent or newly-diagnosed glioblastoma

(see also skin)
Phase II
www.agenus.com
ICT-107
(dendritic cell-based vaccine)
Orphan Drug
ImmunoCellular Therapeutics
Calabasas, CA
newly-diagnosed glioblastoma
Phase II
www.imuc.com
Brain Cancer
Product Name
Sponsor
Indication
Development Phase
ICT-121
(dendritic cell-based vaccine)
ImmunoCellular Therapeutics
Calabasas, CA
Phase I
www.imuc.com
indoximod
(IDO pathway inhibitor)
NewLink Genetics
Ames, IA
primary malignant brain tumors

(see also breast, prostate)
Phase I/II
www.newlinkgenetics.com
INXN-2001
(Ad-RTS-IL-12 gene therapy)
ZIOPHARM Oncology
Boston, MA
anaplastic oligo astrocytoma, glioblastoma

(see also breast, skin)
Phase I/II
www.ziopharm.com
Jevtana
cabazitaxel
Sanofi US
Bridgewater, NJ
malignant central nervous system tumors

(see also prostate)
Phase I/II
www.sanofi.com
KX02
(Src kinase/pre-tubulin inhibitor)
Orphan Drug
Kinex Pharmaceuticals
Buffalo, NY
glioma
Phase I
www.kinexpharma.com
MM-398
(encapsulated irinotecan
nanotherapeutic)
Baxalta
Cambridge, MA
glioma
(see also pancreatic, solid tumors)
Phase I
www.baxalta.com
macitentan
(endothelin A/B receptor antagonist)
Actelion Pharmaceuticals
glioblastoma
Phase I
www.actelion.com
marizomib
(proteasome inhibitor)
Triphase Accelerator
San Diego, CA
glioblastoma
(see also myeloma)
Phase I
www.triphaseco.com
mibefradil
(T-type calcium channel antagonist)
Orphan Drug
Cavion
Charlottesville, VA
high-grade glioma
Phase I
www.cavionpharma.com
mipsagargin
(thapsigargin analogue)
GenSpera
San Antonio, TX
glioblastoma
(see also liver)
Phase II
www.genspera.com
Brain Cancer
Product Name
Sponsor
Indication
Development Phase
NEO-100
(highly purified perillyl alcohol)
Orphan Drug
NEONC Technologies
Tucson, AZ
Phase I
www.neonctech.com
NVX-108
(radiation-sensitizing agent)
NuvOx Pharma
Tucson, AZ
National Cancer Institute
Bethesda, MD
glioblastoma
Phase I/II
www.nuvoxpharma.com
Odomzo
sonidegib
East Hanover, NJ
medulloblastoma
(see also leukemia)
Phase II
www.novartis.com
Opdivo
nivolumab
Princeton, NJ
glioblastoma
(see also bladder, colorectal, head/neck, hematological,
stomach, other)
Phase III
www.bms.com
PEPIDH1M
(dendritic cell vaccine)
Annias Immunotherapeutics
Chapel Hill, NC
glioblastoma
Phase I/II
www.anniasimmuno.com
PLX3397
(CSF-1R inhibitor)
Plexxikon
Berkeley, CA
glioblastoma (adjuvant)
(see also breast, ovarian, skin, other)
Phase II
www.plexxikon.com
Poly-ICLC
Orphan Drug
Oncovir
Washington, DC
glioblastoma
Phase II
www.oncovir.com
Reolysin
pelareorp
Orphan Drug
Oncolytics Biotech
Calgary, Canada
high grade glioma (pediatrics)

(see also colorectal, head/neck, lung,
myeloma, ovarian, other, pancreatic)
Phase I
www.oncolyticsbiotech.com
Brain Cancer
Product Name
rindopepimut
(EGFR antagonist)
Orphan Drug
Sponsor
Indication
Development Phase
Celldex Therapeutics
Hampton, NJ
glioblastoma (1st-line) (Fast Track)
Phase III
www.celldex.com
Phase II
www.celldex.com
selinexor (oral)
(XPO1 antagonist)
Karyopharm Therapeutics
Newton, MA
glioblastoma
(see also head/neck, hematological, leukemia,
lymphoma, myeloma, prostate, sarcoma, other)
Phase II
www.karyopharm.com
Seprehvir
HSV1716
Virttu Biologics
Glasgow, Scotland
Bethesda, MD
glioblastoma
Phase I
www.virttu.com
SL-701
(immunotherapy)
Stemline Therapeutics
New York, NY
adult glioblastoma (first recurrence)
Phase I/II
www.stemline.com
SurVaxM
BIRC5 protein inhibitor
MimiVax
Buffalo, NY
malignant glioma
Phase I
www.mimivax.com
Toca 511 + Toca FC

(gene therapy)
Tocagen
San Diego, CA
anaplastic astrocytoma, glioblastoma

(Fast Track)
Phase II/III
www.tocagen.com
TPI 287
(abeotaxane)
Cortice Biosciences
New York, NY
Phase II
www.corticebio.com
breast cancer brain metastases,

secondary brain metastases
Phase I
www.corticebio.com
Brain Cancer
Product Name
Sponsor
Indication
Development Phase
TRC105
(END protein inhibitor)
TRACON Pharmaceuticals
San Diego, CA
Bethesda, MD
glioblastoma
(see also breast, colorectal, kidney, liver, lung,
sarcoma, other)
Phase II
www.traconpharma.com
TSC
(trans-sodium crocetinate)
Orphan Drug
Diffusion Pharmaceuticals
Charlottesville, VA
glioblastoma
Phase I/II
www.diffusionpharma.com
TVI-Brain-1
(personalized cancer immunotherapy)
Orphan Drug
TVAX Biomedical
Lenexa, KS
glioma
Phase II
www.tvaxbiomedical.com
VAL-083
(N7-alkylating agent)
Orphan Drug
DelMar Pharmaceuticals
Vancouver, Canada
glioblastoma
Phase I/II
www.delmarpharma.com
VB-111
(targeted anti-angiogenic agent)
Orphan Drug
VBL Therapeutics
Tel Aviv, Israel

(see also ovarian, other)
Phase II
www.vblrx.com
veliparib
(PARP inhibitor)
AbbVie
North Chicago, IL
brain metastases
(see also breast, colorectal, lung, skin)
Phase II
www.abbvie.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
abemaciclib
(CDK 4/6 inhibitor)
Eli Lilly
Indianapolis, IN
metastatic breast cancer

(see also lung, lymphoma)
Phase III
www.lilly.com
ABP 980
(trastuzumab biosimilar)
Allergan
Parsippany, NJ
Amgen
Thousand Oaks, CA
breast cancer
Phase III
www.amgen.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
Abraxane
paclitaxel protein-bound
particles for injectable
suspension (albumin-bound)
Celgene
Summit, NJ
triple-negative breast cancer (1st-line)

Phase III
www.celgene.com
ADI-PEG 20
(PEG arginine deiminase)
Polaris Pharmaceuticals
San Diego, CA
HER2-negative breast cancer

(see also liver, lung, ovarian, pancreatic, skin,
stomach)
Phase I
www.polarispharma.com
AE37
(immunotherapeutics)
Antigen Express
Worcester, MA
breast cancer
(see also prostate)
Phase II
www.antigenexpress.com
anti-HER2
Princeton, NJ
breast cancer
Phase I
www.bms.com
ARRY-380/ONT-380
(HER2 inhibitor)
Array BioPharma
Boulder, CO
Oncothyreon
Seattle, WA
breast cancer
Phase I
www.arraybiopharma.com
www.oncothyreon.com
Avastin
bevacizumab
Genentech/Roche
HER2-negative breast cancer (adjuvant),

HER2-positive breast cancer (adjuvant)
(see also brain, lung, ovarian, other)
Phase III
www.roche.com
AZD5363
(Akt kinase inhibitor)
AstraZeneca
Wilmington, DE
breast cancer
Phase II
www.astrazeneca.com
AZD9496
(selective estrogen receptor
downregulator [SERD])
AstraZeneca
Wilmington, DE
estrogen receptor (ER)-positive breast cancer
Phase I
www.astrazeneca.com
bavituximab
Tustin, CA
HER2-negative breast cancer

(see also colorectal, lung, skin)
Phase I completed
www.peregrineinc.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
BBI608
(cancer stem cell inhibitor)
Boston Biomedical
Cambridge, MA
breast cancer
(see also colorectal, hematological, liver, lung,
ovarian, pancreatic, skin, stomach)
Phase II
www.bostonbiomedical.com
BEL-0222
(angiogenesis inhibitor)
Belrose Pharma
Princeton, NJ
triple-negative breast cancer

(see also other)
Phase II
www.belrosepharma.com
buparlisib (BKM120)
(PI3K inhibitor)
East Hanover, NJ
metastatic breast cancer (2nd-line)

(ER-positive aromatase inhibitor (AI)resistant mTOR nave) (combination therapy)
(see also brain, solid tumors)
Phase III
www.novartis.com

(ER-positive post-AI and mTOR inhibitor)
Phase II
www.novartis.com
CC-486
(DNA methylation inhibitor)
Celgene
Summit, NJ

(see also hematological, leukemia, lung, lymphoma,
other)
Phase II
www.celgene.com
cobimetinib
(MEK inhibitor)
Genentech/Roche
triple-negative breast cancer (combination therapy)

(see also skin)
Phase II
www.roche.com
Cynviloq
paclitaxel polymeric micelle
for injection
NantPharma
Lincolnshire, IL
breast cancer
in clinical trials
www.nantpharma.com
docetaxel injection concentrate,

non-alcohol formula
Teikoku Pharma USA

San Jose, CA
breast cancer
(see also head/neck, lung, prostate, stomach)
www.teikokuusa.com
DPX-0907
(T lymphocyte modulator)
Immunovaccine
Halifax, Canada
breast cancer
(see also ovarian, prostate)
Phase I
www.imvaccine.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
ENMD-2076
(aurora A/angiogenic kinase
inhibitor)
CASI Pharmaceuticals
Rockville, MD

(see also ovarian, sarcoma)
Phase II
www.casipharmaceuticals.com
enobosarm
(SARM)
GTx
Memphis, TN
ER-positive and androgen receptor (AR)-positive

breast cancer, AR-positive triple-negative
breast cancer
Phase II
www.gtxinc.com
entinostat
(HDAC inhibitor)
Syndax Pharmaceuticals
Waltham, MA
hormone receptor (HR)-positive metastatic

breast cancer
(see also lung, skin)
Phase III
www.syndax.com
etirinotecan pegol (NKTR-102)

(PEGylated irinotecan)
Nektar Therapeutics
San Francisco, CA
metastatic breast cancer (Fast Track)

(see also colorectal, ovarian)
Phase III
www.nektar.com
Faslodex
fulvestrant
AstraZeneca
Wilmington, DE
HR-positive advanced breast cancer (1st-line)
Phase III
www.astrazeneca.com
ganetespib
(Hsp90 inhibitor)
Synta Pharmaceuticals
Lexington, MA
breast cancer
(see also leukemia, lung, ovarian)
Phase II
www.syntapharma.com
GDC-0810
(SERD)
Genentech/Roche
ER-positive HER2-negative breast cancer
Phase I
www.roche.com
glembatumumab vedotin
CellDex Therapeutics
Hampton, NJ
triple-negative breast cancer (Fast Track)

(see also skin)
Phase II
www.celldex.com
HER2 cancer immunotherapy

(AVX901)
AlphaVax
Research Triangle Park, NC
late-stage breast cancer
Phase I/II
www.alphavax.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
Ibrance
palbociclib
Pfizer
New York, NY
high-risk early breast cancer,

recurrent advanced breast cancer
(see also hematological)
Phase III
www.pfizer.com
IMMU-132
(sacituzumab govitecan)
Immunomedics
Morris Plains, NJ
relapsed/refractory triple-negative breast cancer

(Fast Track)
(see also other)
Phase II
www.immunomedics.com
indoximod
NewLink Genetics
Ames, IA
metastatic HER2-negative breast cancer

(see also brain, prostate)
Phase II
INO-1400
(hTERT immunotherapy)
Inovio Pharmaceuticals
Plymouth Meeting, PA
breast cancer
(see also lung, pancreatic)
Phase I
www.inovio.com
interleukin-12 gene therapy
OncoSec Medical
San Diego, CA

(see also head/neck, skin)
Phase II
www.oncosec.com
INXN-2001
ZIOPHARM Oncology
Boston, MA
breast cancer
(see also brain, skin)
Phase II
www.ziopharm.com
ipatasertib
(Akt inhibitor)
Array BioPharma
Boulder, CO
Genentech/Roche

(see also prostate, stomach)
Phase II
www.roche.com
Jakafi
ruxolitinib
Incyte
Wilmington, DE
breast cancer
(see also colorectal, lung, pancreatic)
Phase II
www.incyte.com
Kadcyla
ado-trastuzumab emtansine
Genentech/Roche
HER2-positive breast cancer (adjuvant monotherapy),

HER2-positive breast cancer (adjuvant combination
therapy), HER2-positive breast cancer
(neoadjuvant combination therapy)
(see also lung, stomach)
Phase III
www.roche.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
Keytruda
pembrolizumab
Merck
Kenilworth, NJ
breast cancer
(see also bladder, head/neck, lung, lymphoma,
stomach)
Phase II
www.merck.com
LEE011
(CDK4/6 inhibitor)
East Hanover, NJ
HR-positive HER2-negative postmenopausal

advanced breast cancer (1st-line)
Phase III
www.novartis.com
HR-positive HER2-negative premenopausal

advanced breast cancer (1st-line)
Phase II
www.novartis.com
HR-positive HER2-negative premenopausal

advanced breast cancer (1st-/2nd-line)
Phase I
www.novartis.com
lucitanib
(FGFR/VEGFR/PDGFR inhibitor)
Clovis Oncology
Boulder, CO

(see also lung)
Phase II
www.clovisoncology.com
LY2606368
(Chk1 inhibitor)
Eli Lilly
Indianapolis, IN

(see also ovarian)
Phase II
www.lilly.com
Lynparza
olaparib
AstraZeneca
Wilmington, DE
germline BRCA-mutated triple-negative breast

cancer (adjuvant), germline BRCA-mutated
(see also ovarian, pancreatic, prostate, stomach)
Phase III
www.astrazeneca.com
margetuximab
(anti-HER2 mAb)
MacroGenics
Rockville, MD
Phase II
www.macrogenics.com
MEDI-573
(anti-CD19 mAb)
MedImmune
Gaithersburg, MD
Phase II
www.medimmune.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
mifepristone
Corcept Therapeutics
Menlo Park, CA
Phase I
www.corcept.com
MM-302
(HER2-targeted nanotheraputic)
Merrimack Pharmaceuticals
Cambridge, MA
advanced HER2-positive breast cancer
Phase II
www.merrimackpharma.com
NeuVax
nelipepimut-S
Galena Biopharma
Portland, OR
node-positive breast cancer

(HER2 IHC 1+/2+)
(see also stomach)
Phase III
www.galenabiopharma.com
node-positive and triple-negative

breast cancer (HER2 IHC 1+/2+)
Phase II
neoadjuvant node-positive and negative

breast cancer (HER2 IHC 3+)
Phase II
niraparib
(PARP inhibitor)
TESARO
Waltham, MA
BRCA-positive breast cancer

(see also ovarian, sarcoma)
Phase III
www.tesarobio.com
NK012
(DNA topoisomerase I inhibitor)
Nippon Kayaku
Tokyo, Japan
breast cancer
(see also colorectal, lung)
Phase II
www.nipponkayaku.co.jp
ONT-10
Oncothyreon
Seattle, WA
breast cancer
(see also ovarian)
Phase I
www.oncothyreon.com
OPT-822/OPT-821
OBI Pharma
Taipei, Taiwan
Phase II/III
www.obipharma.com
patritumab
(anti-HER3 antibody)
Daiichi Sankyo
Parsippany, NJ
breast cancer
(see also lung)
Phase II
www.dsi.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
PB272
(neratinib)
Puma Biotechnology
Los Angeles, CA
breast cancer (adjuvant), metastatic

breast cancer (combination therapy)
(see also lung)
Phase III
www.pumabiotechnology.com
metastatic breast cancer (combination

therapy), breast cancer with brain
metastases (combination therapy)
(combination therapy), breast cancer
(neoadjuvant)
Phase II
Perjeta
pertuzumab
Genentech/Roche
early HER2-positive breast cancer,

HER2-positive metastatic breast cancer
(2nd-line)
(see also stomach)
Phase III
www.roche.com
PF-05280014
(trastuzumab biosimilar)
Pfizer
New York, NY
Phase III
www.pfizer.com
pictilisib
(PI3K inhibitor)
Genentech/Roche
ER-positive breast cancer, metastatic

HER2-negative/HR-positive breast cancer
(see also lung)
Phase II
www.roche.com
PLX3397
(CSF-1R inhibitor)
Plexxikon
Berkeley, CA

(see also brain, ovarian, skin, other)
Phase II
www.plexxikon.com
PM01183
(marine-derived alkylating agent)
Pharma Mar
Madrid, Spain

(see also leukemia, ovarian)
Phase II
www.pharmamar.com
POL6326
(CXCR4 receptor antagonist)
Polyphor
Allschwil, Switzerland

Phase I
www.polyphor.com
pyrotinib
(tyrosine kinase inhibitor)
Jiangsu Hengrui Medicine

Jiangsu Province, China
HER2-positive breast cancer

(see also stomach)
Phase I
www.hrs.com.cn
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
RAD1901
(SERM modulator)
Radius Health
Waltham, MA
Phase I
www.radiuspharm.com
reparixin
(IL-8A/B receptor antagonist)
Dompe
Milan, Italy
early-stage breast cancer
Phase II
www.dompe.com
Phase I
www.dompe.com
RG6047
(SERD)
Genentech/Roche
ER-positive HER2-negative metastatic breast cancer
Phase I
www.roche.com
RG7116
(ERBB-3 receptor antagonist)
Genentech/Roche
Phase I
www.roche.com
RG7446
(anti-PD-L1 mAb)
Genentech/Roche

(see also bladder, kidney, lung, lymphoma, skin)
Phase III
www.roche.com
rucaparib
(PARP inhibitor)
Clovis Oncology
Boulder, CO
breast cancer
(see also ovarian, pancreatic, other)
Phase II
seribantumab (MM-121)
(ErbB-3 receptor antagonist)
Cambridge, MA
breast cancer
(see also lung, ovarian)
Phase II
SGN-LIV1A
Seattle Genetics
Bothell, WA
relapsed breast cancer
Phase I
TAK-228
(mTORC1/2 inhibitor)
Takeda Oncology
Cambridge, MA
breast cancer
(see also kidney, other)
Phase II
www.takedaoncology.com
talazoparib
(PARP inhibitor)
BioMarin Pharmaceutical
Novato, CA

(genetically defined)
Phase III
www.bmrn.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
taselisib
(PI3K inhibitor)
Genentech/Roche
ER-positive HER2-negative metastatic

breast cancer
Phase III
www.roche.com
ER-positive HER2-negative breast cancer
Phase II
www.roche.com
tesevatinib (KD019)
(TKI inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
HER2-positive metastatic breast cancer

(see also lung)
Phase I/II
www.kadmon.com
ThermoDox
doxorubicin liposomal
Celsion
Lawrenceville, NJ
recurrent breast cancer

(see also liver)
Phase II
www.celsion.com
TPIV100
TapImmune
Seattle, WA
breast cancer
Phase I
www.tapimmune.com
TPIV200
(folate receptor alpha vaccine)
TapImmune
Seattle, WA
breast cancer (combination therapy)

(see also ovarian)
Phase I
www.tapimmune.com
TRC105
San Diego, CA
breast cancer
(see also brain, colorectal, kidney, liver, lung, sarcoma,
other)
Phase I
trebananib
(Ang 1 / Ang 2 inhibitor)
Amgen
Thousand Oaks, CA

Phase I
www.amgen.com
vantictumab
(anti-Fzd7)
OncoMed Pharmaceuticals
Redwood City, CA
HER2-negative breast cancer (combination therapy)

Phase I
www.oncomed.com
veliparib
(PARP inhibitor)
AbbVie
North Chicago, IL
BRCA-deficient breast cancer, triple-negative

breast cancer (neoadjuvant therapy)
(see also brain, colorectal, lung, skin)
Phase III
www.abbvie.com
Breast Cancer
Product Name
Sponsor
Indication
Development Phase
Xgeva
denosumab
Amgen
Thousand Oaks, CA
delay of prevention of bone metastases in

breast cancer
(see also lung, myeloma)
Phase III
www.amgen.com
Xtandi
enzalutamide
Astellas Pharma US
Northbrook, IL
Medivation
San Francisco, CA
breast cancer
(see also liver, prostate)
Phase II
www.astellas.com
www.medivation.com
Zytiga
abiraterone acetate

Raritan, NJ
metastatic ER-positive HER2 negative

breast cancer in post-menopausal women
Phase II
www.janssenrnd.com
Colorectal Cancer
Product Name
Sponsor
Indication
Development Phase
ABP 494
(bevacizumab biosimilar)
Allergan
Parsippany, NJ
Amgen
Thousand Oaks, CA
metastatic colorectal cancer
Phase III
www.amgen.com
bavituximab
Tustin, CA
rectal cancer
(see also breast, lung, skin)
Phase I
BBI608
Boston Biomedical
Cambridge, MA
colorectal cancer
(see also breast, hematological, liver,
lung, ovarian, pancreatic, skin, stomach)
Phase III
colorectal cancer (combination therapy)
Phase III
Colorectal Cancer
Product Name
Sponsor
Indication
Development Phase
CEA cancer immunotherapy

(AVX701)
AlphaVax
Duke University
Durham, NC
late-stage colorectal cancer
Phase I/II
www.alphavax.com
CPX-1
(irinotecan/floxuridine liposomal)
Celator Pharmaceuticals
Ewing, NJ
colorectal cancer
Phase II
www.celatorpharma.com
CRLX101
(nanoparticle drug conjugate)
Cerulean Pharma
Cambridge, MA
non-metastatic rectal cancer

(see also kidney, ovarian)
Phase II
www.ceruleanrx.com
E7820
(integrin alpha2 inhibitor)
Eisai
Woodcliff Lake, NJ
colorectal cancer
Phase II
www.eisai.com
encapsulated cell therapy
Rogosin Institute
New York, NY
Metromedia Bio-Science
New York, NY

(see also pancreatic, prostate)
Phase II
www.rogosin.org
www.metromediabioscience.com
ensituximab
(neoplasm antigen inhibitor)
Precision Biologics
Dallas, TX
advanced colorectal cancer

Phase II
www.precision-biologics.com
ETBX-011
(vector cancer vaccine)
Etubics
Seattle, WA
colorectal cancer
Phase II
www.etubics.com

Nektar Therapeutics
San Francisco, CA
colorectal cancer (2nd-line)

(see also breast, ovarian)
Phase II completed
www.nektar.com
GEN 1
Celsion
Lawrenceville, NJ
colorectal cancer
(see also ovarian)
Phase II
www.celsion.com
imalumab (BAX 069)

(MIF inhibitor)
Baxalta
Cambridge, MA
Phase II
www.baxalta.com
Colorectal Cancer
Product Name
Sponsor
Indication
Development Phase
Imprime PGG
intravenous immunostimulant
Biothera
Eagan, MN
metastatic colorectal cancer (3rd-line)

(see also leukemia, lung, lymphoma, pancreatic)
Phase III
www.biothera.com
Jakafi
ruxolitinib
Incyte
Wilmington, DE
colorectal cancer
(see also breast, lung, pancreatic)
Phase II
www.incyte.com
labetuzumab-SN-38
(IMMU-130)
Immunomedics
Morris Plains, NJ
Phase II
MGD007
(gpA33/CD3 bispecific antibody)
MacroGenics
Rockville, MD
late-stage colorectal cancer
Phase I
www.macrogenics.com
MORAb-004
(CD248 antigen inhibitor)
Eisai
Woodcliff Lake, NJ
colorectal cancer
(see also sarcoma, skin)
Phase II
www.eisai.com
NK012
Nippon Kayaku
Tokyo, Japan
colorectal cancer
(see also breast, lung)
Phase II
OncoVAX
cancer immunotherapy
Vaccinogen
Frederick, MD
stage II colon cancer (Fast Track)
Phase III
www.vaccinogeninc.com
Opdivo
nivolumab
Princeton, NJ
microsatellite instability (MSI)-positive colon cancer

(see also bladder, brain, head/neck, hematological,
stomach, other)
Phase II
www.bms.com
polyclonal antibody stimulator

(G17DT)
Cancer Advances
Durham, NC
colorectal cancer
(see also pancreatic, stomach)
Phase II completed
www.canceradvancesinc.com
Reolysin
pelareorp
Oncolytics Biotech
Calgary, Canada

(see also brain, head/neck, lung, myeloma, ovarian,
other, pancreatic)
Phase I
Colorectal Cancer
Product Name
Sponsor
Indication
Development Phase
RG7221
(Ang2-VEGF mAb)
Genentech/Roche
Phase II
www.roche.com
RRx-001
(free radical stimulant)
EpicentRx
Mountain View, CA

(see also liver, lung, lymphoma, other)
Phase II
www.radiorx.com
SM04755
(Wnt inhibitor)
Samumed
San Diego, CA
advanced colorectal cancer

(see also liver, pancreatic, stomach)
Phase I
www.samumed.com
Stivarga
regorafenib
Bayer HealthCare Pharmaceuticals

Whippany, NJ
colorectal cancer with resected liver metastases

(see also kidney, liver)
Phase III
www.healthcare.bayer.com
Tafinlar
dabrafenib
Mekinist
trametinib
combination
East Hanover, NJ
BRAF V600-positive colorectal cancer

Phase I/II
www.novartis.com
TAS-102
(tipiracil/trifluridine)
Taiho Oncology
Princeton, NJ
colorectal cancer (Fast Track)

(see also stomach)
www.taihooncology.com
TRC105
San Diego, CA
colorectal cancer
(see also brain, breast, kidney, liver, lung,
sarcoma, other)
Phase I
Vargatef
nintedanib

Ridgefield, CT

Phase III
www.boeringer-ingelheim.com
Vectibix
panitumumab
Amgen
Thousand Oaks, CA
chemo refractory wild-type KRAS exon 2

Phase III
www.amgen.com
veliparib
(PARP inhibitor)
AbbVie
North Chicago, IL

(see also brain, breast, lung, skin)
Phase II
www.abbvie.com
Head and Neck Cancer

Product Name
Sponsor
Indication
Development Phase
Xilonix
IgG1k Mab
XBiotech
Austin, TX
metastatic colorectal cancer (Fast Track)
Phase III
www.xbiotech.com
Zelboraf
vemurafenib
Genentech/Roche
Daiichi Sankyo
Parsippany, NJ
BRAF mutation-positive metastatic

colorectal cancer (adjuvant)
(see also skin, other)
Phase III
www.roche.com
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
advanced head and neck cancer

(see also bladder, hematological, leukemia, lung,
lymphoma, myeloma, pancreatic)
Phase II
Ad-IL-24
(interleukin-24 gene therapy)
MultiVir
San Diego, CA
head and neck cancer
Phase II
www.multivir.com
ADXS-HPV
(immunotherapy vaccine)
Orphan Drug
Advaxis
Princeton, NJ
head and neck cancer (neoadjuvant)

(see also other)
Phase II
www.advaxis.com
metastatic head and neck cancer

Phase I/II
www.advaxis.com

non-alcohol formula
Teikoku Pharma USA

San Jose, CA

(see also breast, lung, prostate, stomach)
www.teikokuusa.com
GC4419
(superoxide dismutase modulator)
Galera Therapeutics
Malvern, PA
head and neck cancer (1st-line)
Phase I
www.galeratx.com
Gilotrif
afatinib

Ridgefield, CT
squamous cell carcinoma of the head and neck

(see also brain, lung)
Phase III

Product Name
Sponsor
Indication
Development Phase
GL-0817
Orphan Drug
Gliknik
Baltimore, MD
squamous cell cancer of the oral cavity
Phase II
www.gliknik.com
GL-ONC1
(oncolytic virus immunomodulator)
Genelux
San Diego, CA

(see also lung, other)
Phase I
www.genelux.com
HF10
Takara Bio
Shiga, Japan

(see also skin)
Phase I
www.takara-bio.com
INO-3112
head and neck cancer caused by HPV

types 16 and 18
(see also other)
Phase I/II
www.inovio.com
OncoSec Medical
San Diego, CA
metastatic head and neck cancer

Phase II
www.oncosec.com
IRX-2
(immunostimulant)
IRX Therapeutics
New York, NY
Phase II
www.irxtherapeutics.com
Keytruda
pembrolizumab
Merck
Kenilworth, NJ

(see also bladder, breast, lung, lymphoma,
stomach)
Phase III
www.merck.com
MEDI4736
(anti-PD-L1 mAb)
MedImmune
Gaithersburg, MD
squamous cell head and neck cancer (2nd-line)

(see also lung, solid tumors)
Phase III
www.medimmune.com
MGA271
(CD276 protein inhibitor)
Macrogenics
Rockville, MD
squamous cell cancer of the head and neck

Phase I
www.macrogenics.com
Multikine
leukocyte interleukin injection
CEL-SCI
Vienna, VA
head and neck cancer (1st-line)
Phase III
www.cel-sci.com

Product Name
Sponsor
Indication
Development Phase
motolimod
(TLR8 agonist immunotherapy)
VentiRx Pharmaceuticals
Seattle, WA

(see also ovarian)
Phase II
www.ventirx.com
Opdivo
nivolumab
Princeton, NJ
head and neck cancer (2nd-line)

(see also bladder, brain, colorectal, hematological,
stomach, other)
Phase III
www.bms.com
Reolysin
pelareorp
Oncolytics Biotech
Calgary, Canada
platinum-refractory head and neck cancer

(see also brain, colorectal, lung, myeloma,
ovarian, other, pancreatic)
Phase III
RM-1929
(EGFR antagonist)
Aspyrian Therapeutics
San Diego, CA
recurrent head and neck cancer
Phase I
www.aspyriantherapeutics.com
selinexor (oral)
(XPO1 antagonist)
Newton, MA
head and neck squamous cell carcinoma

(see also brain, hematological, leukemia, lymphoma,
myeloma, prostate, sarcoma, other)
Phase II
www.karyopharm.com
Hematological Malignancies
Product Name
Sponsor
Indication
Development Phase
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
B-cell malignancies (combination therapy)

(see also bladder, head/neck, leukemia, lung,
lymphoma, myeloma, pancreatic)
Phase I/II
ALT-803
Altor BioScience
Miramar, FL
hematological malignancies
(see also bladder, myeloma, skin)
Phase I/II
AMG 319
(PI3K-delta inhibitor)
Amgen
Thousand Oaks, CA
Phase I
www.amgen.com
Product Name
Sponsor
Indication
Development Phase
AMG 900
(aurora kinase inhibitor)
Amgen
Thousand Oaks, CA
Phase I
www.amgen.com
anti-LAG3
Princeton, NJ
Phase I
www.bms.com
APTO-253
(MTF-1 inhibitor)
Aptose Biosciences
San Diego, CA
relapsed/refractory blood cancers
Phase I
www.aptose.com
AR-42
(pan-DAC inhibitor)
Arno Therapeutics
Flemington, NJ
Phase I/II
www.arnothera.com
Aranesp
darbepoetin alfa
Amgen
Thousand Oaks, CA
low-risk myelodysplastic syndromes
Phase III
www.amgen.com
ASB183
East Hanover, NJ
Phase I
www.novartis.com
ASTX727
DNA methylation inhibitor/
nucleoside deaminase inhibitor)
Astex Pharmaceuticals
Pleasanton, CA
myelodysplastic syndromes
Phase I
www.astx.com
AZD9150
(STAT3 inhibitor)
AstraZeneca
Wilmington, DE
Isis Pharmaceuticals
Carlsbad, CA
Phase I
www.astrazeneca.com
www.isispharm.com
BBI608
Boston Biomedical
Cambridge, MA
(see also breast, colorectal, liver,
Phase I
Product Name
Sponsor
Indication
Development Phase
BB-MPI-03
(multi-peptide immunotherapy)
Benovus Bio
Atlanta, GA
(see also leukemia, myeloma)
Phase I
www.benovusbio.com
BI 836858

Ridgefield, CT
(see also leukemia)
Phase I/II
birinapant
(apoptosis stimulator)
TetraLogic Pharmaceuticals
Malvern, PA
(see also lymphoma, ovarian)
Phase II
www.tetralogicpharma.com
BP-100-1-01
(liposomal Grb 2)
Bio-Path Holdings
Houston, TX
(see also leukemia)
Phase I
www.biopathholdings.com
BPX-501
(T-cell replacement therapy)
Bellicum Pharmaceuticals
Houston, TX
adjunct T-cell therapy following bone marrow

transplantation in hematological malignancies
Phase I/II
www.bellicum.com
brontictuzumab
(NOTCH-1 inhibitor)
Redwood City, CA
Phase I
www.oncomed.com
BVD-523
(ERK 1/2 kinase inhibitor)
BioMed Valley Discoveries

Kansas City, MO
Phase I/II
www.biomed-valley.com
CB-839
(glutaminase inhibitor)
Calithera Biosciences
Phase I
www.calithera.com
CC-486
Celgene
Summit, NJ
myelodysplastic syndromes (lower risk)

(see also breast, leukemia, lung, lymphoma, other)
Phase III
www.celgene.com
post hypomethylating agent (HMA) failure in

Phase II
www.celgene.com
stem cell transplantation in hematological

malignancies
(see also lymphoma)
Phase II
www.celldex.com
CDX-301
(Fms-like tyrosine kinase 3 ligand)
Hampton, NJ
Product Name
Sponsor
Indication
Development Phase
CM-CS1
(NKG2D CAR T-cell therapy)
Celyad
Rochester, MN
Phase I
www.celyad.com
CPI-0610
(BET inhibitor)
Constellation Pharmaceuticals
Cambridge, MA
myelodysplastic syndromes,
myeloproliferative disorders
(see also leukemia, lymphoma, myeloma)
Phase I
www.constellationpharma.com
DCR-MYC
(c-myc inhibitor)
Dicerna Pharmaceuticals
Watertown, MA
(see also liver)
Phase I
www.dicerna.com
duvelisib
(PI3K inhibitor)
AbbVie
North Chicago, IL
Infinity Pharmaceuticals
Cambridge, MA
advanced hematological malignancies

(see also leukemia, lymphoma)
Phase I
www.abbvie.com
www.infi.com
E6201
(MEK-1/Flt3 dual inhibitor)
Strategia Therapeutics
Boston, MA
Phase I/II
www.strategiarx.com
entospletinib
(Syk inhibitor)
Gilead Sciences
Foster City, CA
Phase II
www.gilead.com
EMD Serono
Rockland, MA
(see also brain, lung, pancreatic, sarcoma, skin)
Phase I
www.emdserono.com
FF-10501
(cell differentiation stimulant)
Strategia Therapeutics
Boston, MA
FUJIFILM Pharmaceuticals USA
Boston, MA
Phase I/II
www.strategiarx.com
glasdegib (PF-04449913)
(SMO [smoothened] antagonist)
Pfizer
New York, NY
(see also leukemia)
Phase II
www.pfizer.com
Product Name
Sponsor
Indication
Development Phase
GS-4059
(BTK inhibitor)
Gilead Sciences
Foster City, CA
B-cell malignancies
Phase I
www.gilead.com
GS-9901
(PI3K delta inhibitor)
Gilead Sciences
Foster City, CA
Phase I
www.gilead.com
HDM201
(tumor suppressor protein
p53 modulator)
East Hanover, NJ
(see also sarcoma, solid tumors)
Phase I
www.novartis.com
HSC835
(stem cell therapy)
East Hanover, NJ
hematological malignancies in single

umbilical cord blood transplantation
Phase II
www.novartis.com
Ibrance
palbociclib
Pfizer
New York, NY
(see also breast)
Phase I
www.pfizer.com
idasanutlin
(MDM2 antagonist)
Genentech/Roche
Phase I
www.roche.com
imetelstat

Raritan, NJ
myelofibrosis
Phase II
www.janssenrnd.com
INCB40093
Incyte
Wilmington, DE
B-cell malignancies
Phase I/II
www.incyte.com
INCB52793
(JAK1 inhibitor)
Incyte
Wilmington, DE
Phase I/II
www.incyte.com
INCB54329
(BRD inhibitor)
Incyte
Wilmington, DE
Phase I
www.incyte.com
Product Name
Sponsor
Indication
Development Phase
JNJ-64052781
(CD19 antigen modulator)

Raritan, NJ
Phase I
www.janssenrnd.com
JTCR016
(T lymphocyte immunotherapy)
Juno Therapeutics
Seattle, WA
(see also leukemia)
Phase I/II
www.junotherapeutics.com
KB004
(EphA3 kinase inhibitor)
KaloBios Pharmaceuticals
EphA3-positive hematological
malignancies
Phase II
www.kalobios.com
KiroVAX-001
Kiromic
Houston, TX
Phase I
www.kiromic.com
luspatercept (ACE-536)
(TGF- protein super family
inhibitor)
Orphan Drug
Acceleron Pharma
Cambridge, MA
Celgene
Summit, NJ
Phase II
www.acceleronpharma.com
www.celgene.com
MEDI-551 + rituximab
(anti-CD19 mAb/anti-CD20 mAb)
MedImmune
Gaithersburg, MD
Phase I
www.medimmune.com
MK-8628
(BRD-2/3/4 inhibitor)
Merck
Kenilworth, NJ
Phase II
www.merck.com
mocetinostat
(HDAC inhibitor)
Orphan Drug
Mirati Therapeutics
San Diego, CA
(see also bladder, lymphoma)
Phase II
www.mirati.com
momelotinib
(JAK inhibitor)
Orphan Drug
Gilead Sciences
Foster City, CA
myelofibrosis
Phase III
www.gilead.com
Product Name
Sponsor
Indication
Development Phase
MRX34
(liposome-encapsulated
miR-34 mimic)
Mirna Therapeutics
Austin, TX
(see also liver)
Phase I
www.mirnarx.com
NiCord
cord blood stem cell therapy
Orphan Drug
Gamida Cell
Jerusalem, Israel
Phase I/II
www.gamida-cell.com
Opdivo
nivolumab
Princeton, NJ
(see also bladder, brain, colorectal, head/neck, kidney,
liver, lung, lymphoma, skin, solid tumors, stomach, other)
Phase I
www.bms.com
oprozomib
Orphan Drug
Onyx Pharmaceuticals
Waldenstrom's macroglobulinemia (monotherapy)

(see also myeloma, solid tumors)
Phase II
www.onyx.com
Phase I
www.onyx.com
OTX015
(BET inhibitor)
Merck
Kenilworth, NJ
Phase I
ww.merck.com
OXi4503
(vascular disrupting agent)
OxiGENE
(see also leukemia)
Phase I
www.oxigene.com
PAC-1
(procaspase activating compound-1)
Vanquish Oncology
Champaign, IL
Phase I
www.vanquishoncology.com
pacritinib
(JAK2/FLT3 dual inhibitor)
Baxalta
Cambridge, MA
myelofibrosis (Fast Track)

(see also leukemia)
Phase III
www.Baxalta.com
Product Name
Sponsor
Indication
Development Phase
PIM447
(proto oncogene protein c
pim-1 inhibitor)
East Hanover, NJ
Phase I
www.novartis.com
POL6326
Polyphor
Allschwil, Switzerland
stem cell mobilization in hematological malignancies

(see also breast)
Phase I
www.polyphor.com
pracinostat
(HDAC inhibitor)
MEI Pharma
San Diego, CA
myelodysplastic syndromes (1st-line),

refractory myelodysplastic syndromes
(see also leukemia)
Phase II
www.meipharma.com
PRM-151
(rhPTX-1 for injection)
Orphan Drug
Promedior
Lexington, MA
myelofibrosis (Fast Track)
Phase II
www.promedior.com
Promacta
eltrombopag
East Hanover, NJ
Phase II
www.novartis.com
Revlimid
lenalidomide
Orphan Drug
Celgene
Summit, NJ
myelodysplastic syndromes (non-deletion 5q)

(see also leukemia, lymphoma, myeloma)
Phase III
www.celgene.com
rexlemestrocel-L
(allogeneic autologous
mesenchymal precursor cells)
Orphan Drug
Mesoblast
New York, NY
for bone marrow regeneration in patients with

hematological malignancies undergoing bone
marrow transplantation
Phase III
www.mesoblast.com
Product Name
rigosertib
(PI3K/Plk1 inhibitor)
Orphan Drug
Sponsor
Indication
Development Phase
Onconova Therapeutics
Newtown, PA
post-HMR high-risk myelodysplastic syndromes

(see also leukemia)
Phase III
www.onconova.com
high-risk myelodysplastic syndromes

(1st-line) (combination therapy),
low-risk myelodysplastic syndromes (1st-line)
Phase II
www.onconova.com
RP-323
(tetradecanoylphorbol acetate)
Rich Pharmaceuticals
Beverly Hills, CA
(see also leukemia)
Phase II
www.richpharmaceuticals.com
sapacitabine
(DNA-directed DNA polymerase
inhibitor)
Orphan Drug
Cyclacel Pharmaceuticals
Berkeley Heights, NJ
(see also leukemia, lung)
Phase II
www.cyclacel.com
selinexor (oral)
(XPO1 antagonist)
Newton, MA
Richter's transformation
(see also brain, head/neck, leukemia, lymphoma,
Phase III
www.karyopharm.com
SGI-110
(DNMT inhibitor)
Pleasanton, CA
(see also leukemia, liver, ovarian)
Phase II
www.astx.com
SL-401
(IL-3R inhibitor)
New York, NY
blastic plasmacytoid dendritic cell neoplasm,

advanced high risk myeloproliferative neoplasm
(see also leukemia)
Phase I/II
www.stemline.com
StemEx
carlecortemcel-L
Gamida Cell-Teva Joint Venture

Jerusalem, Israel
(Fast Track)
Phase III
www.gamida-cell.com
TAK-659
(SYK kinase inhibitor)
Takeda Oncology
Cambridge, MA
Phase I
Product Name
Sponsor
Indication
Development Phase
TEN-010
(BET inhibitor)
Tensha Therapeutics
Cambridge, MA
Phase I
www.tenshatherapeutics.com
TGR-1202
(PI3K inhibitor)
TG Therapeutics
New York, NY
Phase I
www.tgtherapeutics.com
tosedostat
(aminopeptidase inhibitor)
CTI BioPharma
Seattle, WA
(see also leukemia)
Phase II
www.ctibiopharma.com
TZ101
(human recombinant enzyme)
Targazyme
San Antonio, TX
cord blood stem cell transplantation

in hematological malignancies
Phase I/II
www.targazyme.com
ulocuplumab
(anti-CXCR4)
Princeton, NJ
Phase I
www.bms.com
urelumab
Princeton, NJ
Phase I
www.bms.com
urelumab +
Opdivo nivolumab
Princeton, NJ
Phase I
www.bms.com
varlilumab
Hampton, NJ
(see also kidney, skin)
Phase I
www.celldex.com
venetoclax
(Bcl-2 inhibitor)
AbbVie
North Chicago, IL
Genentech/Roche
Phase I
www.abbvie.com
www.roche.com
WT-1 cancer vaccine
SELLAS Life Sciences

Zug, Switzerland
Phase II
www.sellaslifesciences.com
Product Name
Sponsor
Indication
Development Phase
WT2725
Sunovion Pharmaceuticals
Marlborough, MA
Phase I
www.sunovion.com
Kidney Cancer
Product Name
Sponsor
Indication
Development Phase
Argos Therapeutics
Durham, NC
metastatic renal cell carcinoma

(combination therapy) (Fast Track)
Phase III
www.argostherapeutics.com

(monotherapy)
Phase II
www.argostherapeutics.com
AGS-003
(personalized dendritic
cell-based vaccine)
AGS-16C3F
Agensys
Santa Monica, CA
Astellas Pharma
Tokyo, Japan
kidney cancer
Phase I
www.agensys.com
www.astellas.com
AMG 172
Amgen
Thousand Oaks, CA
kidney cancer
Phase I
www.amgen.com
Archexin
Akt1 inhibitor
Orphan Drug
Rexahn Pharmaceuticals
Rockville, MD
Phase II
www.rexahn.com
BNC105
Bionomics
Thebarton, Australia
renal cell carcinoma

(see also ovarian)
Phase II
www.bionomics.com.au
Cometriq
cabozantinib
Exelixis
renal cell carcinoma (Fast Track)

(see also brain, liver)
Phase III
www.exelixis.com
Kidney Cancer
Product Name
Sponsor
Indication
Development Phase
CRLX101
Cerulean Pharma
Cambridge, MA
relapsed renal cell carcinoma

Phase II
www.ceruleanrx.com
dalantercept
(ALK1 antagonist)
Acceleron Pharma
Cambridge, MA

(see also liver)
Phase II
HyperAcute Renal
renal cancer immunotherapy vaccine
NewLink Genetics
Ames, IA
metastatic renal cancer
Phase I
IMA901
(multiple tumor-associated
peptides)
immatics Biotechnologies
Tuebingen, Germany
renal cancer
Phase III
www.immatics.com
Inlyta
axitinib
Orphan Drug
Pfizer
New York, NY

Phase III
www.pfizer.com
Lenvima
lenvatinib
Eisai
Woodcliff Lake, NJ

(see also liver, lung, skin, other, solid tumors)
Phase I/II
www.eisai.com
LY2510924
(CXCR4 peptide antagonist)
Eli Lilly
Indianapolis, IN
clear-cell renal cell carcinoma

(see also lung)
Phase II
www.lilly.com
Nexavar
sorafenib

Whippany, NJ
renal cell carcinoma (adjuvant)

(see also other)
Phase III
OBP-801
(HDAC inhibitor)
Oncolys BioPharma
Tokyo, Japan
recurrent renal cancer
Phase I
www.oncolys.com
Opdivo
nivolumab
Princeton, NJ
renal cell carcinoma (2nd/3rd-line)

(see also bladder, brain, colorectal, head/neck,
hematological, liver, lung, lymphoma, skin,
solid tumors, stomach, other)
Phase III
www.bms.com
Kidney Cancer
Product Name
Sponsor
Indication
Development Phase
Opdivo nivolumab +
Yervoy ipilimumab
Princeton, NJ
renal cell carcinoma (1st-line)

(see also lung, skin, solid tumors)
Phase III
www.bms.com
pexastimogene devacirepvec
(genetically-engineered oncolytic
vaccinia virus)
SillaJen Biotherapeutics
San Francisco, CA
treatment refractory kidney cancer

(see also liver)
Phase II
www.sillajen.com
PT-2385
(HIF-2 inhibitor)
Peloton Therapeutics
Dallas, TX
clear cell renal cell carcinoma
Phase I
www.pelotontherapeutics.com
RG7446
(anti-PD-L1 mAb)
Genentech/Roche

(see also bladder, breast, lung, lymphoma, skin)
Phase III
www.roche.com
savolitinib/volitinib
(MET tyrosine kinase inhibitor)
AstraZeneca
Wilmington, DE
papillary renal cell carcinoma
Phase II
www.astrazeneca.com
SGN-CD70A
Seattle Genetics
Bothell, WA

(see also lymphoma)
Phase I
sonepcizumab
(anti-sphingosine-1-phosphate
mAb)
Lpath
San Diego, CA
Phase II
www.lpath.com
Stivarga
regorafenib

Whippany, NJ

(see also colorectal, liver)
Phase II
Sutent
sunitinib
Pfizer
New York, NY
Phase III
www.pfizer.com
TAK-228
Takeda Oncology
Cambridge, MA
renal cancer
(see also breast, other)
Phase II
Kidney Cancer
Product Name
Sponsor
Indication
Development Phase
TRC105
San Diego, CA

(see also brain, breast, colorectal, liver, lung,
sarcoma, other)
Phase II
TVI-Kidney-1
(personalized cancer
immunotherapy)
TVAX Biomedical
Lenexa, KS
kidney cancer
(see also brain)
Phase II
www.tvaxbiomedical.com
varlilumab
Hampton, NJ
metastatic clear cell renal cell carcinoma

(see also hematological, skin)
Phase I/II
www.celldex.com
Votrient
pazopanib
East Hanover, NJ
Phase III
www.novartis.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
6 peptide
(CD44 antigen stimulant)
Angstrom Pharmaceuticals
Solana Beach, CA
chronic lymphocytic leukemia (CLL),

small lymphocytic leukemia
Phase II
www.angstrominc.com
ABL001
(Bcr-abl tyrosine kinase inhibitor)
East Hanover, NJ
chromic myeloid leukemia (CML)
Phase I
www.novartis.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
CLL
(see also bladder, head/neck, hematological,
lung, lymphoma, myeloma, pancreatic)
Phase III
relapsed/refractory and treatment nave

deletion 17p CLL
Phase II
CLL (combination therapy)
Phase I
ACP-319
(Btk inhibitor)
Acerta Pharma
San Carlos, CA

(see also lymphoma)
Phase I/II
AG-120
(IDH1 inhibitor)
Cambridge, MA
Celgene
Summit, NJ
acute myeloid leukemia (AML)

Phase I
www.agios.com
www.celgene.com
AG-221
(IDH2 inhibitor)
Orphan Drug
Cambridge, MA
Celgene
Summit, NJ
AML
Phase I
www.agios.com
www.celgene.com
alvocidib
Orphan Drug
Tolero Pharmaceuticals
Lehi, UT
AML (1st-line)
Phase III
www.toleropharmaceuticals.com
relapsed/refractory AML
Phase II
www.toleropharmaceuticals.com
AML
(see also myeloma, skin, solid tumors)
Phase I
www.amgen.com
AMG 232
(MDM2 inhibitor)
Amgen
Thousand Oaks, CA
Leukemia
Product Name
Sponsor
Indication
Development Phase
Arzerra
ofatumumab
Orphan Drug
East Hanover, NJ
CLL (maintenance therapy), CLL (relapse)

(see also lymphoma)
Phase III
www.novartis.com
ASP2215
(FLT3/AXL inhibitor)
Astellas Pharma US
Northbrook, IL
AML
(see also lung)
Phase III
www.astellas.com
AST-VAC1
(telomerase-based cancer vaccine)
Asterias Biotherapeutics
Menlo Park, CA
AML
Phase II completed
www.asterias.com
ATTCK20
(viral-ACTR+anti-CD20)
Unum Therapeutics
Cambridge, MA
CLL
(see also lymphoma)
Phase I
www.unumrx.com
BAY1143572

Whippany, NJ
acute leukemia
(see also other)
Phase I
BB-MPI-03
Benovus Bio
Atlanta, GA
AML
(see also hematological, myeloma)
Phase I
www.benovusbio.com
bendamustine ready-to-dilute
liquid formulation
Orphan Drug
Eagle Pharmaceuticals
Woodcliff Lake, NJ
CLL
(see also lymphoma, solid tumors)
www.eagleus.com
BI 836826

Ridgefield, CT
CLL
Phase I
BI 836858

Ridgefield, CT
Phase I
BL-8040
Orphan Drug
BioLineRx
Jerusalem, Israel
AML (combination therapy)
Phase II
www.biolinerx.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
Blincyto
blinatumomab
Amgen
Thousand Oaks, CA
relapsed/refractory acute lymphoblastic

leukemia (ALL) in adults
(see also lymphoma)
Phase III
www.amgen.com
relapsed/refractory Philadelphia
chromosome positive (Ph+) ALL in adults,
minimal residual ALL in adults
Phase II
www.amgen.com
Bosulif
bosutinib
Orphan Drug
Pfizer
New York, NY
chronic myeloid leukemia (CML) (1st-line)
Phase III
www.pfizer.com
BP-100-1-01
(liposomal Grb 2)
Orphan Drug
Bio-Path Holdings
Houston, TX
AML
Phase II
ALL, CML
Phase I
BVD-523

Kansas City, MO
AML
(see also hematological, solid tumors)
Phase I/II
calaspargase pegol
Orphan Drug
Baxalta
Cambridge, MA
ALL
Phase III
www.baxalta.com
CC-122
Celgene
Summit, NJ
CLL
(see also brain, liver, lymphoma)
Phase I
www.celgene.com
CC-292
(Btk inhibitor)
Celgene
Summit, NJ

(see also lymphoma)
Phase I
www.celgene.com
CC-486
Celgene
Summit, NJ
post-induction AML maintenance

(see also breast, hematological, lung,
lymphoma, other)
Phase III
www.celgene.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
cerdulatinib
(dual Syk-JAK inhibitor)
Portola Pharmaceuticals
CLL
(see also lymphoma)
Phase II
www.portola.com
CNDO-109
(natural killer cell stimulant)
Orphan Drug
Fortress Biotech
New York, NY
AML
Phase I/II
www.fortressbiotech.com
CPI-0610
(BET inhibitor)
Cambridge, MA
leukemia
(see also hematological, lymphoma, myeloma)
Phase I
CPX-351
(cytarabine/daunorubicin)
Orphan Drug
Celator Pharmaceuticals
Ewing, NJ
acute AML (Fast Track)
Phase II
www.celatorpharma.com
crenolanib
(PDGFR inhibitor)
Dallas, TX
(see also brain, lung, stomach)
Phase III
www.arogpharma.com
newly-diagnosed AML, maintenance therapy

after bone marrow transplantation in AML
Phase II
www.arogpharma.com
AML (combination therapy)
Phase I
www.arogpharma.com
CTL019
(CAR immunotherapy)
East Hanover, NJ
ALL (Breakthrough Therapy)

(see also lymphoma)
Phase II
www.novartis.com
CWP232291
(Wnt signaling pathway inhibitor)
JW Pharmaceutical
Seoul, South Korea
AML
Phase I
CX-01
(O-desulfated heparin intravenous)
Cantex Pharmaceuticals
Weston, FL
AML
Phase II
www.cantex.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
DFP-10917
(cell cycle inhibitor)
Delta-Fly Pharma
Tokushima, Japan
ALL, AML
Phase I/II
duvelisib
(PI3K inhibitor)
Orphan Drug
AbbVie
North Chicago, IL
Cambridge, MA
relapsed/refractory CLL
Phase III
www.abbvie.com
www.infi.com
relapsed/refractory CLL previously

treated with a BTK inhibitor therapy
Phase I
www.abbvie.com
www.infi.com
EPZ-5676
(DOT1L inhibitor)
Orphan Drug
Celgene
Summit, NJ
Epizyme
Cambridge, MA
ALL and AML with altered MLL gene
Phase I
www.celgene.com
www.epizyme.com
ERY-ASP
(asparaginase pegol)
Orphan Drug
ERYTECH Pharma
Lyon, France
ALL (adults)
Phase I/II
www.erytech.com
ganetespib
(Hsp90 inhibitor)
Lexington, MA
AML
(see also breast, lung, ovarian)
Phase II
www.syntapharma.com
glasdegib (PF-04449913)
(SMO [smoothened] antagonist)
Pfizer
New York, NY
AML
Phase II
www.pfizer.com
GMI-1271
(E-selectin antagonist)
GlycoMimetics
Gaithersburg, MD
AML
Phase I
www.glycomimetics.com
GO-203-2c
(MUC1 inhibitor)
Genus Oncology
Vernon Hills, IL
Phase I/II
www.genusoncology.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
HSV-Tk
(thymidine kinase cell therapy)
Orphan Drug
MolMed
Milan, Italy
high risk acute leukemia
Phase III
www.molmed.com
Iclusig
ponatinib
Orphan Drug
ARAID Pharmaceuticals
Cambridge, MA
Philadelphia chromosome-positive ALL

(Ph+ ALL)
(see also stomach)
Phase II
www.ariad.com
IGN523
Igenica
Burlingame, CA
AML
Phase I
www.igenica.com
Imbruvica
ibrutinib
Orphan Drug

Raritan, NJ
relapsed/refractory CLL (combination therapy),

treatment nave CLL, CLL (1st-line) (combination therapy)
(see also lymphoma)
Phase III
www.janssenrnd.com
IMGN529
ImmunoGen
Waltham, MA
CLL
(see also lymphoma)
Phase I
www.immunogen.com
IMMU-114
(humanized anti-HLA-DR)
Immunomedics
Morris Plains, NJ
CLL
(see also lymphoma)
Phase I
Imprime PGG
Biothera
Eagan, MN
high-risk CLL (1st-line)

(see also colorectal, lung, lymphoma, pancreatic)
Phase II
www.biothera.com
inotuzumab ozogamicin
(CD22-targeted cytotoxic agent)
Orphan Drug
Pfizer
New York, NY
acute lymphoblastic leukemia (ALL)
Phase III
www.pfizer.com
Iomab-B
BC8-I-131 construct
Actinium Pharmaceuticals
New York, NY
hematopoietic stem cell transplantation in ALL
Phase II
www.actiniumpharma.com
JCAR014
Juno Therapeutics
Seattle, WA
acute ALL, refractory CLL

(see also lymphoma)
Phase I/II
Leukemia
Product Name
Sponsor
Indication
Development Phase
JCAR015
Orphan Drug
Juno Therapeutics
Seattle, WA
B-cell ALL
Phase I/II
JCAR017
Juno Therapeutics
Seattle, WA
leukemia
Phase I/II
JCAR018
Juno Therapeutics
Seattle, WA
ALL
(see also lymphoma)
Phase I
JNJ-56022473
(anti-CD123 mAb)
CSL
Victoria, Australia
Raritan, NJ
AML
Phase I
www.janssenrnd.com
JTCR016
Juno Therapeutics
Seattle, WA
ALL, CML
Phase I/II
KX01
(non-ATP competitive Sre
kinase inhibitor)
Buffalo, NY
AML
Phase I completed
www.kinexpharma.com
Kyprolis
carfilzomib
pediatric ALL (combination therapy)

Phase I/II
www.onyx.com
lintuzumab Ac-225
Actinium Pharmaceuticals
New York, NY
AML (1st-line)
Phase I/II
www.actiniumpharma.com
Marqibo
vinCRIStine sulfate LIPOSOME
injection
Orphan Drug
Henderson, NV
elderly Ph-negative ALL (1st-line)

(Fast Track)
(see also lymphoma)
Phase III
www.sppirx.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
MEDI-551
(anti-CD19 mAb)
MedImmune
Gaithersburg, MD
CLL
(see also lymphoma)
Phase II
www.medimmune.com
MGD006
(CD123/CD3 bispecific antibody)
MacoGenics
Rockville, MD
AML
Phase I
www.macrogenics.com
milatuzumab-doxorubicin conjugate
Immunomedics
Morris Plains, NJ
ALL
(see also lymphoma)
Phase I/II
mogamulizumab
(anti-CCR4 antibody)
Orphan Drug
Kyowa Hakko Kirin

Princeton, NJ
adult T-cell leukemia-lymphoma

(see also lymphoma)
Phase II
www.kyowa-kirin.com
MOR208
Orphan Drug
MorphoSys
Martinsried, Germany
ALL, CLL
(see also lymphoma)
Phase II
www.morphosys.com
moxetumomab pasudotox
(anti-CD22 recombinant
immunotoxin)
MedImmune
Gaithersburg, MD
hairy cell leukemia
Phase III
www.medimmune.com
ALL (pediatric)
Phase II
www.medimmune.com
Odomzo
sonidegib
East Hanover, NJ
acute leukemia
(see also brain)
Phase II
www.novartis.com
Oncaspar
pegaspargase
Orphan Drug
Baxalta
Cambridge, MA
lyophilized ALL
Phase III
www.baxalta.com
AML
Phase II
www.baxalta.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
Oncoquest-CLL
personalized cancer vaccine
XEME Biopharma
Monmouth Junction, NJ
CLL (1st-line)
Phase I
www.xemebiopharma.com
Opdivo nivolumab +
Sprycel dasatinib
Princeton, NJ
CML
Phase I
www.bms.com
otlertuzumab
Emergent BioSolutions
Gaithersburg, MD
CLL
Phase II
www.emergentbiosolutions.com
OVI-123 (cordycepin)
(RNA synthesis inhibitor)
Orphan Drug
OncoVista Innovative Therapies

San Antonio, TX
TdT-positive leukemia
Phase I/II
www.oncovista.com
OXi4503
Orphan Drug
OxiGENE
refractory AML
Phase I
www.oxigene.com
pacritinib
(JAK2/FLT3 dual inhibitor)
Baxalta
Cambridge, MA
AML
Phase I
www.baxalta.com
PIM447
pim-1 inhibitor)
East Hanover, NJ
AML
Phase I
www.novartis.com
PKC412
(signal transduction inhibitor)
Orphan Drug
East Hanover, NJ
AML
Phase III
www.novartis.com
PM01183
Pharma Mar
Madrid, Spain
acute leukemia
Phase II
www.pharmamar.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
pracinostat
(HDAC inhibitor)
Orphan Drug
MEI Pharma
San Diego, CA
AML (1st-line)
Phase II
www.meipharma.com
PRI-724
(CBP/beta catenin inhibitor)
PRISM Pharma
Tokyo, Japan
AML, CML
Phase I/II
www.prismbiolabs.com
Qinprezzo
vosaroxin
Orphan Drug
Sunesis Pharmaceuticals
relapsed/refractory AML (Fast Track)
Phase III
www.sunesis.com
quizartinib
(FLT3 inhibitor)
Orphan Drug
Ambit Biosciences
San Diego, CA
relapsed/refractory AML (Fast Track)
Phase III
www.ambitbio.com
REGN1979
(CD20/CD3 antigen inhibitor)
Regeneron Pharmaceuticals
Tarrytown, NY
CLL
(see also lymphoma)
Phase I
www.regeneron.com
Revlimid
lenalidomide
Orphan Drug
Celgene
Summit, NJ
CLL maintenance (2nd-line)

(see also hematological, lymphoma, myeloma)
Phase III
www.celgene.com
RG6016
(LSD1 inhibitor
Genentech/Roche
AML
Phase I
www.roche.com
RG7775
(proto-oncogene protein c
MDM2 inhibitor)
Genentech/Roche
AML
Phase I
www.roche.com
rigosertib
(PI3K/Plk1 inhibitor)
Orphan Drug
Newtown, PA
high-risk AML (1st-line)

Phase III
www.onconova.com
Leukemia
Product Name
Sponsor
Indication
Development Phase
RP-323
(tetradecanoylphorbol acetate)
Rich Pharmaceuticals
Beverly Hills, CA
AML
Phase II
www.richpharmaceuticals.com
sapacitabine
inhibitor)
Orphan Drug
AML
(see also hematological, lung)
Phase III
www.cyclacel.com
selinexor (oral)
(XPO1 antagonist)
Orphan Drug
Newton, MA
AML
(see also brain, head/neck, hematological, lymphoma,
Phase III
www.karyopharm.com
SG2000
(DNA cross linking agent)
Spirogen
London, England
AML, CLL
Phase I/II
SGI-110
(DNMT inhibitor)
Pleasanton, CA
AML
(see also hematological, liver, ovarian)
Phase III
www.astx.com
SGN-CD19A
Seattle Genetics
Bothell, WA
relapsed ALL
(see also lymphoma)
Phase I
SGN-CD33A
Seattle Genetics
Bothell, WA
AML (1st-line), relapsed AML
Phase I
SL-401
(IL-3R inhibitor)
New York, NY
Phase I/II
www.stemline.com
Sprycel
dasatinib
Princeton, NJ
leukemia (pediatric)
Phase II
www.bms.com
TAK-924
(NEDD 8 activating enzyme
inhibitor)
Takeda Oncology
Cambridge, MA
AML
Phase I
Leukemia
Product Name
Tasigna
nilotinib
Orphan Drug
Sponsor
Indication
Development Phase
East Hanover, NJ
CML treatment free remission
Phase III
www.novartis.com
ALL (pediatric), CML (pediatric)
Phase I/II
www.novartis.com
TEN-010
(BET inhibitor)
Tensha Therapeutics
Cambridge, MA
AML
Phase I
TG02
(CDK inhibitor)
Tragara Pharmaceuticals
Carlsbad, CA
refractory AML, relapsed CLL

(see also myeloma)
Phase I
www.tragarapharma.com
TG-1101
(anti-CD20 mAb)
Orphan Drug
TG Therapeutics
New York, NY

(see also lymphoma)
Phase III
CLL (monotherapy)
Phase I/II
tosedostat
(aminopeptidase inhibitor)
Orphan Drug
CTI BioPharma
Seattle, WA
AML
Phase II
venetoclax
(Bcl-2 inhibitor)
AbbVie
North Chicago, IL
Genentech/Roche
CLL (1st-line), relapsed/refractory CLL

(combination therapy) (Breakthrough Therapy)
Phase III
www.abbvie.com
www.roche.com
AML, relapsed/refractory 17p-deletion CLL
Phase II
www.abbvie.com
www.roche.com
AML (Breakthrough Therapy)
Phase III
www.boehringer-ingelehim.com
volasertib
(PLK-1 antagonist)
Orphan Drug

Ridgefield, CT
Leukemia
Product Name
Sponsor
Indication
Development Phase
WT1-CTL
(immunostimulant)
Atara Biotherapeutics
AML
(see also myeloma)
Phase I
www.atarabio.com
Zydelig
idelalisib
Gilead Sciences
Foster City, CA
CLL (1st-line), relapsed/refractory CLL

(see also lymphoma)
Phase III
www.gilead.com
Liver Cancer
Product Name
Sponsor
Indication
Development Phase
AD-p53 gene therapy
MultiVir
San Diego, CA
liver metastases from colorectal cancer
Phase I
www.multivir.com
ADI-PEG 20
Orphan Drug
San Diego, CA
hepatocellular carcinoma
(see also breast, lung, ovarian, pancreatic,
skin, stomach)
Phase III
BA-003
(doxorubicin nanoparticles)
Orphan Drug
Onxeo
Paris, France
hepatocellular carcinoma (2nd-line)
Phase III
www.onxeo.com
BBI503
(cancer stemness kinase inhibitor)
Boston Biomedical
Cambridge, MA
(see also ovarian)
Phase I
BBI608
Boston Biomedical
Cambridge, MA
(see also breast, colorectal, hematological,
Phase I
CC-122
(PPM Pleiotropic pathway modifier)
Celgene
Summit, NJ
(see also brain, leukemia, lymphoma)
Phase I
www.celgene.com
CF102
(A3 adenosine receptor agonist)
Can-Fite BioPharma
Petach Tikva, Israel
metastatic hepatocellular carcinoma
Phase II
www.canfite.com
Liver Cancer
Product Name
Sponsor
Indication
Development Phase
Cometriq
cabozantinib
Exelixis
advanced hepatocellular carcinoma

(see also brain, kidney)
Phase III
www.exelixis.com
CX-4945
(CK2 inhibitor)
Senhwa Biosciences
San Diego, CA
cholangiocarcinoma (combination therapy)
Phase I/II
www.senhwabiosciences.com
Cyramza
ramucirumab
Orphan Drug
Eli Lilly
Indianapolis, IN
(see also bladder, lung, stomach)
Phase III
www.lilly.com
dalantercept
(ALK1 antagonist)
Acceleron Pharma
Cambridge, MA
(see also kidney)
Phase I/II
DCR-MYC
(c-myc inhibitor)
Dicerna Pharmaceuticals
Watertown, MA
Phase I/II
www.dicerna.com
galunisertib
Eli Lilly
Indianapolis, IN
metastatic hepatocellular carcinoma

(see also brain, pancreatic)
Phase II
www.lilly.com
ipafricept
(Wnt protein inhibitor)

Whippany, NJ
Redwood City, CA
(see also ovarian, pancreatic)
Phase I
www.oncomed.com
Lenvima
lenvatinib
Orphan Drug
Eisai
Woodcliff Lake, NJ
(see also kidney, lung, skin, other,
solid tumors)
Phase III
www.eisai.com
melphalan drug delivery system

(drug-device combination)
Orphan Drug
Delcath Systems
New York, NY
secondary liver cancer arising from

metastatic ocular melanoma
www.delcath.com
hepatocellular carcinoma,
intrahepatic cholangiocarcinoma
Phase II
www.delcath.com
Liver Cancer
Product Name
Sponsor
Indication
Development Phase
mipsagargin
(thapsigargin analogue)
Orphan Drug
GenSpera
San Antonio, TX
(see also brain)
Phase II
www.genspera.com
MRX34
(liposome-encapsulated
miR-34 mimic)
Mirna Therapeutics
Austin, TX
unresectable primary liver cancer,

liver metastases from other solid tumors
Phase I
www.mirnarx.com
oncolytic virus
(genetically engineered strain
of vesicular stomatitis virus)
Omnis Pharmaceuticals
Rochester, MN
hepatocellular carcinoma, liver metastases
Phase I
www.omnispharma.com
Opdivo
nivolumab
Princeton, NJ
hematological, kidney, lung, lymphoma, skin,
Phase I
www.bms.com
pexastimogene devacirepvec
(genetically-engineered oncolytic
vaccinia virus)
Orphan Drug
SillaJen Biotherapeutics
San Francisco, CA
advanced primary liver cancer

(see also kidney)
Phase II
www.sillajen.com
PDT with Photofrin

porfimer sodium
Orphan Drug
Concordia Laboratories
Toronto, Canada
Pinnacle Biologics
Chicago, IL
unresectable advanced perihilar

cholangiocarcinoma Bismuth type III/IV
Phase III
www.pinnaclebiologics.com
PV-10
(rose bengal disodium)
Orphan Drug
Provectus Biopharmaceuticals
Knoxville, TN
hepatocellular carcinoma, liver metastases

(see also skin)
Phase I
www.pvct.com
RG7686
(glypican-3 mAb)
Genentech/Roche
Phase II
www.roche.com
Liver Cancer
Product Name
Sponsor
Indication
Development Phase
RRx-001
EpicentRx
Mountain View, CA
cholangiocarcinoma
(see also colorectal, lung, lymphoma, other)
Phase II
www.radiorx.com
SGI-110
(DNMT inhibitor)
Pleasanton, CA
(see also hematological, leukemia, ovarian)
Phase II
www.astx.com
SM04755
(Wnt inhibitor)
Samumed
San Diego, CA
advanced liver cancer

(see also colorectal, pancreatic, stomach)
Phase I
www.samumed.com
SPI-1620
(endothelin B receptor agonist)
Henderson, NV
biliary cancer
(see also lung)
Phase II
www.sppirx.com
Stivarga
regorafenib

Whippany, NJ
hepatocellular carcinoma (2nd-line)

(see also colorectal, kidney)
Phase III
tepotinib
(c-Met kinase inhibitor)
EMD Serono
Rockland, MA
hepatocellular cancer
(see also lung)
Phase II
www.emdserono.com
ThermoDox
doxorubicin liposomal
Orphan Drug
Celsion
Lawrenceville, NJ
inoperable/unresectable hepatocellular
carcinoma (1st-line) (Fast Track)
(see also breast)
Phase III
www.celsion.com
liver metastases
Phase II
www.celsion.com
tivantinib
(c-Met inhibitor)
ArQule
Woburn, MA
Daiichi Sankyo
Parsippany, NJ
Phase III
www.arqule.com
www.dsi.com
TRC105
San Diego, CA
(see also brain, breast, colorectal, kidney, lung,
sarcoma, other)
Phase I
Liver Cancer
Product Name
Sponsor
Indication
Development Phase
VT-122
Vicus Therapeutics
Morristown, NJ
(see also prostate)
Phase II
www.vicustherapeutics.com
Xtandi
enzalutamide
Astellas Pharma US
Northbrook, IL
Medivation
San Francisco, CA
Phase II
www.astellas.com
www.medivation.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
abemaciclib
(CDK 4/6 inhibitor)
Eli Lilly
Indianapolis, IN
non-small-cell lung cancer (NSCLC)

(see also breast, lymphoma)
Phase III
www.lilly.com
ABP 215
Allergan
Parsippany, NJ
Amgen
Thousand Oaks, CA
advanced NSCLC
Phase III
www.amgen.com
AC0100MA
(epidermal growth factor receptor
inhibitor)
ACEA Biosciences
San Diego, CA
NSCLC
Phase I/II
www.aceabio.com
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
advanced NSCLC
leukemia, lymphoma, myeloma, pancreatic)
Phase II
ADI-PEG 20
Orphan Drug
San Diego, CA
malignant pleural mesothelioma, NSCLC

(see also breast, liver, ovarian, pancreatic,
skin, stomach)
Phase I
Afinitor
everolimus
East Hanover, NJ
neuroendocrine lung tumors

(see also lymphoma, stomach)
Phase III
www.novartis.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
aldoxorubicin
Orphan Drug
CytRx
Los Angeles, CA
small-cell lung cancer (SCLC)

(see also brain, sarcoma)
Phase II
www.cytrx.com
alectinib
(ALK inhibitor)
Genentech/Roche
ALK-positive NSCLC (1st-line)

(Breakthrough Therapy)
Phase III
www.roche.com
ALK-positive NSCLC (2nd-line)

Phase II
www.roche.com
alisertib
(aurora A kinase inhibitor)
Takeda Oncology
Cambridge, MA
SCLC
Phase II
anti-fucosyl-GM1
Princeton, NJ
lung cancer
Phase I
www.bms.com
antroquinonol
Golden Biotechnology
New Taipei City, Taiwan
NSCLC
Phase II
www.goldenbiotech.com.tw
apatorsen
(Hsp27 inhibitor)
Bothell, WA
NSCLC
(see also bladder, pancreatic, prostate)
Phase II
www.oncogenex.com
ASP2215
(FLT3/AXL inhibitor)
Astellas Pharma US
Northbrook, IL
NSCLC
(see also leukemia)
Phase I
www.astellas.com
ASP8273
(mutant-selective irreversible
EGFR inhibitor)
Astellas Pharma US
Northbrook, IL
NSCLC
Phase I
www.astellas.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
Avastin
bevacizumab
Genentech/Roche
NSCLC (adjuvant)
(see also brain, breast, ovarian, other)
Phase III
www.roche.com
EGFR-positive NSCLC
Phase II
www.roche.com
avelumab
(anti-PD-L1 mAb)
EMD Serono
Rockland, MA
Pfizer
New York, NY
NSCLC (2nd-line)
(see also skin, solid tumors)
Phase III
www.emdserono.com
www.pfizer.com
AZD3759
(EGFR tyrosine kinase inhibitor)
AstraZeneca
Wilmington, DE
advanced EGFR metastatic NSCLC
Phase I
www.astrazeneca.com
AZD9291
(EGFR tyrosine kinase inhibitor)
AstraZeneca
Wilmington, DE
advanced EGFR mutation-positive T790M NSCLC

(2nd-line or greater) (Breakthrough Therapy)
(Fast Track), advanced EGFR mutation-positive NSCLC
(1st-line)
Phase II/III
www.astrazeneca.com
advanced EGFR mutation-positive NSCLC

Phase I
www.astrazeneca.com
NSCLC (2nd-line)
(see also breast, colorectal, skin)
Phase III
NSCLC (1st-line)
Phase I completed
NSCLC
liver, ovarian, pancreatic, skin, stomach)
Phase II
bavituximab
BBI608
Tustin, CA
Boston Biomedical
Cambridge, MA
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
Beleodaq
belinostat
Henderson, NV
NSCLC
(see also lymphoma)
Phase II
www.sppirx.com
BGB324
(RTK inhibitor)
BerGenBio
Bergen, Norway
NSCLC
Phase I
www.bergenbio.com
BIND-014
(PSMA-targeted docetaxel)
BIND Therapeutics
Cambridge, MA
KRAS-mutated NSCLC, squamous histology NSCLC
Phase II
www.bindtherapeutics.com
brigatinib
(ALK inhibitor)
ARIAD Pharmaceuticals
Cambridge, MA
ALK-positive NSCLC (Breakthrough Therapy)
Phase II
www.ariad.com
CC-486
Celgene
Summit, NJ
advanced NSCLC
(see also breast, hematological, leukemia,
lymphoma, other)
Phase II
www.celgene.com
CD40LGVAX
Cellular Biomedicine
Palo Alto, CA
NSCLC
Phase II completed
www.cellbiomedgroup.com
crenolanib
(PDGFR inhibitor)
Dallas, TX
NSCLC
(see also brain, leukemia, stomach)
Phase II
www.arogpharma.com
CRS-207
Orphan Drug
Aduro BioTech
Berkeley, CA
mesothelioma (combination therapy)

Phase I
www.aduro.com
custirsen (OGX-111)
(antisense olignucleotide)
Bothell, WA
advanced NSCLC
(see also prostate)
Phase III
www.oncogenex.com
CX-01
Weston, FL
SCLC
Phase II
www.cantex.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
Cyramza
ramucirumab
Eli Lilly
Indianapolis, IN
EGFR-positive NSCLC (1st-line)

(see also bladder, liver, stomach)
Phase III
www.lilly.com
dacomitinib
(pan-HER inhibitor)
Orphan Drug
Pfizer
New York, NY
EGFR-mutant NSCLC
Phase III
www.pfizer.com
demcizumab
(DLL4 inhibitor)
Redwood City, CA
non-squamous NSCLC
(see also ovarian, pancreatic)
Phase II
www.oncomed.com
DKN-01
(DKK1 protein inhibitor)
HealthCare Pharmaceuticals
Cambridge, MA
NSCLC
(see also myeloma, other)
Phase I
www.healthcarepharmaceuticals.com

non-alcohol formula
Teikoku Pharma USA

San Jose, CA
NSCLC
(see also breast, head/neck, prostate, stomach)
www.teikokuusa.com
DPV-001
(toll-like receptor agonist)
UbiVac
Portland, OR
definitely-treated stage IIIA/B NSCLC

(see also prostate)
Phase II
www.ubivac.com
EGF816
(TKI inhibitor)
East Hanover, NJ
NSCLC (combination therapy)
Phase I/II
www.novartis.com
emibetuzumab
(c-Met antibody)
Eli Lilly
Indianapolis, IN
NSCLC
(see also other)
Phase II
www.lilly.com
entinostat
(HDAC inhibitor)
Waltham, MA

Phase I/II
www.syndax.com
epacadostat
(IDO1 inhibitor)
Incyte
Wilmington, DE
NSCLC
(see also ovarian, skin, other)
Phase I/II
www.incyte.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
EMD Serono
Rockland, MA
NSCLC
(see also brain, hematological, pancreatic,
sarcoma, skin)
Phase II
www.emdserono.com
ficlatuzumab
(HGF/c-Met inhibitor)
AVEO Oncology
Cambridge, MA
advanced NSCLC
Phase II
www.aveooncology.com
FP-1039
(FGF ligand trap)
Five Prime Therapeutics

mesothelioma, squamous NSCLC
Phase I
www.fiveprime.com
ganetespib
(Hsp90 inhibitor)
Lexington, MA
NSCLC (Fast Track)

(see also breast, leukemia, ovarian)
Phase III
www.syntapharma.com
GI-4000
(mutated Ras cancer vaccine)
GlobeImmune
Louisville, CO
NSCLC
Phase II
www.globeimmune.com
Gilotrif
afatinib

Ridgefield, CT
squamous cell carcinoma of the lung

(see also brain, head/neck)
Phase III
GL-ONC1
Genelux
San Diego, CA
pleural cavity cancers

(see also head/neck, other)
Phase I
www.genelux.com
Halaven
eribulin
Eisai
Woodcliff Lake, NJ
NSCLC
(see also bladder, sarcoma)
Phase III
www.eisai.com
Imprime PGG
Biothera
Eagan, MN
metastatic NSCLC (1st-line)

(see also colorectal, leukemia, lymphoma, pancreatic)
Phase II
www.biothera.com
INC280
(c-Met inhibitor)
East Hanover, NJ
NSCLC
Phase I/II
www.novartis.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
INCB39110
(JAK1 inhibitor)
Incyte
Wilmington, DE
NSCLC
(see also lymphoma, pancreatic)
Phase II
www.incyte.com
INO-1400
lung cancer
(see also breast, pancreatic)
Phase I
www.inovio.com
Jakafi
ruxolitinib
Incyte
Wilmington, DE
NSCLC
(see also breast, colorectal, pancreatic)
Phase II
www.incyte.com
Kadcyla
Genentech/Roche
HER2-positive NSCLC
(see also breast, stomach)
Phase II
www.roche.com
Keytruda
pembrolizumab
Merck
Kenilworth, NJ
NSCLC
(see also bladder, breast, head/neck,
lymphoma, stomach)
www.merck.com
Kyprolis
carfilzomib
SCLC
Phase I/II
www.onyx.com
L-DOS47
(urease stimulant)
Helix BioPharma
Aurora, Canada
non-squamous NSCLC
Phase I
www.helixbiopharma.com
Lenvima
lenvatinib
Eisai
Woodcliff Lake, NJ
NSCLC (3rd-line), NSCLC (RET translocations)

(see also kidney, liver, skin, solid tumors, other)
Phase II
www.eisai.com
lifastuzumab vedotin
Genentech/Roche
NSCLC
(see also ovarian)
Phase I
www.roche.com
lucitanib
(FGFR/VEGFR/PDGFR inhibitor)
Clovis Oncology
Boulder, CO
squamous NSCLC
(see also breast)
Phase II
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
lung cancer DNA vaccine

(IC 1001)
Immune Cell Therapy

Chicago, IL
NSCLC
Phase I
www.immcellther.com
LY2510924
(CXCR4 peptide antagonist)
Eli Lilly
Indianapolis, IN
SCLC
(see also kidney)
Phase II
www.lilly.com
LY3023414
(PI3K/mTOR dual inhibitor)
Eli Lilly
Indianapolis, IN
NSCLC
(see also prostate)
Phase II
www.lilly.com
ME-344
(mitochondrial inhibitor)
MEI Pharma
San Diego, CA
SCLC
(see also ovarian)
Phase II
www.meipharma.com
MEDI4736
(anti-PD-L1 mAb)
MedImmune
Gaithersburg, MD
stage III NSCLC, NSCLC (3rd-line)

(see also head/neck, solid tumors)
Phase III
www.medimmune.com
MEDI4736 + AZD9291
(anti-PD-L1 mAb/EGFR tyrosine
kinase inhibitor)
MedImmune
Gaithersburg, MD
advanced EGFR metastatic NSCLC
Phase I
www.medimmune.com
NSCLC
Phase I
www.medimmune.com
MEDI4736 + Iressa
(anti-PD-L1 mAb/EGFR tyrosinene
kinase inhibitor)
MedImmune
Gaithersburg, MD
NSCLC
Phase I
www.medimmune.com
MGA271
Macrogenics
Rockville, MD
metastatic NSCLC (combination therapy)

(see also head/neck, skin)
Phase I
www.macrogenics.com
MGCD265
(c-Met/Axl kinase inhibitor)
Mirati Therapeutics
San Diego, CA
late-stage NSCLC
Phase I/II
www.mirati.com
MORAb-003
(IgG1 mAb)
Eisai
Woodcliff Lake, NJ
NSCLC
(see also ovarian)
Phase II
www.eisai.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
MORAb-009
(amatuximab)
Eisai
Woodcliff Lake, NJ
mesothelioma
Phase II
www.eisai.com
NC-6004
(nanoparticle cisplatin)
NanoCarrier
Tokyo, Japan
NSCLC
Phase I/II
www.nanocarrier.co.jp
necitumumab
(EGFR inhibitor)
Eli Lilly
Indianapolis, IN
squamous NSCLC
www.lilly.com
NGR-TNF
(recombinant fusion protein)
MolMed
Milan, Italy
late-stage mesothelioma
Phase III
www.molmed.com
NK012
Nippon Kayaku
Tokyo, Japan
SCLC
(see also breast, colorectal)
Phase II
onalespib (AT13387)
(Hsp90 inhibitor)
Pleasanton, CA
NSCLC
(see also skin)
Phase II
www.astx.com
Opdivo
nivolumab
Princeton, NJ
NSCLC (1st-line),
non-squamous NSCLC (2nd-line)
hematological, kidney, liver, lymphoma, skin,
Phase III
www.bms.com
Opdivo nivolumab +
Yervoy ipilimumab
Princeton, NJ
NSCLC
(see also kidney, skin, solid tumors)
Phase I
www.bms.com
patritumab
(anti-HER3 antibody)
Daiichi Sankyo
Parsippany, NJ
NSCLC
(see also breast)
Phase II
www.dsi.com
PB272
(neratinib)
Puma Biotechnology
Los Angeles, CA
HER2-mutated NSCLC
(see also breast)
Phase II
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
PEGPH20
(pegylated recombinant
human hyaluronidase)
Halozyme Therapeutics
San Diego, CA
NSCLC
Phase I/II
www.halozyme.com
PF-06439535
Pfizer
New York, NY
NSCLC
Phase III
www.pfizer.com
PF-06463922
(ALK/ROS1 inhibitor)
Orphan Drug
Pfizer
New York, NY
ALK-mutant NSCLC
Phase I
www.pfizer.com
PF-06664178
Pfizer
New York, NY
lung cancer
Phase I
www.pfizer.com
PF-06747775
(EGFR antagonist)
Pfizer
New York, NY
NSCLC
Phase I
www.pfizer.com
pictilisib
(PI3K inhibitor)
Genentech/Roche
metastatic NSCLC
(see also breast)
Phase II
www.roche.com
plinabulin
(tumor vascular disrupting agent)
BeyondSpring Pharmaceuticals
New York, NY
NSCLC (2nd-line)
Phase II
www.beyondspringpharma.com
PT-107
(allogeneic B7.1/HLA-A1
transfected tumor cell vaccine)
Pique Therapeutics
Durham, NC
NSCLC
Phase II
www.piquetherapeutics.com
Reolysin
pelareorp
Oncolytics Biotech
Calgary, Canada
NSCLC, squamous cell carcinoma of the lung

(see also brain, colorectal, head/neck,
myeloma, ovarian, other, pancreatic)
Phase II
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
RG7446
(anti-PD-L1 mAb)
Genentech/Roche
NSCLC (1st-line combination therapy),

NSCLC (2nd-line)
(see also bladder, breast, kidney, lymphoma,
skin)
Phase III
www.roche.com
NSCLC (3rd-line)
Phase II
www.roche.com
Phase I
www.roche.com
rociletinib
(EGFR inhibitor)
Clovis Oncology
Boulder, CO
EGFR-mutated NSCLC
roniciclib
(CDK inhibitor)

Whippany, NJ
SCLC
Phase II
RRx-001
EpicentRx
Mountain View, CA
NSCLC, SCLC
(see also colorectal, liver, lymphoma, other)
Phase II
www.radiorx.com
sapacitabine
inhibitor)
NSCLC
(see also hematological, leukemia)
Phase II
www.cyclacel.com
SAR125844
Sanofi US
Bridgewater, NJ
NSCLC
Phase II
www.sanofi.com
SC-002
(immunoconjugate)
Stemcentrx
SCLC
(see also other)
Phase I
www.stemcentrx.com
SC16LD6.5
Stemcentrx
recurrent SCLC
Phase I/II
www.stemcentrx.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
selumetinib
(MEK inhibitor)
AstraZeneca
Wilmington, DE
KRAS-positive NSCLC
(see also other)
Phase III
www.astrazeneca.com
KRAS-negative NSCLC
Phase II
www.astrazeneca.com
Cambridge, MA
NSCLC
Phase II
SPI-1620
(endothelin B receptor agonist)
Henderson, NV
NSCLC
(see also liver)
Phase II
www.sppirx.com
Tafinlar
dabrafenib
Mekinist
trametinib
combination
East Hanover, NJ
BRAF V600-positive NSCLC

(see also colorectal, skin)
Phase II
www.novartis.com
tarextumab
(anti-NOTCH 2/3 mAb)
Orphan Drug
Redwood City, CA
extensive-stage SCLC (1st-line)

Phase II
www.oncomed.com
Tavocept
BioNumerik pharmaceuticals
San Antonio, TX
lung cancer
Phase III completed

www.bionumerik.com
tepotinib
EMD Serono
Rockland, MA
NSCLC
(see also liver)
Phase II
www.emdserono.com
tergenpumatucel-L
NewLink Genetics
Ames, IA
advanced or metastatic NSCLC
Phase II/III
tesevatinib (KD019)
(TKI inhibitor)
Kadmon Pharmaceuticals
Warrendale, PA
NSCLC
(see also breast)
Phase II
www.kadmon.com
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
TG4010
(MVA-MUC1-IL2 vaccine)
Transgene
Cambridge, MA
advanced NSCLC
Phase II/III
www.transgene.fr
TH-4000
(EGFR antagonist)
T790M-negative NSCLC
Phase II
TRC105
San Diego, CA
lung cancer
(see also brain, breast, colorectal, kidney, liver,
sarcoma, other)
Phase I
trebananib
Amgen
Thousand Oaks, CA
NSCLC
Phase II
www.amgen.com
tremelimumab
(anti-CTLA-4 mAb)
Orphan Drug
MedImmune
Gaithersburg, MD
mesothelioma
Phase III
www.medimmune.com
TSR-011
(ALK/TRK inhibitor)
TESARO
Waltham, MA
NSCLC
(see also lymphoma)
Phase I/II
www.tesarobio.com
TUSC2
(gene therapy)
Genprex
Austin, TX
NSCLC
Phase I/II
www.genprex.com
vantictumab
(anti-Fzd7)
Redwood City, CA
advanced NSCLC (combination therapy)

(see also breast, pancreatic)
Phase I
www.oncomed.com
Vargatef
nintedanib

Ridgefield, CT

Phase III
mesothelioma
Phase II
NSCLC
(see also brain, breast, colorectal, skin)
Phase III
www.abbvie.com
veliparib
(PARP inhibitor)
AbbVie
North Chicago, IL
Lung Cancer
Product Name
Sponsor
Indication
Development Phase
viagenpumatucel-L
Heat Biologics
Durham, NC
NSCLC
Phase II
www.heatbio.com
vintafolide
(folate-DAVLBH)
Endocyte
West Lafayette, IN
NSCLC
Phase II
www.endocyte.com
VS-6063
(FAK inhibitor)
Orphan Drug
Verastem
Cambridge, MA
KRAS-mutant NSCLC, mesothelioma

(see also ovarian)
Phase II
www.verastem.com
X396
(ALK inhibitor)
Xcovery
Palm Beach Gardens, FL
ALK-positive NSCLC
Phase I/II
www.xcovery.com
Xgeva
denosumab
Amgen
Thousand Oaks, CA
metastatic NSCLC (1st-line)

(see also breast, myeloma)
Phase II
www.amgen.com
Yervoy
ipilimumab
Princeton, NJ
squamous NSCLC (1st-line)

(see also skin)
Phase III
www.bms.com
Zykadia
ceritinib
East Hanover, NJ
treatment nave ALK-positive NSCLC (1st-line)
Phase II
www.novartis.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
ABC294640
(sphingosine kinase inhibitor)
RedHill Biopharma
Tel Aviv, Israel
diffuse large B-cell lymphoma (DLBCL)
Phase I/II
www.redhillbio.com
abemaciclib
(CDK 4/6 inhibitor)
Eli Lilly
Indianapolis, IN
mantle cell lymphoma

Phase II
www.lilly.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
abexinostat
(HDAC inhibitor)
Pharmacyclics
Sunnyvale, CA
follicular lymphoma,
Phase II
www.pharmacyclics.com
ABP 798
(rituximab biosimilar)
Allergan
Parsippany, NJ
Amgen
Thousand Oaks, CA
non-Hodgkin lymphoma (NHL)
Phase III
www.amgen.com
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA

leukemia, lung, myeloma, pancreatic)
Phase II
activated B-cell (ABC) DLBCL,

follicular lymphoma, Waldenstrom's
macroglobulinemia
Phase I
ACP-319
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
B-cell lymphoma (combination therapy)

(see also leukemia)
Phase I/II
Adcetris
brentuximab vedotin
Orphan Drug
Seattle Genetics
Bothell, WA
post-transplant Hodgkin lymphoma

relapse prevention, relapsed CD30-positive
cutaneous T-cell lymphoma, Hodgkin
lymphoma (1st-line), CD30-positive mature
T-cell lymphoma (1st-line)
Phase III
Hodgkin lymphoma in elderly (1st-line),

CD30-positive DLBCL
Phase II
AEB071
(PKC inhibitor)
East Hanover, NJ
CD79-mutant or ABC-subtype DLBCL

(see also other)
Phase I/II
www.novartis.com
Afinitor
everolimus
East Hanover, NJ
DLBCL
(see also lung, stomach)
Phase III
www.novartis.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
AFM 13
Orphan Drug
Affimed Therapeutics
Heidelberg, Germany
Hodgkin lymphoma
Phase II
www.affimed.com
AR-12
(PI3K/Akt inhibitor)
Arno Therapeutics
Flemington, NJ
lymphoma
Phase I
www.arnothera.com
Arzerra
ofatumumab
East Hanover, NJ
refractory NHL, relapsed NHL

(see also leukemia)
Phase III
www.novartis.com
ASP4132
Astellas Pharma US
Northbrook, IL
advanced lymphoma
Phase I
www.astellas.com
ATTCK20
(viral-ACTR+anti-CD20)
Unum Therapeutics
Cambridge, MA
NHL
(see also leukemia)
Phase I
www.unumrx.com
Beleodaq
belinostat
Orphan Drug
Henderson, NV
peripheral T-cell lymphoma (PTCL) (1st-line)

(see also lung)
Phase I
www.sppirx.com
liquid formulation
Orphan Drug
Woodcliff Lake, NJ
NHL
www.eagleus.com
BI 695500

Ridgefield, CT
follicular lymphoma (1st-line)
Phase III
birinapant
Malvern, PA
cutaneous T-cell lymphoma (CTCL)

(see also hematological, ovarian)
Phase II
Blincyto
blinatumomab
Amgen
Thousand Oaks, CA
DLBCL
(see also leukemia)
Phase II
www.amgen.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
CC-122
Celgene
Summit, NJ
DLBCL, relapsed/refractory indolent lymphoma

(see also brain, leukemia, liver)
Phase I
www.celgene.com
CC-292
(Btk inhibitor)
Celgene
Summit, NJ
relapsed/refractory B-cell lymphoma

(see also leukemia)
Phase I
www.celgene.com
CC-486
Celgene
Summit, NJ
lymphoma
(see also breast, hematological, leukemia, lung, other)
Phase I
www.celgene.com
CDX-301
(Fms-like tyrosine kinase 3 ligand)
Hampton, NJ
B-cell lymphoma
Phase I/II
www.celldex.com
cerdulatinib
(dual Syk-JAK inhibitor)
Portola Pharmaceuticals
NHL
(see also leukemia)
Phase II
www.portola.com
CMD-003
(cell therapy)
Cell Medica
London, England
EBV-positive, extranodal natural killer/T-cell lymphoma
Phase II
www.cellmedica.co.uk
coltuximab ravtansine
ImmunoGen
Waltham, MA
DLBCL
Phase II
www.immunogen.com
copanlisib
(PI3K inhibitor)
Orphan Drug

Whippany, NJ
NHL
Phase III
DLBCL
Phase II
CPI-0610
(BET inhibitor)
Cambridge, MA
lymphoma
(see also hematological, leukemia, myeloma)
Phase I
CPI-1205
(EZH2 enzyme inhibitor)
Cambridge, MA
B-cell lymphoma
Phase I
Lymphoma
Product Name
Sponsor
Indication
Development Phase
CTL019
(CAR immunotherapy)
East Hanover, NJ
DLBCL
(see also leukemia)
Phase I
www.novartis.com
CUDC-427
(IAP inhibitor)
Curis
Lexington, MA
late-stage lymphoma
Phase I
www.curis.com
CUDC-907
(HDAC/PI3K inhibitor)
Curis
Lexington, MA
late-stage lymphoma
(see also myeloma, solid tumors)
Phase I
www.curis.com
DI-Leu16-IL2
ALOPEXX Oncology
Concord, MA
NHL
Phase I/II
www.alopexx.com
DS-3032
(MDM2 inhibitor)
Daiichi Sankyo
Parsippany, NJ
late-stage lymphoma
Phase I
www.dsi.com
DS-3078
(mTOR inhibitor)
Daiichi Sankyo
Parsippany, NJ
lymphoma
Phase I
www.dsi.com
DS-8273
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ
late-stage lymphoma
Phase I
www.dsi.com
duvelisib
(PI3K inhibitor)
Orphan Drug
AbbVie
North Chicago, IL
Cambridge, MA
previously-treated follicular lymphoma

Phase III
www.abbvie.com
www.infi.com
refractory indolent NHL
Phase II
www.abbvie.com
www.infi.com
treatment nave follicular lymphoma
Phase I
www.abbvie.com
www.infi.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
EPZ-6438
(EZH2 inhibitor)
Epizyme
Cambridge, MA
NHL
Phase I/II
www.epizyme.com
Folotyn
pralatrexate injection
Orphan Drug
Henderson, NV
PTCL
Phase I
www.sppirx.com
Gazyva
obinutuzumab
Genentech/Roche
DLBCL, indolent NHL (1st-line),

refractory indolent NHL
Phase III
www.roche.com
GDC-0575 (RG7741)
(ChK1 inhibitor)
Genentech/Roche
lymphoma
Phase I
www.roche.com
GS-5829
(BET inhibitor)
Gilead Sciences
Foster City, CA
DLBCL
Phase I
www.gilead.com
Imbruvica
ibrutinib

Raritan, NJ
relapsed/refractory mantle cell lymphoma,

treatment nave mantle cell lymphoma
(combination therapy), relapsed/refractory
indolent NHL (combination therapy),
newly-diagnosed non-germinal center
B-cell subtype of DLBCL, previously treated
Waldenstrom's macroglobulinemia
(see also leukemia)
Phase III
www.janssenrnd.com
IMGN529
ImmunoGen
Waltham, MA
NHL
(see also leukemia)
Phase I
www.immunogen.com
IMMU-114
(humanized anti-HLA-DR)
Immunomedics
Morris Plains, NJ
NHL
(see also leukemia)
Phase I
Lymphoma
Product Name
Sponsor
Indication
Development Phase
IMO-8400
(TLR antagonist)
Orphan Drug
Idera Pharmaceuticals
Cambridge, MA
DLBCL, Waldenstrom's macroglobulinemia
Phase I/II
www.iderapharma.com
Imprime PGG
Biothera
Eagan, MN
advanced indolent NHL

(see also colorectal, leukemia, lung, pancreatic)
Phase II
www.biothera.com
INCB39110+INCB40093
(JAK1 inhibitor)
Incyte
Wilmington, DE
B-lymphoid malignancies
Phase I/II
www.incyte.com
INCB50465
Incyte
Wilmington, DE
B-lymphoid malignancies
Phase I
www.incyte.com
Istodax
romidepsin
Celgene
Summit, NJ
PTCL (1st-line)
Phase III
www.celgene.com
JCAR014
Juno Therapeutics
Seattle, WA
NHL
(see also leukemia)
Phase I/II
JCAR018
Juno Therapeutics
Seattle, WA
NHL
(see also leukemia)
Phase I
JNJ-42756493
(FGFR inhibitor)

Raritan, NJ
late-stage lymphoma
(see also bladder)
Phase I
www.janssenrnd.com
Keytruda
pembrolizumab
Merck
Kenilworth, NJ
Hodgkin lymphoma
(see also bladder, breast, head/neck, lung, stomach)
Phase II
www.merck.com
Lymphoma
Product Name
KTE-C19 CAR
(chimeric antigen receptor)
Orphan Drug
Sponsor
Indication
Development Phase
Kite Pharma
Santa Monica, CA
B-cell lymphoma
Phase II/III
www.kitepharma.com
DLBCL
Phase I/II
www.kitepharma.com
Marqibo
vinCRIStine sulfate LIPOSOME
injection
Henderson, NV
aggressive NHL (1st-line)

(see also leukemia)
Phase III
www.sppirx.com
MEDI-551
(anti-CD19 mAb)
MedImmune
Gaithersburg, MD
DLBCL
(see also leukemia)
Phase II
www.medimmune.com
MEDI-551 + MEDI0680
(anti-CD19 mAb/anti-PD-1 mAb)
MedImmune
Gaithersburg, MD
DLBCL
Phase I
www.medimmune.com
milatuzumab-doxorubicin conjugate
Immunomedics
Morris Plains, NJ
NHL
(see also leukemia)
Phase I/II
mocetinostat
(HDAC inhibitor)
Orphan Drug
Mirati Therapeutics
San Diego, CA
DLBCL
(see also bladder, hematological)
Phase II
www.mirati.com
mogamulizumab
(anti-CCR4 antibody)
Orphan Drug
Kyowa Hakko Kirin

Princeton, NJ
CTCL
(see also leukemia)
Phase III
www.kyowa-kirin.com
adult T-cell leukemia-lymphoma
Phase II
www.kyowa-kirin.com
NHL
(see also leukemia)
Phase II
www.morphosys.com
MOR208
MorphoSys
Lymphoma
Product Name
Sponsor
Indication
Development Phase
MT-3724
Molecular Templates
Georgetown, TX
NHL
Phase I
www.moleculartemplates.com
Oncoquest-L
personalized cancer vaccine
XEME Biopharma
Monmouth Junction, NJ
follicular lymphoma
Phase II
www.xemebiopharma.com
Opdivo
nivolumab
Princeton, NJ
Hodgkin lymphoma (Breakthrough

Therapy), DLBCL, follicular lymphoma
(see also bladder, brain, colorectal,
head/neck, hematological, kidney, liver,
lung, skin, solid tumors, stomach, other)
Phase II
www.bms.com
PF-05280586
Pfizer
New York, NY
follicular lymphoma (1st-line therapy)
Phase III
www.pfizer.com
pidilizumab
Medivation
San Francisco, CA
DLBCL
Phase II completed
www.medivation.com
Pixuvri
pixantrone
CTI BioPharma
Seattle, WA
DLBCL, follicular grade 3 lymphoma
Phase III
PNT2258
(Bcl-2 oncogene inhibitor)
ProNAi Therapeutics
Plymouth, MI
relapsed/refractory DLBCL,
relapsed/refractory NHL
Phase II
www.pronai.com
polatuzumab vedotin
Genentech/Roche
DLBCL, NHL
Phase II
www.roche.com
REGN1979
(CD20/CD3 antigen inhibitor)
Tarrytown, NY
NHL
(see also leukemia)
Phase I
www.regeneron.com
Resimmune
A-dmDT390-bisFv immunotoxin
Angimmune
Rockville, MD
CTCL
(see also skin)
Phase I/II
www.angimmune.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
Revlimid
lenalidomide
Celgene
Summit, NJ
DLBCL (maintenance therapy),

DLBCL-ABC subtype (1st-line),
follicular lymphoma (1st-line),
relapsed/refractory indolent lymphoma
(see also hematological, leukemia, myeloma)
Phase III
www.celgene.com
RG7446
(anti-PD-L1 mAb)
Genentech/Roche
lymphoma
(see also bladder, breast, kidney, lung,
skin)
Phase I
www.roche.com
ricolinostat
(HDAC inhibitor)
Acetylon Pharmaceuticals
Boston, MA
lymphoma
(see also myeloma)
Phase I/II
www.acetylon.com
RRx-001
EpicentRx
Mountain View, CA
lymphoma
(see also colorectal, liver, lung, other)
Phase I
www.radiorx.com
SD101
(TLR9 agonist)
Dynavax Technologies
Berkeley, CA
B-cell lymphoma
Phase I/II
www.dynavax.com
selinexor (oral)
(XPO1 antagonist)
Orphan Drug
Newton, MA
DLBCL
(see also brain, head/neck, hematological,
leukemia, myeloma, prostate, sarcoma, other)
Phase III
www.karyopharm.com
SGN-CD19A
Seattle Genetics
Bothell, WA
NHL
(see also leukemia)
Phase I
SGN-CD70A
Seattle Genetics
Bothell, WA
relapsed NHL
(see also kidney)
Phase I
SGX301
(hypericin)
Soligenix
Princeton, NJ
cutaneous T-cell lymphoma (Fast Track)
Phase II
www.soligenix.com
Lymphoma
Product Name
Sponsor
Indication
Development Phase
SHAPE
(HDAC inhibitor)
Orphan Drug
Malvern, PA
CTCL
Phase II
SP-02 (darinaparsin)
(apoptosis stimulant)
Orphan Drug
Solasia Pharma
Tokyo, Japan
PTCL
Phase II
www.solasia.co.jp
TG-1101
(anti-CD20 mAb)
Orphan Drug
TG Therapeutics
New York, NY

(see also leukemia)
Phase III
NHL (monotherapy)
Phase I/II
indolent B-cell NHL (1st-line)
www.tevapharm.com
Phase II
www.tevapharm.com
Treanda
bendamustine
Orphan Drug
Teva Oncology
Frazer, PA
TSR-011
(ALK/TRK inhibitor)
TESARO
Waltham, MA
lymphoma
(see also lung)
Phase I/II
www.tesarobio.com
veltuzumab
(humanized anti-CD20 mAb)
Immunomedics
Morris Plains, NJ
NHL
Phase II
veltuzumab
(humanized anti-CD20 mAb)/
Y-90 epratuzumab tetraxetan
Immunomedics
Morris Plains, NJ
aggressive NHL
Phase II
Lymphoma
Product Name
Sponsor
Indication
Development Phase
venetoclax
(Bcl-2 inhibitor)
AbbVie
North Chicago, IL
Genentech/Roche
DLBCL, NHL
Phase II
www.abbvie.com
www.roche.com
VS-5584
(PI3K/mTOR inhibitor)
Verastem
Cambridge, MA
lymphoma
Phase I
www.verastem.com
VX-803
Vertex Pharmaceuticals
Boston, MA
lymphoma
Phase I
www.vrtx.com
Zydelig
idelalisib
Gilead Sciences
Foster City, CA
relapsed/refractory indolent NHL

(see also leukemia)
Phase III
www.gilead.com
indolent NHL (1st-line)
Phase II
www.gilead.com
Multiple Myeloma
Product Name
Sponsor
Indication
Development Phase
ABBV-838
AbbVie
North Chicago, IL
multiple myeloma
Phase I
www.abbvie.com
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
multiple myeloma
leukemia, lung, lymphoma, pancreatic)
Phase I
ACY-241
(HDAC6 protein inhibitor)
Boston, MA
multiple myeloma
Phase I
www.acetylon.com
ALT-803
Altor BioScience
Miramar, FL
multiple myeloma
(see also bladder, hematological, skin)
Phase I/II
Multiple Myeloma
Product Name
Sponsor
Indication
Development Phase
AMG 232
(MDM2 inhibitor)
Amgen
Thousand Oaks, CA
multiple myeloma
(see also leukemia, skin, solid tumors)
Phase I
www.amgen.com
AT7519
(CDK inhibitor)
Pleasanton, CA
multiple myeloma
Phase II
www.astx.com
BB-MPI-03
Benovus Bio
Atlanta, GA
multiple myeloma
Phase I
www.benovusbio.com
CB-5083
(P97 ATPase inhibitor)
Cleave Biosciences
Burlingame, CA
multiple myeloma
Phase I
www.cleavebio.com
CPI-0610
(BET inhibitor)
Cambridge, MA
multiple myeloma
(see also hematological, leukemia, lymphoma)
Phase I
CUDC-907
Curis
Lexington, MA
multiple myeloma
(see also lymphoma, solid tumors)
Phase I
www.curis.com
daratumumab
(IgG1k mAb)

Raritan, NJ
double refractory multiple myeloma

(Breakthrough Therapy) (Fast Track)
www.janssenrnd.com
multiple myeloma (1st-line),

multiple myeloma (1st-line, combination
therapy), recurrent/relapsed multiple
myeloma (combination therapy)
Phase III
www.janssenrnd.com
multiple myeloma
(see also lung, other)
Phase I/II
DKN-01
Cambridge, MA
Multiple Myeloma
Product Name
elotuzumab
Sponsor
Indication
Development Phase
AbbVie
North Chicago, IL
Princeton, NJ
multiple myeloma (1st-line)

(combination therapy),
relapsed/refractory multiple myeloma
(combination therapy) (Breakthrough Therapy)
Phase III
www.abbvie.com
www.bms.com
multiple myeloma (2nd-line)

Phase II
www.abbvie.com
www.bms.com
filanesib
(KSP inhibitor)
Array BioPharma
Boulder, CO
multiple myeloma
Phase II
I-131-CLR1404
(molecular radiotherapeutic)
Cellector Biosciences
Madison, WI
Phase I
www.cellector.com
indatuximab ravtansine (BT062)

(tubulin polymerisation inhibitor)
Orphan Drug
Biotest Pharmaceuticals
Dreiech, Germany
multiple myeloma
Phase I/II
www.biotest.de
isatuximab
(anti-CD38 naked mAb)
Sanofi US
Bridgewater, NJ
multiple myeloma
Phase II
www.sanofi.com
ixazomib
Orphan Drug
Takeda Oncology
Cambridge, MA

previously untreated multiple myeloma,

maintenance therapy in newly-diagnosed
multiple myeloma following stem cell
transplantation, maintenance therapy in
newly-diagnosed multiple myeloma not
treated with stem cell transplantation
Phase III
Multiple Myeloma
Product Name
Kyprolis
carfilzomib
Orphan Drug
Sponsor
Indication
Development Phase
relapsed multiple myeloma (combination therapy)

www.onyx.com
relapsed multiple myeloma,

multiple myeloma (1st-line)
Phase III
www.onyx.com
lirilumab + elotuzumab
Princeton, NJ
multiple myeloma
Phase I
www.bms.com
marizomib
Triphase Accelerator
San Diego, CA

(see also brain)
Phase II
www.triphaseco.com
melphalan intravenous
(Captisol-enabled melphalan)
Orphan Drug
Henderson, NV
multiple myeloma autologous stem cell

transplantation
www.sppirx.com
NY-ESO-1/LAGE-1-specific T-cells
Adaptimmune
Oxon, England
advanced multiple myeloma

(see also ovarian, sarcoma, skin)
Phase I/II
www.adaptimmune.com
oprozomib
Orphan Drug
multiple myeloma (monotherapy)

Phase II
www.onyx.com
multiple myeloma (combination therapy)
Phase I
www.onyx.com
PIM447
pim-1 inhibitor)
East Hanover, NJ
multiple myeloma
Phase I/II
www.novartis.com
plitidepsin
(marine-derived medicine)
Orphan Drug
PharmaMar
Madrid, Spain
Phase III
www.pharmamar.com
Multiple Myeloma
Product Name
Sponsor
Indication
Development Phase
PVX-410
(therapeutic cancer vaccine)
Orphan Drug
OncoPep
North Andover, MA
smoldering multiple myeloma
Phase I/II
www.oncopep.com
Reolysin
pelareorp
Oncolytics Biotech
Calgary, Canada

(see also brain, colorectal, head/neck, lung,
ovarian, other, pancreatic)
Phase I
Revlimid
lenalidomide
Orphan Drug
Celgene
Summit, NJ
multiple myeloma (maintenance therapy)

(see also hematological, leukemia, lymphoma)
Phase III
www.celgene.com
ricolinostat
(HDAC inhibitor)
Boston, MA

(see also lymphoma)
Phase II
www.acetylon.com
selinexor (oral)
(XPO1 antagonist)
Orphan Drug
Newton, MA
multiple myeloma
leukemia, lymphoma, prostate, sarcoma,
other)
Phase III
www.karyopharm.com
multiple myeloma (combination therapy)
Phase II
www.karyopharm.com
Sylvant
siltuximab

Raritan, NJ
smoldering multiple myeloma
Phase II
www.janssenrnd.com
TAS-120
(FGF/FGFR inhibitor)
Taiho Oncology
Princeton, NJ
advanced multiple myeloma

Phase I/II
TG02
(CDK inhibitor)
Tragara Pharmaceuticals
Carlsbad, CA
multiple myeloma
(see also leukemia)
Phase I
www.tragarapharma.com
Multiple Myeloma
Product Name
Sponsor
Indication
Development Phase
urelumab + elotuzumab
Princeton, NJ
multiple myeloma
Phase I
www.bms.com
VLX1570
Vivolux
Ashburn, VA
multiple myeloma
Phase I/II
www.vivolux.com
WT1-CTL
(immunostimulant)
multiple myeloma
(see also leukemia)
Phase I
www.atarabio.com
Xgeva
denosumab
Amgen
Thousand Oaks, CA
prevention of skeletal-related events in

multiple myeloma
Phase III
www.amgen.com
Ovarian Cancer
Product Name
Sponsor
Indication
Development Phase
ADI-PEG 20
San Diego, CA
ovarian cancer
(see also breast, liver, lung, pancreatic, skin, stomach)
Phase I
Avastin
bevacizumab
Orphan Drug
Genentech/Roche
metastatic ovarian cancer (1st-line)

(see also brain, breast, lung, other)
Phase III
www.roche.com
AZD1775
(WEE-1 inhibitor)
AstraZeneca
Wilmington, DE
ovarian cancer
Phase II
www.astrazeneca.com
BBI503
(cancer stemness kinase inhibitor)
Boston Biomedical
Cambridge, MA
ovarian cancer
(see also liver)
Phase II
BBI608
Boston Biomedical
Cambridge, MA
ovarian cancer
liver, lung, pancreatic, skin, stomach)
Phase II
Ovarian Cancer
Product Name
Sponsor
Indication
Development Phase
binimetinib
(MEK inhibitor)
Array BioPharma
Boulder, CO
low-grade serous ovarian cancer

(see also skin)
Phase III
birinapant
Malvern, PA
ovarian cancer
Phase II
BNC105
Bionomics
Thebarton, Australia
ovarian cancer
(see also kidney)
Phase I/II
www.bionomics.com.au
CRLX101
Orphan Drug
Cerulean Pharma
Cambridge, MA
relapsed platinum-resistant ovarian cancer

(see also colorectal, kidney)
Phase I
www.ceruleanrx.com
demcizumab
(DLL4 inhibitor)
Redwood City, CA
platinum-resistant ovarian cancer

Phase I/II
www.oncomed.com
DPX-0907
Immunovaccine
Halifax, Canada
ovarian cancer
Phase I
www.imvaccine.com
DPX-Survivac
(peptide cancer vaccine)
Immunovaccine
Halifax, Canada
ovarian cancer
Phase I/II
www.imvaccine.com
ENMD-2076
inhibitor)
Orphan Drug
Rockville, MD
ovarian clear cell carcinoma

(see also breast, sarcoma)
Phase II
EP-100
(membrane disrupting peptide)
Esperance Pharmaceuticals
San Francisco, CA
ovarian cancer
Phase II completed
www.esperancepharma.com
epacadostat
(IDO1 inhibitor)
Incyte
Wilmington, DE
ovarian cancer
(see also lung, skin, other)
Phase II
www.incyte.com
Ovarian Cancer
Product Name
Sponsor
Indication
Development Phase

Orphan Drug
Nektar Therapeutics
San Francisco, CA

(see also breast, colorectal)
Phase II completed
www.nektar.com
fosbretabulin
(vascular targeting agent)
Orphan Drug
OXiGENE
ovarian cancer (combination therapy) (Fast Track)

(see also stomach)
Phase II
www.oxigene.com
GALE-301
(folate binding protein
immunotherapy)
Galena Biopharma
Portland, OR
ovarian cancer
(see also other)
Phase II
ganetespib
(Hsp90 inhibitor)
Lexington, MA
ovarian cancer
(see also breast, leukemia, lung)
Phase II
www.syntapharma.com
GEN 1
Celsion
Lawrenceville, NJ
ovarian cancer
(see also colorectal)
Phase II
www.celsion.com
ipafricept

Whippany, NJ
Redwood City, CA
ovarian cancer (combination therapy)

(see also liver, pancreatic)
Phase I
www.oncomed.com
Karentitecin
cositecan
BioNumerik Pharmaceuticals
San Antonio, TX
advanced ovarian cancer
Phase III
www.bionumerik.com
lifastuzumab vedotin
Genentech/Roche

(see also lung)
Phase II
www.roche.com
ovarian cancer
Phase I
www.roche.com
Ovarian Cancer
Product Name
Sponsor
Indication
Development Phase
LY2606368
(Chk1 inhibitor)
Eli Lilly
Indianapolis, IN
metastatic ovarian cancer

(see also breast)
Phase II
www.lilly.com
Lynparza
olaparib
Orphan Drug
AstraZeneca
Wilmington, DE
BRCA-mutated ovarian cancer (1st-line),

germline BRCA-mutated, platinum-sensitive
recurrent ovarian cancer
(see also breast, pancreatic, prostate, stomach)
Phase III
www.astrazeneca.com
ME-344
(mitochondrial inhibitor)
MEI Pharma
San Diego, CA
ovarian cancer
(see also lung)
Phase II
www.meipharma.com
mirvetuximab soravtansine
(folate receptor 1 inhibitor)
Orphan Drug
ImmunoGen
Waltham, MA

(see also other)
Phase I
www.immunogen.com
MORAb-003
(IgG1 mAb)
Orphan Drug
Eisai
Woodcliff Lake, NJ
platinum-sensitive ovarian cancer

(see also lung)
Phase II
www.eisai.com
motolimod
(TLR8 agonist immunotherapy)
Orphan Drug
VentiRx Pharmaceuticals
Seattle, WA
ovarian cancer (Fast Track)

(see also head/neck)
Phase II
www.ventirx.com
niraparib
(PARP inhibitor)
TESARO
Waltham, MA
ovarian cancer maintenance

(see also breast, sarcoma)
Phase III
www.tesarobio.com
ovarian cancer treatment
Phase III
www.tesarobio.com
Phase I
www.tesarobio.com
Ovarian Cancer
Product Name
Sponsor
Indication
Development Phase
Adaptimmune
Oxon, England
ovarian cancer
(see also myeloma, sarcoma, skin)
Phase I/II
www.adaptimmune.com
ONT-10
Oncothyreon
Seattle, WA
ovarian cancer
(see also breast)
Phase I
www.oncothyreon.com
oregovomab
Orphan Drug
Quest PharmaTech
Edmonton, Canada
ovarian cancer
Phase II
www.questpharmatech.com
ovarian cancer vaccine

(pentavalent)
MabVax Therapeutics
San Diego, CA
ovarian cancer
Phase II
www.mabvax.com
paclitaxel poliglumex
CTI BioPharma
Seattle, WA
ovarian cancer (1st-line)
Phase III
PLX3397
(CSF-1R inhibitor)
Plexxikon
Berkeley, CA
advanced ovarian cancer

(see also brain, breast, skin, other)
Phase I
www.plexxikon.com
PM01183
Orphan Drug
Pharma Mar
Madrid, Spain
ovarian cancer
Phase III
www.pharmamar.com
ralimetinib
(p38 MAP kinase inhibitor)
Eli Lilly
Indianapolis, IN
ovarian cancer
Phase II
www.lilly.com
Reolysin
pelareorp
Orphan Drug
Oncolytics Biotech
Calgary, Canada
ovarian cancer
myeloma, other, pancreatic)
Phase II
RG7882
Genentech/Roche
ovarian cancer
Phase I
www.roche.com
Ovarian Cancer
Product Name
rucaparib
(PARP inhibitor)
Orphan Drug
Sponsor
Indication
Development Phase
Clovis Oncology
Boulder, CO
ovarian cancer (maintenance)

(see also breast, pancreatic, other)
Phase III
gBRCA-mutation ovarian cancer

Phase II
Cambridge, MA
ovarian cancer
Phase II
SGI-110
(DNMT inhibitor)
Pleasanton, CA
ovarian cancer
(see also hematological, leukemia, liver)
Phase II
www.astx.com
STM 434
(activin inhibitor)
ovarian cancer
Phase I
www.atarabio.com
TPIV200
(folate receptor alpha vaccine)
TapImmune
Seattle, WA

(see also breast)
Phase I
www.tapimmune.com
trebananib
Amgen
Thousand Oaks, CA
ovarian cancer
Phase III
www.amgen.com
Vargatef
nintedanib

Ridgefield, CT
ovarian cancer (1st-line)

Phase III
VB-111
VBL Therapeutics
Tel Aviv, Israel
ovarian cancer
(see also brain, other)
Phase II
www.vblrx.com
Vigil
autologous immunotherapy
Gradalis
Dallas, TX
stage III/IV ovarian cancer

(see also sarcoma)
Phase III
www.gradalisinc.com
Ovarian Cancer
Product Name
Sponsor
Indication
Development Phase
VS-6063
(FAK inhibitor)
Orphan Drug
Verastem
Cambridge, MA
late-stage ovarian cancer

(see also lung)
Phase II
www.verastem.com
Yondelis
trabectedin
Orphan Drug

Raritan, NJ
relapsed ovarian cancer

(see also sarcoma)
Phase III
www.janssenrnd.com
Sponsor
Indication
Development Phase
Abraxane
paclitaxel protein-bound
particles for injectable
suspension (albumin-bound)
Orphan Drug
Celgene
Summit, NJ
pancreatic cancer (adjuvant)

(see also breast)
Phase III
www.celgene.com
ACP-196
(Btk inhibitor)
Acerta Pharma
San Carlos, CA
advanced pancreatic cancer (combination therapy)

leukemia, lung, lymphoma, myeloma)
Phase II
ADI-PEG 20
San Diego, CA
pancreatic cancer
(see also breast, liver, lung, ovarian, skin, stomach)
Phase I
(gene therapy)
Advantagene
Auburndale, MA
pancreatic cancer
Phase I/II
www.advantagene.com
algenpantucel-L
Orphan Drug
NewLink Genetics
Ames, IA
pancreatic cancer (resected) (Fast Track),

pancreatic cancer (borderline resectable of
locally advanced unresectable)
Phase III
anti-MUC1 AR20.5 mAb

(chemotherapy-enhanced
immunotherapy)
Quest PharmaTech
Edmonton, Canada
pancreatic cancer
Phase I/II
Pancreatic Cancer
Product Name
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Phase
apatorsen
(Hsp27 inhibitor)
Bothell, WA
metastatic pancreatic cancer

(see also bladder, lung, prostate)
Phase II
www.oncogenex.com
BBI608
Boston Biomedical
Cambridge, MA
pancreatic cancer
liver, lung, ovarian, skin, stomach)
Phase I
BC-819
(gene therapy)
Orphan Drug
BioCancell Therapeutics
Jerusalem, Israel
pancreatic cancer (1st-line) (Fast Track)

(see also bladder)
Phase II
www.biocancell.com
CPI-613
(KGDH/PHD complex inhibitor)
Orphan Drug
Cornerstone Pharmaceuticals
Cranbury, NJ
pancreatic cancer
(see also other)
Phase II
www.cornerstonepharma.com
CRS-207
Orphan Drug
Aduro BioTech
Berkeley, CA
pancreatic cancer (combination therapy)

(see also lung)
Phase II
www.aduro.com
demcizumab
(DLL4 inhibitor)
Orphan Drug
Redwood City, CA
metastatic pancreatic ductal cancer

Phase II
www.oncomed.com
Rogosin Institute
New York, NY
New York, NY

(see also colorectal, prostate)
Phase II
www.rogosin.org
ensituximab
(neoplasm antigen inhibitor)
Orphan Drug
Precision Biologics
Dallas, TX
advanced pancreatic cancer

Phase II
www.precision-biologics.com
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Phase
Orphan Drug
EMD Serono
Rockland, MA
pancreatic cancer (Fast Track)

(see also brain, hematological, lung, sarcoma, skin)
Phase III
www.emdserono.com
FG-3019
(connective tissue growth
factor inhibitor)
Fibrogen
San Francisco, CA
Phase II
www.fibrogen.com
galunisertib
Eli Lilly
Indianapolis, IN
pancreatic cancer
(see also brain, liver)
Phase I/II
www.lilly.com
GI-4000
(mutated Ras cancer vaccine)
GlobeImmune
Louisville, CO
pancreatic cancer
(see also lung)
Phase II
www.globeimmune.com
glufosfamide
Orphan Drug
Eleison Pharmaceuticals
St. Petersburg, FL
metastatic pancreatic cancer (Fast Track)
Phase III
www.eleison-pharma.com
Imprime PGG
Biothera
Eagan, MN
advanced pancreatic ductal cancer

(see also colorectal, leukemia, lung, lymphoma)
Phase I
www.biothera.com
INCB39110
(JAK1 inhibitor)
Incyte
Wilmington, DE
pancreatic cancer
(see also lung, lymphoma)
Phase I
www.incyte.com
INO-1400
pancreatic cancer
Phase I
www.inovio.com
ipafricept

Whippany, NJ
Redwood City, CA
pancreatic cancer (combination therapy)

(see also liver, ovarian)
Phase I
www.oncomed.com
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Phase
Jakafi
ruxolitinib
Incyte
Wilmington, DE
pancreatic cancer (Fast Track)

(see also breast, colorectal, lung)
Phase III
www.incyte.com
KLT injection
(kanglaite)
KangLaiTe USA
Redwood City, CA
Phase II
www.kanglaite-usa.com
LipoPlatin
cisplatin liposomal
In Ovations Holdings
Doral, FL
Regulon
Alimos, Greece
pancreatic cancer
Phase III
www.regulon.org
Lynparza
olaparib
AstraZeneca
Wilmington, DE
pancreatic cancer
(see also breast, ovarian, prostate, stomach)
Phase III
www.astrazeneca.com
masitinib
AB Science USA
Short Hills, NJ

(see also stomach)
Phase III
www.ab-science.com
MM-141
(IGF-1R/ErbB3 bispecific
tetravalent antibody)
Orphan Drug
Cambridge, MA
metastatic pancreatic cancer (1st-line)
Phase II
MM-398
nanotherapeutic)
Orphan Drug
Baxalta
Cambridge, MA
metastatic pancreatic cancer (1st-line) (Fast Track)

www.baxalta.com
momelotinib
(JAK inhibitor)
Gilead Sciences
Foster City, CA
pancreatic cancer
Phase III
www.gilead.com
necuparanib
Orphan Drug
Momenta Pharmaceuticals
Cambridge, MA
pancreatic cancer (1st-line)

(Fast Track)
Phase II
www.momentapharma.com
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Phase
OGF/MENK
(methionine enkephalin)
Immune Therapeutics
Orlando, FL
pancreatic cancer
Phase II
www.immunetherapeutics.com
oregovomab
Orphan Drug
Quest PharmaTech
Edmonton, Canada
pancreatic cancer
(see also ovarian)
Phase II
PBI-05204
(triple kinase inhibitor)
Phoenix Biotechnology
San Antonio, TX
pancreatic cancer
Phase II
www.phoenixbiotechnology.com
PEGPH20
(pegylated recombinant
human hyaluronidase)
Orphan Drug
Halozyme Therapeutics
San Diego, CA

(see also lung)
Phase II
www.halozyme.com
PLX7486
(TRK inhibitor)
Plexxikon
Berkeley, CA
pancreatic cancer
Phase I
www.plexxikon.com

(G17DT)
Orphan Drug
Cancer Advances
Durham, NC
pancreatic cancer
(see also colorectal, stomach)
Phase III completed

PRI-724
(CBP/beta catenin inhibitor)
PRISM Pharma
Tokyo, Japan
metastatic pancreatic adenocarcinoma

(see also leukemia)
Phase I/II
www.prismbiolabs.com
Reolysin
pelareorp
Orphan Drug
Oncolytics Biotech
Calgary, Canada

myeloma, ovarian, other)
Phase II
RG7882
Genentech/Roche
pancreatic cancer
(see also ovarian)
Phase I
www.roche.com
Pancreatic Cancer
Product Name
Sponsor
Indication
Development Phase
rucaparib
(PARP inhibitor)
Clovis Oncology
Boulder, CO
pancreatic cancer
(see also breast, ovarian, other)
Phase II
SM04755
(Wnt inhibitor)
Samumed
San Diego, CA

(see also colorectal, liver, stomach)
Phase I
www.samumed.com
TAK-264
(antibody drug conjugate
targeting GCC)
Takeda Oncology
Cambridge, MA
pancreatic cancer
(see also stomach)
Phase II
tarextumab
(anti-NOTCH 2/3 mAb)
Orphan Drug
Redwood City, CA

(see also lung)
Phase II
www.oncomed.com
TL-118
Tiltan Pharma
Jerusalem, Israel
Phase II
www.tiltanpharma.com
vantictumab
(anti-Fzd7)
Redwood City, CA

Phase I
www.oncomed.com
X-82
(VEGFR/PDGFR antagonist)
Tyrogenex
Palm Beach Gardens, FL
pancreatic neuroendocrine tumors
Phase I/II
www.tyrogenex.com
Y-90 clivatuzumab tetraxetan

Orphan Drug
Immunomedics
Morris Plains, NJ
relapsed pancreatic cancer

(Fast Track)
Phase III

(Fast Track)
Phase I/II
www.immomedics.com
Prostate Cancer
Product Name
Sponsor
Indication
Development Phase
177Lu-J591
(PSMA mAb)
BZL Biologics
New York, NY
Cornell University
Ithaca, NY
metastatic prostate cancer
Phase II
ADXS-PSA
Advaxis
Princeton, NJ
hormone refractory prostate cancer
Phase I/II
www.advaxis.com
AE37
(immunotherapeutics)
Antigen Express
Worcester, MA
prostate cancer
(see also breast)
Phase II
(gene therapy)
Advantagene
Auburndale, MA
newly-diagnosed prostate cancer

Phase III
www.advantagene.com
apatorsen
(Hsp27 inhibitor)
Bothell, WA
prostate cancer
(see also bladder, lung, pancreatic)
Phase II
www.oncogenex.com
APC100
(androgen antagonist)
Adamis Pharmaceuticals
San Diego, CA
prostate cancer
Phase I/II
www.adamispharmaceuticals.com
ASN001
(CYP17 lyase inhibitor)
Asana BioSciences
Bridgewater, NJ
prostate cancer
Phase I/II
www.asanabiosciences.com
BPX-201
Bellicum Pharmaceuticals
Houston, TX
metastatic castration-resistant prostate cancer
Phase I
www.bellicum.com
CFG920
(CYP17 inhibitor)
East Hanover, NJ
Phase I/II
www.novartis.com
custirsen (OGX-111)
(antisense olignucleotide)
Bothell, WA

(2nd-line)
Phase III
www.oncogenex.com
Prostate Cancer
Product Name
Sponsor
Indication
Development Phase

non-alcohol formula
Teikoku Pharma USA

San Jose, CA
prostate cancer
(see also breast, head/neck, lung, stomach)
www.teikokuusa.com
DPV-001
(toll-like receptor agonist)
UbiVac
Portland, OR
advanced prostate cancer

(see also lung)
Phase I
www.ubivac.com
DPX-0907
Immunovaccine
Halifax, Canada
prostate cancer
Phase I
www.imvaccine.com
EC1169
(PSMA tubulysin)
Endocyte
West Lafayette, IN
prostate cancer
Phase I
www.endocyte.com
Rogosin Institute
New York, NY
New York, NY

(see also colorectal, pancreatic)
Phase II
www.rogosin.org
FP-001
(leuprolide mesylate)
Foresee Pharmaceuticals
Newark, DE
late-stage prostate cancer
Phase III
www.foreseepharma.com
galeterone
(androgen receptor antagonist)
Tokai Pharmaceuticals
Cambridge, MA
metastatic prostate cancer (1st-line)

(Fast Track
Phase III
www.tokaipharma.com
treatment-resistant prostate cancer

(Fast Track)
Phase I
www.tokaipharma.com
GTx-758
(ER alpha agonist)
GTx
Memphis, TN
secondary hormone therapy for

castration-resistant prostate cancer
Phase II
www.gtxinc.com
indoximod
NewLink Genetics
Ames, IA
metastatic castration-resistant
prostate cancer
(see also brain, breast)
Phase II
Prostate Cancer
Product Name
Sponsor
Indication
Development Phase
ipatasertib
(Akt inhibitor)
Array BioPharma
Boulder, CO
Genentech/Roche
prostate cancer
(see also breast, stomach)
Phase II
www.roche.com
IRX4204
(retinoid X receptor factor)
Io Therapeutics
Santa Ana, CA
prostate cancer
Phase II
www.io-therapeutics.com
Jevtana
cabazitaxel
Sanofi US
Bridgewater, NJ
metastatic prostate cancer (1st-line)

(see also brain)
Phase III
www.sanofi.com
JNJ927/ARN-509

Raritan, NJ
castration-resistant prostate cancer,

treatment nave metastatic
Phase III
www.janssenrnd.com
KLT gel cap

(kanglaite)
KangLaiTe USA
Redwood City, CA
prostate cancer
Phase II
www.kanglaite-usa.com
LY3023414
Eli Lilly
Indianapolis, IN
prostate cancer
(see also lung)
Phase II
www.lilly.com
Lynparza
olaparib
AstraZeneca
Wilmington, DE
prostate cancer
(see also breast, ovarian, pancreatic, stomach)
Phase III
www.astrazeneca.com
MER-104
(oral acyline)
Merrion Pharmaceuticals
Dublin, Ireland
prostate cancer
Phase I
www.merrionpharma.com
MOR209/ES414
(bispecific immunotherapeutic)
Emergent BioSolutions
Gaithersburg, MD
MorphoSys
Phase I
www.emergentbiosolutions.com
www.morphosys.com
Prostate Cancer
Product Name
Sponsor
Indication
Development Phase
MVI-816
(PAP plasmid DNA vaccine)
Madison Vaccines
Madison, WI
prostate cancer (1st-line)
Phase II
www.madisonvaccinesinc.com
NX-1207
Nymox Pharmaceutical
Hasbrouck Heights, NJ
prostate cancer
Phase III
www.nymox.com
ODM-201

Whippany, NJ
prostate cancer
Phase III
ONC1-13B
AllaChem
Hallandale Beach, FL
Phase I/II
www.allachem.com
ozarelix
(GnRH inhibitor)
Henderson, NV
hormone dependent prostate cancer
Phase II
www.sppirx.com
pasireotide long acting release

(SOM230)
East Hanover, NJ

(see also other, skin)
Phase I/II
www.novartis.com
prostate cancer vaccine

(PSA/IL-2/GM-CSF vaccine)
OncBioMune
Baton Rouge, LA
prostate cancer
Phase I
www.oncbiomune.com
Prostvac
rilimogene galvacirepvecrilimogene glafolivec
Bavarian Nordic
Mountain View, VA
Princeton, NJ
metastatic castration-resistant
prostate cancer (Fast Track)
Phase III
www.bms.com
Provenge
sipuleucel-T
Dendreon
Seattle, WA
recurrent early-stage prostate cancer
Phase III
www.dendreon.com
recurrent hormone refractory

Phase II
www.dendreon.com
Prostate Cancer
Product Name
Sponsor
Indication
Development Phase
PRX302
(recombinant protein)
Sophiris Bio
La Jolla, CA
localized low to intermediate risk

prostate cancer
Phase II
www.sophirisbio.com
PSMA ADC therapeutic

Progenics Pharmaceuticals
Tarrytown, NY
prostate cancer
Phase II
www.progenics.com
REIC gene therapy
Momotaro-Gene
Okayama, Japan
prostate cancer
Phase I/II
www.mt-gene.com
relugolix (TAK-385)
(LH-RH antagonist)
Takeda Oncology
Cambridge, MA
prostate cancer
Phase II
RG7450
(anti-STEAP1 antibody drug
conjugate)
Genentech/Roche
prostate cancer
Phase I
www.roche.com
selinexor (oral)
(XPO1 antagonist)
Newton, MA
prostate cancer
leukemia, lymphoma, myeloma, sarcoma, other)
Phase II
www.karyopharm.com
stapuldencel-T
(active cellular immunotherapy)
Sotio
Prague, Czech Republic
Phase III
www.sotio.com
TT-100
(IGF-1/EGF dual inhibitor)
TriAct Therapeutics
San Francisco, CA
prostate cancer
Phase II completed
VT-122
Vicus Therapeutics
Morristown, NJ
prostate cancer
(see also liver)
Phase II
www.vicustherapeutics.com
VT-464
(CYP17 lyase inhibitor)
Innocrin Pharmaceuticals
Durham, NC
Phase II
www.innocrinpharma.com
Prostate Cancer
Product Name
Sponsor
Indication
Development Phase
Xofigo
radium-223 dichloride

Whippany, NJ
bone metastases in castration-resistant

prostate cancer (1st-line) (combination therapy)
Phase III
bone metastases in castration-resistant

prostate cancer (combination therapy)
Phase II
Xtandi
enzalutamide
Astellas Pharma US
Northbrook, IL
Medivation
San Francisco, CA
non-metastatic castration-resistant prostate

cancer, prostate cancer in patients with
non-metastatic biochemical recurrence
(see also breast, liver)
Phase III
www.astellas.com
www.medivation.com
zoptarelin doxorubicin
(type II DNA topoisomerase
inhibitor)
Aeterna Zentaris
Quebec, Canada
castration-/taxane-resistant prostate cancer

(see also other)
Phase II
www.aezsinc.com
Sponsor
Indication
Development Phase
CytRx
Los Angeles, CA
soft tissue sarcoma (2nd-line)

(see also brain, lung)
Phase III
www.cytrx.com
Kaposi's sarcoma,
soft tissue sarcoma (1st-line)
Phase II
www.cytrx.com
soft tissue sarcoma

Phase II
Sarcoma
Product Name
aldoxorubicin
Orphan Drug
ENMD-2076
inhibitor)
Rockville, MD
Sarcoma
Product Name
Sponsor
Indication
Development Phase
Orphan Drug
EMD Serono
Rockland, MA
soft tissue sarcoma (Fast Track)

(see also brain, hematological, lung, pancreatic, skin)
Phase III
www.emdserono.com
G100
(TLR4 agonist)
Immune Design
Seattle, WA
metastatic soft tissue sarcoma

(see also skin)
Phase I
www.immunedesign.com
GPX-150
inhibitor)
Gem Pharmaceuticals
Birmingham, AL
soft tissue sarcoma
Phase II
www.gempharmaceuticals.com
Halaven
eribulin
Orphan Drug
Eisai
Woodcliff Lake, NJ
soft tissue sarcoma

(see also bladder, lung)
www.eisai.com
HDM201
p53 modulator)
East Hanover, NJ
liposarcoma
Phase I/II
www.novartis.com
inhaled lipid-complexed cisplatin
Eleison Pharmaceuticals
St. Petersburg, MD
prevention of pulmonary metastases

from osteosarcoma (pediatric)
Phase II
www.eleison-pharma.com
MORAb-004
Orphan Drug
Eisai
Woodcliff Lake, NJ
soft tissue sarcoma

Phase II
www.eisai.com
niraparib
(PARP inhibitor)
TESARO
Waltham, MA
Ewing's sarcoma
Phase I
www.tesarobio.com
Adaptimmune
Oxon, England
synovial sarcoma
(see also myeloma, ovarian, skin)
Phase I
www.adaptimmune.com
Sarcoma
Product Name
Sponsor
Indication
Development Phase
olaratumab
(PDGF-alpha receptor antagonist)
Eli Lilly
Indianapolis, IN
soft tissue sarcoma
Phase II
www.lilly.com
sarcoma vaccine
MabVax Therapeutics
San Diego, CA
metastatic sarcoma
Phase II
www.mabvax.com
selinexor (oral)
(XPO1 antagonist)
Newton, MA
liposarcoma
(see also brain, head/neck, hematological, leukemia,
lymphoma, myeloma, prostate, other)
Phase II
www.karyopharm.com
TRC105
San Diego, CA
soft tissue sarcoma

lung, other)
Phase II
Vigil
autologous immunotherapy
Gradalis
Dallas, TX
Ewing's sarcoma
(see also ovarian)
Phase II
www.gradalisinc.com
Yondelis
trabectedin
Orphan Drug

Raritan, NJ
soft tissue sarcoma

(see also ovarian)
www.janssenrnd.com
Sponsor
Indication
Development Phase
ADI-PEG 20
Orphan Drug
San Diego, CA
melanoma
(see also breast, liver, lung, ovarian, pancreatic,
stomach)
Phase I
AE-M
(immunotherapeutic)
Antigen Express
Worcester, MA
melanoma
Phase I
Skin Cancer
Product Name
Skin Cancer
Product Name
Sponsor
Indication
Development Phase
alpha-gal glycosphingolipid
(immunotherapy)
Agalimmune
Irvine, CA
melanoma
Phase I
www.agalimmune.com
ALT-803
Altor BioScience
Miramar, FL
metastatic melanoma
(see also bladder, hematological, myeloma)
Phase I/II
AMG 232
(MDM2 inhibitor)
Amgen
Thousand Oaks, CA
metastatic melanoma
(see also leukemia, myeloma, solid tumors)
Phase I/II
www.amgen.com
avelumab
(anti-PD-L1 mAb)
EMD Serono
Rockland, MA
Pfizer
New York, NY
metastatic Merkel cell carcinoma

Phase II
www.emdserono.com
www.pfizer.com
bavituximab
Tustin, CA
advanced melanoma
(see also breast, colorectal, lung)
Phase I
BBI608
Boston Biomedical
Cambridge, MA
melanoma
(see also breast, colorectal, hematological, liver,
lung, ovarian, pancreatic, stomach)
Phase I
binimetinib
(MEK inhibitor)
Array BioPharma
Boulder, CO
BRAF-mutant melanoma, NRAS-mutant melanoma

(see also ovarian)
Phase III
Cavatak
coxsackievirus A21
Orphan Drug
Vitalytics
Sydney, Australia
metastatic melanoma
Phase II
www.viralytics.com
CDX-1401
(NY-ESO-1 cancer vaccine)
Hampton, NJ
metastatic melanoma
Phase II
www.celldex.com
Skin Cancer
Product Name
Sponsor
Indication
Development Phase
cobimetinib
(MEK inhibitor)
Genentech/Roche
metastatic melanoma
www.roche.com
diphencyprone
(immunomodulator)
Rxi Pharmaceuticals
Marlborough, MA
cutaneous cancer metastases
Phase II
www.rxipharma.com
dorgenmeltucel-L
NewLink Genetics
Ames, IA
metastatic melanoma
Phase II
eltrapuldencel-T (CLBS20)
(dendritic cell immunotherapy)
Orphan Drug
Caladrius Biosciences
New York, NY
metastatic melanoma (Fast Track)
Phase III
www.caladrius.com
encorafenib (LGX818)
(BRAF inhibitor)
Array BioPharma
Boulder, CO
BRAF mutant melanoma
Phase III
entinostat
(HDAC inhibitor)
Waltham, MA
melanoma (combination therapy)

Phase I/II
www.syndax.com
epacadostat
(IDO1 inhibitor)
Incyte
Wilmington, DE
metastatic melanoma
(see also lung, ovarian, other)
Phase II
www.incyte.com
Erivedge
vismodegib
Genentech/Roche
operable basal cell carcinoma
Phase II
www.roche.com
EMD Serono
Rockland, MA
melanoma
(see also brain, hematological, lung,
pancreatic, sarcoma)
Phase II
www.emdserono.com
G100
(TLR4 agonist)
Immune Design
Seattle, WA
Merkel cell carcinoma

(see also sarcoma)
Phase I
Skin Cancer
Product Name
Sponsor
Indication
Development Phase
glembatumumab vedotin
CellDex Therapeutics
Hampton, NJ
stage III or IV metastatic melanoma

(see also breast)
Phase II
www.celldex.com
GR-MD-02
(galectin-3 inhibitor)
Galectin Therapeutics
Norcross, GA
melanoma
Phase II
www.galectintherapeutics.com
heat shock protein vaccine

(Prophage Series)
Orphan Drug
Agenus
Lexington, MA
metastatic melanoma
(see also brain)
Phase II
www.agenus.com
HF10
Takara Bio
Shiga, Japan
metastatic melanoma
Phase II
www.tkara-bio.com
IMCgp100
Immunocore
Oxon, England
metastatic melanoma
Phase II
www.immunocore.com
OncoSec Medical
San Diego, CA
metastatic melanoma
(see also breast, head/neck)
Phase II
www.oncosec.com
INXN-2001
ZIOPHARM Oncology
Boston, MA
metastatic melanoma
Phase II
www.ziopharm.com
Lenvima
lenvatinib
Orphan Drug
Eisai
Woodcliff Lake, NJ
melanoma
(see also kidney, liver, lung, other, solid tumors)
Phase II
www.eisai.com
LN-144
(autologous cell therapy)
Orphan Drug
Lion Biotechnologies
Woodland Hills, CA
Bethesda, MD
metastatic melanoma (2nd-line)
Phase II completed
www.lbio.com
metastatic melanoma (1st-line)

Phase I
www.lbio.com
Skin Cancer
Product Name
Sponsor
Indication
Development Phase
MEDI4736 + dabrafenib +
trametinib
(anti-PD-L1 mAb/murine OX40
agonist/MEK inhibitor)
MedImmune
Gaithersburg, MD
melanoma
Phase I
www.medimmune.com
MGA271
Macrogenics
Rockville, MD
metastatic melanoma (combination therapy)

Phase I
www.macrogenics.com
MORAb-004
Eisai
Woodcliff Lake, NJ
melanoma
(see also colorectal, sarcoma)
Phase II
www.eisai.com
Adaptimmune
Oxon, England
melanoma
(see also myeloma, ovarian, sarcoma)
Phase I/II
www.adaptimmune.com
onalespib (AT13387)
(Hsp90 inhibitor)
Pleasanton, CA
B-raf melanoma
(see also lung)
Phase II
www.astx.com
Ontak
denileukin diftitox
Eisai
Woodcliff Lake, NJ
metastatic melanoma
Phase II
www.eisai.com
Opdivo
nivolumab
Princeton, NJ
melanoma (adjuvant),
hematological, kidney, liver, lung, lymphoma,
Phase III
www.bms.com
Opdivo nivolumab +
Yervoy ipilimumab
Princeton, NJ
melanoma (1st-line)
(see also kidney, lung, solid tumors)
Phase III
www.bms.com

(SOM230)
East Hanover, NJ
merkel cell carcinoma, metastatic melanoma

(see also prostate, other)
Phase I
www.novartis.com
pimasertib
(MEK inhibitor)
EMD Serono
Rockland, MA
melanoma
Phase II
www.emdserono.com
Skin Cancer
Product Name
Sponsor
Indication
Development Phase
PLX3397
(CSF-1R inhibitor)
Plexxikon
Berkeley, CA
melanoma
(see also brain, breast, ovarian, other)
Phase I
www.plexxikon.com
Resimmune
A-dmDT390-bisFv immunotoxin
Angimmune
Rockville, MD
metastatic melanoma
(see also lymphoma)
Phase I/II
www.angimmune.com
RG7446
(anti-PD-L1 mAb)
Genentech/Roche
metastatic melanoma
(see also bladder, breast, kidney, lung, lymphoma)
Phase I
www.roche.com
RTA 408
(NF/E2-related factor 2 stimulant)
AbbVie
North Chicago, IL
Reata Pharmaceuticals
Irving, TX
melanoma
Phase II
www.abbvie.com
www.reatapharma.com
seviprotimut-L
Orphan Drug
Polynoma
San Diego, CA
metastatic melanoma
Phase III
www.polynoma.com
Tafinlar
dabrafenib
Mekinist
trametinib
combination
East Hanover, NJ
BRAF V600-positive melanoma (adjuvant)

Phase III
www.novartis.com
talimogene laherparepvec
Amgen
Thousand Oaks, CA
regionally and distantly metastatic melanoma
www.amgen.com
mid- to late-stage metastatic melanoma
Phase II
www.amgen.com
melanoma
Phase II
www.cancerinsight.com
www.eliostherapeutics.com
TLPLDC
(tumor lysate particle-loaded
dendritic cell vaccine)
Cancer Insight
San Antonio, TX
Elios Therapeutics
Austin, TX
Skin Cancer
Product Name
Sponsor
Indication
Development Phase
TRX518
(GITR receptor antagonist)
GITR
Cambridge, MA
advanced melanoma
Phase I
www.gitrrx.com
varlilumab
Hampton, NJ
unresectable stage III or IV melanoma

(see also hematological, kidney)
Phase I/II
www.celldex.com
veliparib
(PARP inhibitor)
AbbVie
North Chicago, IL
melanoma
(see also brain, breast, colorectal, lung)
Phase II
www.abbvie.com
Yervoy
ipilimumab
Orphan Drug
Princeton, NJ
melanoma (adjuvant)
(see also lung)
Phase III
www.bms.com
melanoma (adolescent)
Phase II
www.bms.com
BRAF mutation-positive metastatic

melanoma (adjuvant)
(see also colorectal, other)
Phase III
www.roche.com
BRAF mutation-positive metastatic melanoma
Phase I
www.roche.com
Zelboraf
vemurafenib
Genentech/Roche
Daiichi Sankyo
Parsippany, NJ
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
ABBV-221
(epidermal growth factor modulator)
AbbVie
North Chicago, IL
solid tumors
Phase I
www.abbvie.com
ABBV-399
AbbVie
North Chicago, IL
solid tumors
Phase I
www.abbvie.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
ABT-165
(dual variable immunoglobulin)
AbbVie
North Chicago, IL
solid tumors
Phase I
www.abbvie.com
ABT-414
AbbVie
North Chicago, IL
squamous cell solid tumors

(see also brain)
Phase II
www.abbvie.com
ABT-700
(c-Met inhibitor)
AbbVie
North Chicago, IL
solid tumors
Phase I
www.abbvie.com
ABT-767
(PARP inhibitor)
AbbVie
North Chicago, IL
solid tumors
Phase I
www.abbvie.com
ABT-806
(epidermal growth factor receptor
antagonist)
AbbVie
North Chicago, IL
solid tumors
Phase I
www.abbvie.com
AG-120
(IDH1 inhibitor)
Cambridge, MA
Celgene
Summit, NJ
solid tumors
(see also brain, leukemia)
Phase I
www.agios.com
www.celgene.com
AG-221
(IDH2 inhibitor)
Cambridge, MA
Celgene
Summit, NJ
advanced solid tumors

(see also leukemia)
Phase I/II
www.agios.com
www.celgene.com
AG-881
(pan-IDH inhibitor)
Cambridge, MA
Celgene
Summit, NJ
Phase I
www.agios.com
www.celgene.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
AGS-22ME
Agenesys
Santa Monica, CA
Seattle Genetics
Bothell, WA
relapsed solid tumors
Phase I
www.agenesys.com
ALRN-6924
(next-generation dual-specific
MDM2/MDMX antagonist)
Aileron Therapeutics
Cambridge, MA
Phase I/II
www.aileronrx.com
ALT-836
(recombinant chimeric
anti-tissue factor antibody)
Altor BioScience
Miramar, FL
solid tumors
Phase I/II
altiratinib
(MET/TIE2/VEGFR2 kinase
inhibitor)
Deciphera Pharmaceuticals
Cambridge, MA
solid tumors
Phase I
www.deciphera.com
AM0010
(PEGylated recombinant
human IL-10)
ARMO BioSciences
Redwood City, CA
solid tumors
Phase I
www.armobio.com
AMG 208
(c-Met inhibitor)
Amgen
Thousand Oaks, CA
solid tumors
Phase I
www.amgen.com
AMG 211/MEDI-565
(anti-CEA BiTE mAb)
Amgen
Thousand Oaks, CA
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.amgen.com
www.medimmune.com
AMG 228
(mAb)
Amgen
Thousand Oaks, CA
solid tumors
Phase I
www.amgen.com
AMG 232
(MDM2 inhibitor)
Amgen
Thousand Oaks, CA
solid tumors
(see also leukemia, myeloma, skin)
Phase I
www.amgen.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
AMG 780
(angiopoietin inhibitor)
Amgen
Thousand Oaks, CA
Phase I
www.amgen.com
AMG 820
(c-fms inhibitor)
Amgen
Thousand Oaks, CA
Phase I
www.amgen.com
AMG 900
(aurora kinase inhibitor)
Amgen
Thousand Oaks, CA

Phase I
www.amgen.com
anetumab ravtansine

Whippany, NJ
solid tumors
Phase II
anti-LAG3 antibody +
Opdivo nivolumab
Princeton, NJ
solid tumors
Phase I
www.bms.com
apatinib mesylate
(YN968D1)
LSK BioPartners Inc.

Salt Lake City, UT
Bukwang Pharmaceutical
Seoul, South Korea
solid tumors
Phase I/II
www.lskbiopharma.com
APN401
(siRNA-transfected peripheral blood
mononuclear cells)
Apeiron Biologics
Vienna, Austria
solid tumors
Phase I
www.apeiron-biologics.com
APS001F
(recombinant anaerobic bacteria)
Anaeropharma Science
Tokyo, Japan
solid tumors
Phase I
www.anaeropharma.co.jp
APX005M
Apexigen
San Carlos, CA
solid tumors
Phase I
www.apexigen.com
AR-12
(PI3K/Akt inhibitor)
Arno Therapeutics
Flemington, NJ
solid tumors
(see also lymphoma)
Phase I
www.arnothera.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
AR-42
(pan-DAC inhibitor)
Arno Therapeutics
Flemington, NJ
solid tumors
Phase I
www.arnothera.com
ARQ 087
(FGFR antagonist)
ArQule
Woburn, MA
metastatic solid tumors
Phase I
www.arqule.com
ARQ 092
(Akt inhibitor)
ArQule
Woburn, MA
Phase I
www.arqule.com
ARQ 761
(E2F1 transcription factor
stimulant)
ArQule
Woburn, MA
Phase I
www.arqule.com
ASB183
East Hanover, NJ
solid tumors
Phase I
www.novartis.com
ASP4132
Astellas Pharma US
Northbrook, IL

(see also lymphoma)
Phase I
www.astellas.com
AT13148
(ROCK inhibitor)
Pleasanton, CA
solid tumors
Phase I
www.astx.com
ATI-1123
(docetaxel liposomal)
Azaya Therapeutics
San Antonio, TX
solid tumors
Phase I
www.azayatherapeutics.com
AV-203
AVEO Oncology
Cambridge, MA
Phase I completed
www.aveooncology.com
avelumab
(anti-PD-L1 mAb)
EMD Serono
Rockland, MA
Pfizer
New York, NY
solid tumors
Phase I
www.emdserono.com
www.pfizer.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
AZD2014
(mTOR serine/threonine
kinase inhibitor)
AstraZeneca
Wilmington, DE
solid tumors
Phase II
www.astrazeneca.com
AZD4547
(FGFR tyrosine kinase inhibitor)
AstraZeneca
Wilmington, DE
solid tumors
Phase II
www.astrazeneca.com
AZD5312
(androgen receptor inhibitor)
AstraZeneca
Wilmington, DE
Isis Pharmaceuticals
Carlsbad, CA
solid tumors
Phase I
www.astrazeneca.com
www.isispharm.com
AZD6738
(ATR serine/threonine
kinase inhibitor)
AstraZeneca
Wilmington, DE
solid tumors
Phase I
www.astrazeneca.com
AZD8186
(PI3K beta inhibitor)
AstraZeneca
Wilmington, DE
solid tumors
Phase I
www.astrazeneca.com
AZD8835
(PI3K alpha inhibitor)
AstraZeneca
Wilmington, DE
solid tumors
Phase I
www.astrazeneca.com
BAY1125976
(allosteric Akt-1/2 inhibitor)

Whippany, NJ
Phase I
BAY1129980

Whippany, NJ
Phase I
BAY1161909
(MPS1 inhibitor)

Whippany, NJ
Phase I
BAY1187982
(type 2 FGFR antagonist)

Whippany, NJ
Phase I
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
BAY1217389
(MPS1 inhibitor)

Whippany, NJ
Phase I
Beigene-283
(BRAF inhibitor)
EMD Serono
Rockland, MA
solid tumors
Phase I
www.emdserono.com
Beigene-290
(PARP inhibitor)
EMD Serono
Rockland, MA
solid tumors
Phase I
www.emdserono.com
liquid formulation
Woodcliff Lake, NJ
solid tumors
Phase I
www.eagleus.com
BET inhibitor
Princeton, NJ
solid tumors
Phase I
www.bms.com
BGJ398
(FGF-R kinase inhibitor)
East Hanover, NJ
solid tumors
(see also brain)
Phase II
www.novartis.com
BI 836845
(somatomedin inhibitor)

Ridgefield, CT
solid tumors
Phase I
BI 853520
(PTK2 protein inhibitor)

Ridgefield, CT
solid tumors
Phase I
BI 860585

Ridgefield, CT
solid tumors
Phase I
BPM31510
(ubidecarenone)
Berg Pharma
Framingham, MA
solid tumors
Phase I
www.berghealth.com
briciclib
(cyclin D1 modulator)
Newtown, PA
Phase I
www.onconova.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
brontictuzumab
(NOTCH-1 inhibitor)
Redwood City, CA
solid tumors
Phase I
www.oncomed.com
buparlisib (BKM120)
(PI3K inhibitor)
East Hanover, NJ
solid tumors
Phase I
www.novartis.com
BVD-523

Kansas City, MO

Phase I/II
BVD-CNV
(C. novyi-NT)

Kansas City, MO
Phase I
BYL719
(PI3K-alpha inhibitor)
East Hanover, NJ
solid tumors
Phase I
www.novartis.com
CB-839
(glutaminase inhibitor)
Calithera Biosciences
solid tumors
Phase I
www.calithera.com
CBL0102
Cleveland BioLabs
Buffalo, NY
Phase I
www.cbiolabs.com
CBL0137
(curaxin)
Incuron
Buffalo, NY
Phase I
www.incuron.ru/en
CC-115
(dual TORK/DNA PK inhibitor)
Celgene
Summit, NJ
solid tumors
Phase I
www.celgene.com
CC-223
(dual TORK inhibitor)
Celgene
Summit, NJ
solid tumors
Phase I
www.celgene.com
CC-90002
(anti-CD47 antibody)
Celgene
Summit, NJ
solid tumors
Phase I
www.celgene.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
CC-90003
(ERK inhibitor)
Celgene
Summit, NJ
solid tumors
Phase I
www.celgene.com
CEP-37440
(dual anaplastic lymphoma
kinase and PTK2 protein inhibitor)
Teva Oncology
Frazer, PA
Phase I
www.tevapharm.com
CGM097
(p53/MDM2-interaction inhibitor)
East Hanover, NJ
solid tumors with p53 wild type status
Phase I
www.novartis.com
CLR457
(PI3K inhibitor)
East Hanover, NJ
Phase I/II
www.novartis.com
CMB305
Immune design
Seattle, WA
Phase I
crolibulin
Immune Pharmaceuticals
Cambridge, MA
solid tumors
Phase II
www.immunepharmaceuticals.com
CUDC-427
(IAP inhibitor)
Curis
Lexington, MA
late-stage solid tumors

(see also lymphoma)
Phase I
www.curis.com
CUDC-907
Curis
Lexington, MA

(see also lymphoma, myeloma)
Phase I
www.curis.com
CX-01
Weston, FL
solid tumors (pediatric)

(see also leukemia, lung)
Phase I
www.cantex.com
CYT-6091
(nanomedicine)
CytImmune
Rockville, MD
solid tumors
Phase I
www.cytimmune.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
DCVax-Direct
dendritic cell vaccine
Northwest Biotherapeutics
Bethesda, MD
inoperable solid tumors
Phase I/II
www.nwbio.com
Debio 1347
(FGFR inhibitor)
Debiopharm
Lausanne, Switzerland
Phase I
www.debiopharm.com
DFP-11207
(thymidylate synthase
expression inhibitor)
Delta-Fly Pharma
Tokushima, Japan
Phase I
DLYE-5953A
Genentech/Roche
refractory solid tumors
Phase I
www.roche.com
DS-3032
(MDM2 inhibitor)
Daiichi Sankyo
Parsippany, NJ

(see also lymphoma)
Phase I
www.dsi.com
DS-3078
(mTOR inhibitor)
Daiichi Sankyo
Parsippany, NJ
solid tumors
(see also lymphoma)
Phase I
www.dsi.com
DS-6051
(ROS1/NTRK inhibitor)
Daiichi Sankyo
Parsippany, NJ
Phase I
www.dsi.com
DS-7423
Daiichi Sankyo
Parsippany, NJ
solid tumors
Phase I
www.dsi.com
DS-8273
(anti-DR5 antibody)
Daiichi Sankyo
Parsippany, NJ

(see also lymphoma)
Phase I
www.dsi.com
duligotuzumab
(anti-HER3/EGFR DAF mAb)
Genentech/Roche
solid tumors with mutant KRAS
Phase I
www.roche.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
E7046
Eisai
Woodcliff Lake, NJ
solid tumors
Phase I
www.eisai.com
EC1456
(folate tubulysin)
Endocyte
West Lafayette, IN
solid tumors
Phase I
www.endocyte.com
entolimod
Cleveland BioLabs
Buffalo, NY
Phase I
www.cbiolabs.com
EPZ-6438
(EZH2 inhibitor)
Epizyme
Cambridge, MA
solid tumors
(see also lymphoma)
Phase I/II
www.epizyme.com
GDC-0575 (RG7741)
(ChK1 inhibitor)
Genentech/Roche
solid tumors
(see also lymphoma)
Phase I
www.roche.com
GDC-0919 (RG6078)
(IDO inhibitor)
Genentech/Roche
solid tumors
Phase I
www.roche.com
GDC-0994 (RG7842)
(ERK inhibitor)
Genentech/Roche
solid tumors
Phase I
www.roche.com
gedatolisib
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
GS-5745
(MMP9 mAb inhibitor)
Gilead Sciences
Foster City, CA
solid tumors
(see also stomach)
Phase I
www.gilead.com
GS-5829
(BET inhibitor)
Gilead Sciences
Foster City, CA
solid tumors
(see also lymphoma)
Phase I
www.gilead.com
HDM201
p53 modulator)
East Hanover, NJ

(see also hematological, sarcoma)
Phase I
www.novartis.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
hetIL-15
(heterodimeric interleukin-16)
Admune Therapeutics
Danvers, MA
Bethesda, MD
Phase I
www.admune.com
idasanutlin
(MDM2 antagonist)
Genentech/Roche
solid tumors
Phase I
www.roche.com
IDH305
(IDH inhibitor)
East Hanover, NJ
advanced solid tumors with IDHR132

mutations
Phase I
www.novartis.com
INCB54828
(FGFR inhibitor)
Incyte
Wilmington, DE
solid tumors
Phase I
www.incyte.com
Inlyta
axitinib
Pfizer
New York, NY
solid tumors (combination therapy)

(see also kidney)
Phase I
www.pfizer.com
IT-139
(GRP78 protein inhibitor)
Intezyne
Tampa, FL
solid tumors
Phase I
www.intezyne.com
ixazomib
Takeda Oncology
Cambridge, MA
solid tumors
(see also myeloma)
Phase I
KBP-5209
(pan-HER inhibitor)
Sihuan Pharmaceutical
Beijing, China
solid tumors
Phase I
www.sihuanpharm.com
KiroVAX-002
Kiromic
Houston, TX
Phase I/II
www.kiromic.com
KiroVAX-003
Kiromic
Houston, TX
Phase I/II
www.kiromic.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
KNK2801/CEP-37250
(anti-tumor specific glycoprotein
humanized antibody)
Kyowa Hakko Kirin Pharma

Princeton, NJ
Teva Oncology
Frazer, PA
Phase I
www.kyowa-hakko-kirin.com
www.tevapharm.com
KTN3379
(ErbB3 kinase inhibitor)
Kolltan Pharmaceuticals
New Haven, CT

(see also other)
Phase I
www.kolltan.com
LB-100
(PP2A inhibitor)
Lixte Biotechnology
East Setauket, NY
solid tumors
Phase I
www.lixte.com
Lenvima
lenvatinib
Eisai
Woodcliff Lake, NJ

(see also kidney, liver, lung, skin, other)
Phase I/II
www.eisai.com
LEQ506
(SMO antagonist)
East Hanover, NJ
Phase I
www.novartis.com
lirilumab + Opdivo nivolumab
Princeton, NJ
solid tumors
Phase I
www.bms.com
LJM716
East Hanover, NJ
solid tumors
Phase I
www.novartis.com
LOXO-101
(PanTrk inhibitor)
Array BioPharma
Boulder, CO
Loxo Oncology
Stamford, CT
solid tumors
Phase I
www.loxooncology.com
LY2780301
(p70S6/Akt dual inhibitor)
Eli Lilly
Indianapolis, In
solid tumors
Phase I
www.lilly.com
M2698 (MSC 2363318A)

(P70S6K/Akt dual inhibitor)
EMD Serono
Rockland, MA
solid tumors
Phase I
www.emdserono.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
M3814 (MSC 2490484A)

(DNA-PK inhibitor)
EMD Serono
Rockland, MA
solid tumors
Phase I
www.emdserono.com
M9241 (NHS-IL12)
EMD Serono
Rockland, MA
solid tumors
Phase I
www.emdserono.com
MEDI0562
(humanized OX40 agonist)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI0639
(anti-DLL-4 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI0680
(anti-PD-1 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI3617
(anti-ANG-2 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI4736
(anti-PD-L1 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase II
www.medimmune.com
solid tumors
Phase I
www.medimmune.com
MEDI4736 + MEDI0680
(anti-PD-L1 mAb/anti-PD-1 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI4736 + MEDI6469
(anti-PD-L1 mAb/murine
OX40 agonist)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
MEDI4736 + tremelimumab
(anti-PD-L1 mAb/anti-CTLA-4 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI6383
(OX40 agonist)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI6469
(murine OX40 agonist)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI6469 + rituximab
(murine OX40 agonist/anti-CD20 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
MEDI6469 + tremelimumab
(murine OX40 agonist/anti-CTLA-4 mAb)
MedImmune
Gaithersburg, MD
solid tumors
Phase I
www.medimmune.com
mesothelin antibody drug conjugate
Princeton, NJ
solid tumors
Phase I
www.bms.com
MGCD516
(Trk/RET/DDR kinase inhibitor)
Mirati Therapeutics
San Diego, CA
Phase I
www.mirati.com
MK-2206
(Akt inhibitor)
Merck
Kenilworth, NJ
solid tumors
Phase II
www.merck.com
MK-4166
(TNF-RSF18 protein stimulant)
Merck
Kenilworth, NJ
solid tumors
Phase I
www.merck.com
MK-8242
(MDM-2 inhibitor)
Merck
Kenilworth, NJ
solid tumors
Phase I completed
www.merck.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
MM-151
(EGFR antagonist)
Cambridge, MA
refractory advanced solid tumors
Phase I
MM-398
nanotherapeutic)
Baxalta
Cambridge, MA
solid tumors (pediatric)

(see also brain, pancreatic)
Phase I
www.baxalta.com
MNK-010
Mallinckrodt Pharmaceuticals
St. Louis, MO
solid tumors
Phase I
www.mallinckrodt.com
MORAb-066
(tissue factor antigen inhibitor)
Eisai
Woodcliff Lake, NJ
solid tumors
Phase I
www.eisai.com
MUC-1 dendritic cancer vaccine
MicroVAX
Manassas, VA
solid tumors
Phase I
MVA-BN Brachyury
Bavarian Nordic
Mountain View, CA
Bethesda, MD
solid tumors
Phase I
NC-4016
(DACH platin micelle)
NanoCarrier
Chiba, Japan
solid tumors
Phase I
www.nanocarrier.co.jp
OMP-305B83
(DLL3 protein inhibitor)
Redwood City, CA
solid tumors
Phase I
www.oncomed.com
ONC201
(TRAIL-inducing compound)
Oncoceutics
Hummelstown, PA
Phase I
www.oncoceutics.com
OPB-111077
Otsuka Pharmaceutical
Rockville, MD
solid tumors
Phase I
www.otsuka.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
Opdivo
nivolumab
Princeton, NJ
solid tumors (signal detection)

hematological, kidney, liver, lung, lymphoma,
skin, stomach, other)
Phase I
www.bms.com
Opdivo nivolumab +
Yervoy ipilimumab
Princeton, NJ
solid tumors
(see also kidney, lung, skin)
Phase I
www.bms.com
oprozomib

Phase I
www.onyx.com
oratecan
(oral irinotecan)
Buffalo, NY
solid tumors
Phase I
www.kinexpharma.com
oraxol
(oral paclitaxel)
Buffalo, NY
solid tumors
Phase I
www.kinexpharma.com
OTS167
(MELK protein inhibitor)
OncoTherapy Science
Kanagawa Prefecture, Japan
solid tumors
Phase I
www.oncotherapy.co.jp
OTX015
(BET inhibitor)
Merck
Kenilworth, NJ
solid tumors
Phase I
ww.merck.com
OVI-117
(L-nucleoside conjugate)
OncoVista Innovative Therapies

San Antonio, TX
solid tumors
Phase I/II
www.oncovista.com
p28 peptide
CDG Therapeutics
Chicago, IL
solid tumors
Phase I completed
www.cdgti.com
PAC-1
(procaspase activating compound-1)
Vanquish Oncology
Champaign, IL
solid tumors
Phase I
www.vanquishoncology.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
paclitaxel liposomal
Sun Pharma Advanced Research

Mumbai, India
solid tumors
Phase I
www.sunpharma.in
pbi-shRNA STMN1 LP
gene therapy
Gradalis
Dallas, TX
Phase I
www.gradalisinc.com
PDR001
(PDCD 1 protein inhibitor)
East Hanover, NJ
solid tumors
Phase I
www.novartis.com
PEG-BCT-100
(recombinant human arginase)
Bio-Cancer Treatment International

Hong Kong
solid tumors
Phase I
www.bio-cancer.org
PF-04518600
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
PF-05082566
(4-1BB [CD-137] protein receptor)
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
Phase I
www.pfizer.com
PF-06647020
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
PF-06647263
(immunoconjugate)
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
PF-06650808
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
PFK-158
(PFKFB3 inhibitor)
Advanced Cancer Therapeutics

Louisville, KY
solid tumors
Phase I
www.advancedcancertherapeutics.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
PLX8394
(BRAF inhibitor)
Plexxikon
Berkeley, CA
BRAF-mutant solid tumors
Phase I/II
www.plexxikon.com
PLX 9486
(proto oncogene protein
c-kit inhibitor)
Plexxikon
Berkeley, CA
KIT-mutant solid tumors

(see also stomach)
Phase I
www.plexxikon.com
PM060184
(tubulin polymerisation inhibitor)
PharmaMar
Madrid, Spain
solid tumors
Phase I
www.pharmamar.com
Poly-ICLC
Oncovir
Washington, DC
advanced accessible solid tumors
Phase II
www.oncovir.com
PQR309
(pan-PI3K/mTOR inhibitor)
PIQUR Therapeutics
Basel, Switzerland
Phase I
www.piqur.com
PT-112
Phosplatin Therapeutics
New York, NY
Phase I
www.phosplatin.com
PTC596
(BMI1 protein inhibitor)
PTC Therapeutics
South Plainfield, NJ
solid tumors
Phase I
www.ptcbio.com
purine nucleoside phosphorylase

gene therapy
PNP Therapeutics
Birmingham, AL
Phase I
www.pnptherapeutics.com
QBI-139
(RNA inhibitor)
Quintessence Biosciences
Madison, WI
solid tumors
Phase I
www.quintbio.com
rebastinib
(TRK/BCR-ABL/TIE-2 inhibitor)
Deciphera Pharmaceuticals
Cambridge, MA
solid tumors
Phase I/II
www.deciphera.com
RG6061
(HIF1 alpha inhibitor)
Genentech/Roche
solid tumors
Phase I
www.roche.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
RG7155
(CSF-1R antagonist)
Genentech/Roche
solid tumors
Phase I
www.roche.com
RG7304
(Raf/MEK dual inhibitor)
Genentech/Roche
solid tumors
Phase I
www.roche.com
RG7802
Genentech/Roche
solid tumors
Phase I
www.roche.com
RG7813
(CEA inhibitor)
Genentech/Roche
solid tumors
Phase I
www.roche.com
RG7841
Genentech/Roche
solid tumors
Phase I
www.roche.com
RG7876
Genentech/Roche
solid tumors
Phase I
www.roche.com
RG7888
(anti-OX40 mAb)
Genentech/Roche
solid tumors
Phase I
www.roche.com
RX-3117
(DNA synthesis inhibitor)
Rockville, MD
Phase I
www.rexahn.com
RX-5902
(RNA helicase inhibitor)
Rockville, MD
Phase I
www.rexahn.com
RXDX 101
(selective tyrosine kinase inhibitor)
Ignyta
San Diego, CA
Phase I/II
www.ignyta.com
RXDX 105
(BRAF kinase inhibitor)
Ignyta
San Diego, CA
Phase I
www.ignyta.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
sapacitabine/seliciclib
combination
Berkeley Heights, N
solid tumors
Phase I
www.cyclacel.com
SAR125844
c-Met kinase inhibitor)
Sanofi US
Bridgewater, NJ
solid tumors
Phase I
www.sanofi.com
SAR245408
(PI3K inhibitor)
Sanofi US
Bridgewater, NJ
solid tumors
Phase I
www.sanofi.com
SAR408701
Sanofi US
Bridgewater, NJ
solid tumors
Phase I
www.sanofi.com
SAR566658
(maytansin-loaded anti-CA6 mAb)
Sanofi US
Bridgewater, NJ
solid tumors
Phase I
www.sanofi.com
SEA-CD40
Seattle Genetics
Bothell, WA
relapsed solid tumors
Phase I
sEphB4-HSA
(recombinant albumin fusion
protein)
VasGene Therapeutics
Los Angeles, CA
solid tumors
Phase I
www.vasgene.com
Seprehvir
HSV1716
Virttu Biologics
Glasgow, Scotland
Nationwide Children's Hospital
Columbus, OH
non-CNS solid tumors

(see also brain)
Phase I
www.virttu.com
SF1126
SignalRx Pharmaceuticals
San Diego, CA
solid tumors
Phase I completed
www.signalrx.com
SOR-C13
(TRPV6 protein inhibitor)
Soricimed Biopharma
Sackville, Canada
cancers that overexpress the TRPV6

calcium channel
Phase I
www.soricimed.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
TAK-117
(PI3K alpha inhibitor)
Takeda Oncology
Cambridge, MA
solid tumors
Phase I
TAK-243
(UAE inhibitor)
Takeda Oncology
Cambridge, MA
solid tumors
Phase I
TAK-580
(pan-Raf kinase inhibitor)
Takeda Oncology
Cambridge, MA
solid tumors
Phase I
TAK-659
(SYK kinase inhibitor)
Takeda Oncology
Cambridge, MA
solid tumors
Phase I
TAS-114
(dUTPase/DPD inhibitor)
Taiho Oncology
Princeton, NJ
Phase I
TAS-119
(aurora kinase A inhibitor)
Taiho Oncology
Princeton, NJ
Phase I
TAS-120
(FGF/FGFR inhibitor)
Taiho Oncology
Princeton, NJ

(see also myeloma)
Phase I/II
TEN-010
(BET inhibitor)
Tensha Therapeutics
Cambridge, MA
solid tumors
Phase I
TEW-7197
(TGF-beta type 1 receptor antagonist)
MedPacto
Suwan, South Korea
solid tumors
Phase I
www.medpacto.com
thioureidobutyronitrile
p53 stimulant)
Cellceutix
Beverly, MA
solid tumors
Phase I
www.cellceutix.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
TRX518
(GITR receptor antagonist)
GITR
Cambridge, MA
solid tumors
(see also skin)
Phase I
www.gitrrx.com
TVB-2640
(FASN inhibitor)
3-V Biosciences
Menlo Park, CA
solid tumors
Phase I
www.3vbio.com
U3-1565
(anti-HB=EGF antibody)
Daiichi Sankyo
Parsippany, NJ
solid tumors
Phase I
www.dsi.com
urelumab
Princeton, NJ
solid tumors
Phase I
www.bms.com
urelumab + Opdivo nivolumab
Princeton, NJ
solid tumors
Phase I
www.bms.com
VGX 100
(VEGF-C antibody)
Ceres Oncology
Victoria, Australia
solid tumors
Phase I
www.ceresoncology.com
VLX600
(UCHL5/USP14 protein inhibitor)
Vivolux
Ashburn, VA
Phase I
www.vivolux.com
VS-4718
(FAK inhibitor)
Verastem
Cambridge, MA
Phase I
www.verastem.com
VS-5584
Verastem
Cambridge, MA

(see also lymphoma)
Phase I
www.verastem.com
VX15
Vaccinex
Rochester, NY
solid tumors
Phase I
www.vaccinex.com
VX-803
Boston, MA
solid tumors
(see also lymphoma)
Phase I
www.vrtx.com
Solid Tumors
Product Name
Sponsor
Indication
Development Phase
VX-970
(ATR protein inhibitor)
Boston, MA
solid tumors
Phase I
www.vrtx.com
WT2725
Sunovion Pharmaceuticals
Marlborough, MA
solid tumors
Phase I
www.sunovion.com
Xalkori
crizotinib
Pfizer
New York, NY
solid tumors
Phase I
www.pfizer.com
Stomach Cancer
Product Name
Sponsor
Indication
Development Phase
ADI-PEG 20
San Diego, CA
advanced gastrointestinal malignancies

(see also breast, liver, lung, ovarian, pancreatic, skin)
Phase I
Afinitor
everolimus
East Hanover, NJ
non-functioning gastrointestinal neuroendocrine

tumors
(see also lung)
Phase III
www.novartis.com
AMG 337
(c-Met inhibitor)
Amgen
Thousand Oaks, CA
gastric/esophageal cancer
Phase II
www.amgen.com
BBI608
Boston Biomedical
Cambridge, MA
gastric cancer, gastro-esophageal adenocarcinoma

(see also breast, colorectal, hematological, liver,
lung, ovarian, pancreatic, skin)
Phase III
gastrointestinal cancer (combination therapy)
Phase I
gastrointestinal stromal tumors (GIST)

(see also brain, leukemia, lung)
Phase III
www.arogpharma.com
crenolanib
(PDGFR inhibitor)
Dallas, TX
Stomach Cancer
Product Name
Sponsor
Indication
Development Phase
Cyramza
ramucirumab
Orphan Drug
Eli Lilly
Indianapolis, IN
gastric cancer (1st-line)

(see also bladder, liver, lung)
Phase III
www.lilly.com

non-alcohol formula
Teikoku Pharma USA

San Jose, CA
gastric adenocarcinoma
(see also breast, head/neck, lung, prostate)
www.teikokuusa.com
fosbretabulin
(vascular targeting agent)
OXiGENE
gastrointestinal neuroendocrine tumors

(see also ovarian)
Phase II
www.oxigene.com
FPA144
(FGFR2b antibody)
Five Prime Therapeutics

treatment-resistant gastric cancer
Phase I
www.fiveprime.com
GS-5745
(MMP9 mAb inhibitor)
Gilead Sciences
Foster City, CA
gastric cancer
Phase II
www.gilead.com
Iclusig
ponatinib
ARAID Pharmaceuticals
Cambridge, MA
GIST
(see also leukemia)
Phase II
www.ariad.com
ipatasertib
(Akt inhibitor)
Array BioPharma
Boulder, CO
Genentech/Roche
gastric cancer
Phase II
www.roche.com
Kadcyla
Genentech/Roche
HER2-positive gastric cancer (2nd-line)

Phase III
www.roche.com
Keytruda
pembrolizumab
Merck
Kenilworth, NJ
gastric cancer
(see also bladder, breast, head/neck, lung, lymphoma)
Phase II
www.merck.com
Lynparza
olaparib
AstraZeneca
Wilmington, DE
gastric cancer (2nd-line)

(see also breast, ovarian, pancreatic, prostate)
Phase III
www.astrazeneca.com
Stomach Cancer
Product Name
Sponsor
Indication
Development Phase
masitinib
Orphan Drug
AB Science USA
Short Hills, NJ
late-stage GIST (1st-line)

Phase III
www.ab-science.com
MBP-426
(transferrin-conjugated nano-particle
formulation of oxaliplatin)
Mebiopharm
Tokyo, Japan
gastric cancer, gastroesophageal junction carcinoma
Phase I/II
www.mebiopharm.com
Minnelide 001
HSP70 inhibitor
Minneamrita Therapeutics
Moline, IL
advanced gastrointestinal cancer
Phase I
NeuVax
nelipepimut-S
Galena Biopharma
Portland, OR
gastric carcinoma (HER2 IHC 1+/2+ or 3+)

(see also breast)
Phase I completed
Opdivo
nivolumab
Princeton, NJ
gastric cancer
hematological, kidney, liver, lung, lymphoma, skin,
solid tumors, other)
Phase III
www.bms.com
Perjeta
pertuzumab
Genentech/Roche
HER2-positive gastric cancer

(see also breast)
Phase III
www.roche.com
PLX9486
(proto oncogene protein c-kit inhibitor)
Plexxikon
Berkeley, CA
GIST
Phase I
www.plexxikon.com

(G17DT)
Orphan Drug
Cancer Advances
Durham, NC
gastric cancer
(see also colorectal, pancreatic)
Phase III completed

pyrotinib
(tyrosine kinase inhibitor)
Jiangsu Hengrui Medicine

Jiangsu Province, China
HER2-positive gastric cancer

(see also breast)
Phase I
www.hrs.com.cn
SM04755
(Wnt inhibitor)
Samumed
San Diego, CA
advanced gastric cancer

(see also colorectal, liver, pancreatic)
Phase I
www.samumed.com
Stomach Cancer
Product Name
Sponsor
Indication
Development Phase
TAK-264
(antibody drug conjugate
targeting GCC)
Takeda Oncology
Cambridge, MA
gastric cancer
Phase II
TAS-102
(tipiracil/trifluridine)
Taiho Oncology
Princeton, NJ
advanced gastrointestinal tumors

Phase I
telatinib
(VEGFR inhibitor)
Orphan Drug
Eddingpharm
Westlake Village, CA
gastric cancer
Phase II completed
www.eddingpharm.com
TKM-PLK1
(PLK1 inhibitor)
Arbutus Biopharma
Burnaby, Canada
gastrointestinal neuroendocrine tumors

(see also other)
Phase I/II
www.arbutusbio.com
Other Cancers
Product Name
Sponsor
Indication
Development Phase
177Lu-DOTATAE
(somastatin receptor antagonist)
Orphan Drug
Advanced Accelerator Applications

New York, NY
somastatin receptor-positive neuroendocrine

tumors of the small bowel (midgut carcinoid tumors)
Phase III
www.adacap.com
212-Pb-TCMC trastuzumab
AREVA Med
Bethesda, MD
intra-abdominal HER-2 expressing cancers
Phase I
www.averamed.avera.com
ADXS-HPV
Orphan Drug
Advaxis
Princeton, NJ
anal cancer, cervical cancer

Phase II
www.advaxis.com
cervical cancer (combination therapy)
Phase I/II
www.advaxis.com
metastatic uveal melanoma

(see also lymphoma)
Phase I/II
www.novartis.com
AEB071
(PKC inhibitor)
East Hanover, NJ
Other Cancers
Product Name
Sponsor
Indication
Development Phase
ATR-101
(ACAT1 inhibitor)
Orphan Drug
Atterocor
Ann Arbor, MI
adrenocortical carcinoma
Phase I
www.atterocor.com
Avastin
bevacizumab
Genentech/Roche
high-risk carcinoid tumors

(see also brain, breast, lung, ovarian)
Phase III
www.roche.com
Azedra
iobenguane I-131
Orphan Drug
Progenics Pharmaceuticals
Tarrytown, NY
neuroblastoma (pediatric), neuroendocrine

tumors (pediatric), pheochromocytoma (Fast Track)
Phase II
www.progenics.com
BAY1143572

Whippany, NJ
advanced cancer
(see also leukemia)
Phase I
BEL-0222
Orphan Drug
Belrose Pharma
Princeton, NJ
pediatric neuroblastoma
(see also breast)
Phase I/II
www.belrosepharma.com
CC-486
Celgene
Summit, NJ
advanced nasopharyngeal carcinoma

(see also breast, hematological, leukemia,
lung, lymphoma)
Phase II
www.celgene.com
CPI-613
(KGDH/PHD complex inhibitor)
Cornerstone Pharmaceuticals
Cranbury, NJ
advanced malignancies
Phase I/II
www.cornerstonepharma.com
CPP-1X
(eflornithine)
Cancer Prevention Pharmaceuticals

Tucson, AZ
neuroblastoma
Phase II
www.canprevent.com
CPP-1X/sulindac
(eflornithine/sulindac)
Cancer Prevention Pharmaceuticals

Tucson, AZ
colorectal cancer (risk reduction)

(see also other)
Phase III
www.canprevent.com
Other Cancers
Product Name
Sponsor
Indication
Development Phase
cridanimod
(progesterone receptor modulator)
Kevelt
Tallinn, Estonia
Pharmsynthez
St. Petersburg, Russia
endometrial cancer
Phase II
www.kevelt.ee.en
www.pharmsynthez.com
DKN-01
Cambridge, MA
esophageal cancer
Phase I
emibetuzumab
(c-Met antibody)
Eli Lilly
Indianapolis, IN
advanced cancers
(see also lung)
Phase I/II
www.lilly.com
epacadostat
(IDO1 inhibitor)
Incyte
Wilmington, DE
fallopian tube cancer, peritoneal cancer

(see also lung, ovarian, skin)
Phase II
www.incyte.com
fenretinide lipid matrix
BioMolecular Products
Newburyport, MA
The EVAN Foundation
Germantown, MD
Texas Tech University
Lubbock, TX
recurrent/resistant neuroblastoma
Phase I
www.biomolecularproducts.com
GALE-301
(folate binding protein
immunotherapy)
Galena Biopharma
Portland, OR
endometrial cancer
(see also ovarian)
Phase II
GI-6207
(T-cell stimulator)
GlobeImmune
Louisville, CO
medullary thyroid cancer
Phase II
www.globeimmune.com
GI-6301
(brachyury peptide vaccine)
GlobeImmune
Louisville, CO
chordoma
Phase II
www.globeimmune.com
advanced cancers
Phase I
www.globeimmune.com
Other Cancers
Product Name
Sponsor
Indication
Development Phase
GL-ONC1
Genelux
San Diego, CA
peritoneal carcinomatosis
Phase I/II
www.genelux.com
HPV-16 E6 TCR
(T-cell receptor antigen antagonist)
Kite Pharma
Santa Monica, CA
Bethesda, MD
HPV-associated cancers (vaginal, cervical, anal,

penile, or oropharyngeal cancers)
Phase I/II
www.kitepharma.com
IMMU-132
(sacituzumab govitecan)
Immunomedics
Morris Plains, NJ
advanced epithelial cancer

(see also breast)
Phase I/II
INO-3106
HPV-6-associated aerodigestive cancers
Phase I/II
www.inovio.com
INO-3112
cervical cancer caused by HPV types 16 and 18
Phase I/II
www.inovio.com
JCAR023
Juno Therapeutics
Seattle, WA
neuroblastoma (pediatric)
Phase I
KTN3379
(ErbB3 kinase inhibitor)
Kolltan Pharmaceuticals
New Haven, CT
BRAF mutant, radioiodine-refractory thyroid cancer

Phase I
www.kolltan.com
Lenvima
lenvatinib
Eisai
Woodcliff Lake, NJ
endometrial cancer
(see also kidney, liver, lung, skin, solid tumors)
Phase II
www.eisai.com
LY2940680
(hedgehog/SMO inhibitor)
Eli Lilly
Indianapolis, IN
advanced cancer
Phase II
www.lilly.com
milciclib
(CDK inhibitor)
Nerviano Medical Sciences

Nerviano, Italy
malignant thymoma
Phase II
www.nervianoms.com
Other Cancers
Product Name
Sponsor
Indication
Development Phase
mirvetuximab soravtansine
(folate receptor 1 inhibitor)
ImmunoGen
Waltham, MA
FOLR1-overexpressing endometrial cancer

(see also ovarian)
Phase I
www.immunogen.com
neuroblastoma vaccine
Orphan Drug
MabVax Therapeutics
San Diego, CA
neuroblastoma
Phase I
www.mabvax.com
Nexavar
sorafenib

Whippany, NJ
differentiated thyroid cancer

(see also kidney)
Phase III
Opdivo
nivolumab
Princeton, NJ
esophageal cancer
hematological, kidney, liver, lung, lymphoma, skin,
solid tumors, stomach)
Phase II
www.bms.com
pediatric cancer
Phase I
www.bms.com

(SOM230)
East Hanover, NJ
neuroendocrine tumors, pituitary cancer

(see also prostate, skin)
Phase II
www.novartis.com
PDS0101
PDS Biotechnology
North Brunswick, NJ
cervical cancer prevention (HPV-16)
Phase I
www.pdsbiotech.com
PLX3397
(CSF-1R inhibitor)
Orphan Drug
Plexxikon
Berkeley, CA
tenosynovial giant cell tumor

(see also brain, breast, ovarian, skin)
Phase III
www.plexxikon.com
PU-H71
(HSP90 heat-shock protein inhibitor)
Samus Therapeutics
New York, NY
Memorial Sloan-Kettering Cancer Center
New York, NY
advanced malignancies
Phase I
Other Cancers
Product Name
Sponsor
Indication
Development Phase
refametinib
(MEK inhibitor)

Whippany, NJ
advanced or metastatic cancer
Phase II
Reolysin
pelareorp
Orphan Drug
Oncolytics Biotech
Calgary, Canada

myeloma, ovarian, pancreatic)
Phase II
RRx-001
EpicentRx
Mountain View, CA
neuroendocrine tumors
(see also colorectal, liver, lung, lymphoma)
Phase II
www.radiorx.com
rucaparib
(PARP inhibitor)
Clovis Oncology
Boulder, CO

(see also breast, ovarian, pancreatic)
Phase III
SC-002
(immunoconjugate)
Stemcentrx
neuroendocrine tumors
(see also lung)
Phase I
www.stemcentrx.com
selinexor (oral)
(XPO1 antagonist)
Newton, MA
gynecologic malignancies
leukemia, lymphoma, myeloma, prostate, sarcoma)
Phase II
www.karyopharm.com
selumetinib
(MEK inhibitor)
Orphan Drug
AstraZeneca
Wilmington, DE
differentiated thyroid cancer,

uveal melanoma
Phase III
www.astrazeneca.com
TAK-228
Takeda Oncology
Cambridge, MA
endometrial cancer
(see also breast, kidney)
Phase II
telotristat etiprate
(TPH1 inhibitor)
Orphan Drug
Lexicon Pharmaceuticals
The Woodlands, TX
malignant carcinoid syndrome (Fast Track)
Phase III
www.lexicon-genetics.com
Other Cancers
Product Name
Sponsor
Indication
Development Phase
TKM-PLK1
(PLK1 inhibitor)
Arbutus Biopharma
Burnaby, Canada
adrenocortical carcinoma
(see other stomach)
Phase I
www.arbutusbio.com
TRC105
San Diego, CA
choriocarcinoma
lung, sarcoma)
Phase II
Triapine
ribonuclease inhibitor
Nanotherapeutics
Alachua, FL
Bethesda, MD
non-localized cervical cancer
Phase II
www.nanotherapeutics.com
Unituxin
dinutuximab
Orphan Drug
United Therapeutics
Silver Spring, MD
neuroblastoma (adults up to age 30 years)
Phase III
www.unither.com
VB-111
VBL Therapeutics
Tel Aviv, Israel
thyroid cancer
(see also brain, ovarian)
Phase II
www.vblrx.com
WNT974
(WNT signaling pathway inhibitor)
East Hanover, NJ
malignancies dependent on Wnt ligands
Phase I
www.novartis.com
Zelboraf
vemurafenib
Genentech/Roche
Daiichi Sankyo
Parsippany, NJ
BRAF mutation-positive papillary thyroid cancer

Phase II
www.roche.com
zoptarelin doxorubicin
inhibitor)
Aeterna Zentaris
Quebec, Canada
endometrial cancer (2nd-line)

(see also prostate)
Phase III
www.aezsinc.com
Unspecified
Product Name
Sponsor
ABBV-075
(bromodomain inhibitor)
AbbVie
North Chicago, IL
Phase I
www.abbvie.com
AGS67E
Agensys
Santa Monica, CA
Astellas Pharma
Tokyo, Japan
Phase I
www.agensys.com
www.astellas.com
BAY1082439
(allosteric Akt 1/2 inhibitor)

Whippany, NJ
Phase I
BAY1163877
(Pan-FGFR inhibitor)

Whippany, NJ
Phase I
BAY1179470
(FGFR2 antibody drug conjugate)

Whippany, NJ
Phase I
BAY2020112
(PSMA BiTE antibody)

Whippany, NJ
Phase I
CHML
(cytotropic heterogeneous molecular lipids)
Glory Pharmaceuticals
Vienna, VA
in clinical trials
www.anticancerdrug.com
CSF-1R mAb
(LY3022855)
Eli Lilly
Indianapolis, IN
Phase I
www.lilly.com
fenretinide intravenous
CerRx
Lubbock, TX
Phase I
www.cerrx.com
G1T28
(CDK 4/6 inhibitor)
G1 Therapeutics
Phase I
www.g1therapeutics.com
Indication
Development Phase
Unspecified
Product Name
Sponsor
HBI-8000
(HDAC inhibitor)
Huya Bioscience
San Diego, CA
Phase I
www.huyabio.com
IGF-methotrexate conjugate
IGF Oncology
Birchwood, MN
Phase I
www.igfoncology.com
IP-112
InnoPharma
Piscataway, NJ
www.innopharmainc.com
LY2874455
(FGF receptor inhibitor)
Eli Lilly
Indianapolis, IN
Phase II
www.lilly.com
LY3009120
(Pan-Raf inhibitor)
Eli Lilly
Indianapolis, IN
Phase I
www.lilly.com
LY3039478
(NOTCH inhibitor)
Eli Lilly
Indianapolis, IN
Phase I
www.lilly.com
LY3164530
(MET/EGFR bispecific antibody)
Eli Lilly
Indianapolis, IN
Phase I
www.lilly.com
merestinib
(c-Met inhibitor)
Eli Lilly
Indianapolis, IN
Phase II
www.lilly.com
notch inhibitor
Princeton, NJ
Phase I
www.bms.com
OMN54
(signal transduction pathway
inhibitor)
Omnitura Therapeutics
Redwood Shores, CA
Phase I
www.omnitura.com
Indication
Development Phase
Unspecified
Product Name
Sponsor
OPB-51602
(molecular targeting drug)
Otsuka Pharmaceutical
Rockville, MD
Phase I
www.otsuka.com
REGN1400
(ERBB-3 receptor modulator)
Tarrytown, NY
Phase I
www.regeneron.com
REGN2810
(PD-1 protein inhibitor)
Tarrytown, NY
Phase I
www.regeneron.com
SNX-5422
(Hsp90 inhibitor)
Esanex
Indianapolis, In
Phase I
TRF-DOX
(doxorubicin transferrin conjugate)
Faulk Pharmaceuticals
Raleigh, NC
Panther Biotechnology
Chicago, IL
Phase I completed
www.faulkpharma.com
www.pantherbiotechnology.com
VEGFR-3 mAb
Eli Lilly
Indianapolis, IN
Phase I
www.lilly.com
VOLT03
(thromboxane synthase inhibitor)
Levolta Pharmaceuticals
Bethlehem, PA
Phase I
www.levoltapharma.com
Indication
Development Phase
Definitions
Application SubmittedAn application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA).
Fast TrackUpon request by a sponsor, the FDA can grant this designation to facilitate the development and expedite the review of a drug or biologic to treat a serious condition and fill an
unmet medical need. When considering a biopharmaceutical companys request for Fast Track designation for an investigational drug or biologic, the FDA evaluates whether it will affect
factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one, and whether a condition
can be adequately addressed by available therapy. With Fast Track designation, early and frequent communication between the FDA and the biopharmaceutical company is encouraged
throughout the entire drug development and review process to help to quickly resolve and questions or issues that arise, potentially leading to an earlier approval and access by patients.
Orphan DesignationUpon request by a sponsor, the FDA can grant special status (orphan status) to a drug or biologic to treat a rare disease or disease or condition. In order to
receive an orphan designation, a qualifying drug or biologic must be intended for the treatment, diagnosis, or prevention of a rare disease or condition that affects fewer than 200,000
people in the United States, or that affects more than 200,000 persons but is not expected to recover the costs of its development and marketing.
Phase IResearchers test the investigational drug or biologic in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and
tolerability profile, determine a safe dosage range, and identify potential side effects.
Phase IIThe investigational drug or biologic is given to volunteer patients, usually between 100 and 500, to determine whether it is effective, identify an optimal dose, and to further
evaluate its short-term safety.
Phase IIIThe investigational drug or biologic is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients ( but sometimes many more),
to generate statistically significant evidence to confirm its safety and effectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world.
The content of this report has been obtained through public, government and industry sources, and the Adis R&D Insight database based on the latest information. Report current as of
August 21, 2015. The medicines in this listing include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting
trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. The information may not be comprehensive. For more specific information about a
particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA's website at www.phrma.org.

2015 Cancer Drug List PDF

Enviado por

Dados do documento

Descrição original:

Título original

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

2015 Cancer Drug List PDF

Enviado por

Direitos autorais:

Formatos disponíveis

2015 Medicines in Development for Cancer

non-muscle invasive bladder cancer

platinum-refractory bladder cancer

advanced bladder cancer,

non-muscle invasive bladder cancer

metastatic bladder cancer

non-muscle invasive bladder cancer

relapsed bladder cancer

metastatic bladder cancer (2nd-line)

bladder cancer (2nd-line)

non-muscle invasive bladder cancer

bladder cancer (2nd-line)

HER2-positive urothelial cancer

superficial bladder cancer

Janssen Research & Development

refractory non-muscle invasive

bladder cancer (2nd-line)

bladder cancer (2nd-line) (Breakthrough Therapy)

bladder cancer (1st-line)

brain metastases in advanced solid tumors,

anaplastic astrocytoma, recurrent glioblastoma

brain metastases from breast cancer and

Burzynski Research Institute

diffuse intrinsic brainstem glioma

recurrent glioblastoma (Fast Track)

glioma (combination therapy)

glioblastoma (Fast Track)

high grade glioma

Boehringer Ingelheim Pharmaceuticals

heat shock protein vaccine

recurrent or newly-diagnosed glioblastoma

primary malignant brain tumors

anaplastic oligo astrocytoma, glioblastoma

malignant central nervous system tumors

high grade glioma (pediatrics)

glioblastoma (1st-line) (Fast Track)

recurrent glioblastoma (Fast Track)

adult glioblastoma (first recurrence)

Toca 511 + Toca FC

anaplastic astrocytoma, glioblastoma

breast cancer brain metastases,

recurrent glioblastoma (Fast Track)

metastatic breast cancer

triple-negative breast cancer (1st-line)

HER2-negative breast cancer

HER2-negative breast cancer (adjuvant),

estrogen receptor (ER)-positive breast cancer

HER2-negative breast cancer

triple-negative breast cancer

metastatic breast cancer (2nd-line)

metastatic breast cancer

metastatic breast cancer

triple-negative breast cancer (combination therapy)

docetaxel injection concentrate,

Teikoku Pharma USA

triple-negative breast cancer

ER-positive and androgen receptor (AR)-positive

hormone receptor (HR)-positive metastatic

etirinotecan pegol (NKTR-102)

metastatic breast cancer (Fast Track)

HR-positive advanced breast cancer (1st-line)

ER-positive HER2-negative breast cancer